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ct 
The halichondrins, isolated from the Kaikoura sponge Lissodendoryx sp., are a series of 
polyether macrolides displaying potent in vivo antitumour activity. As such, they 
represent important leads as potential anticancer dmgs. This research was focused on 
methodology that would enhance and complement the progress ofhalichondrins toward 
clinical trials. 
A method was established for transforming 53-methoxyneoisohomohalichondrin B, an 
ruiefact of the methanol extraction method, to the more useful isohomohalichondrin B. 
A by-product of this acid treatment was identified as the C38 epimer of 
isohomohalichondrin B. The equilibrium character of the C38 epimerisation was 
studied. 
The production of halichondrins by aquacultured Lissodendoryx sp. has been confirmed. 
Haptens presenting the macrocyclic portion of the halichondrins were produced using 
three different linkers PMPI, PMSI and EMCR. The chemistry required to selectively 
oxidise the C26 methylene was established. 
A polymer dmg conjugate incorporating a halichondrin species has been prepared. This 
required the modification of homohalichondrin B to form an amino halichondrin. 
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1.1 Natural Products as Potential Pharmaceuticals 
Williams l defines a natural product as a substance that has no knawn role in the 
internal economy of the producing organism. It is suggested that the ability to produce 
a battery of secondary metabolites (natural products) which interact with other 
organisms has evolved as one facet of the organism's survival strategy. Furthermore, 
all natural products have evolved under the pressure of natural selection to bind to 
specific receptors. 
It has been observed that natural products are common in organisms that lack an 
immune system. 1 The converse of this suggests that natural products will be sparse in 
organisms which possess an immune system. In the absence of an established immune· 
system plants, microorganisms such as fungi and at least the most primitive 
invertebrates have to rely on chemical defences to aid their survival. It is these natural 
products produced as defence chemicals that ofter a vast resource of potential 
pharmaceuticals. The best example of this resource of potential pharmaceuticals has 
been the sessile higher plants, from which a rich array of pharmaceuticals have been 
developed. Based on the currently accepted arguments l it can be suggested that these 
same plants are those that have evolved a range of metabolites as a chemical defence 
against parasites and predators. 
The search for new and improved pharmaceuticals is ongoing. There is an estimated 
worldwide incidence of six million new cases of cancer every year.2 Considering this 
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alongside the occunence of and the growing resistance of bacterial infections to 
present day antibiotics, the demand for new and efficacious phannaceuticals is 
Immense. 
The unique, varied and structurally complex nature of secondary metabolites make them 
an invaluable resource in the search for novel bioactive ~,",'.U'U. 
1 Marine Natural Products 
The majority of phyla and more than 90% of all classes of organisms are represented in 
the marine environment.3 Marine organisms thus provide a rich resource for the 
discovery of novel biologically active compounds. It has been estimated that 72% of 
known life fOHnS are from the Animal Kingdom.4 The overwhelming number of 
animals belong to the two insect phyla. However, the balance of the Animal Kingdom, 
representing ~ 20% of all known life fOHnS, are primarily aquatic, notably marine, in 
habitat. Of the twenty seven animal phyla, twenty are found in the marine 
environment. This distribution of animal phyla in favour of mainly marine benthic 
environments is illustrated in Figure 1 1. By sampling marine animals one is 
sampling from the most biodiverse source on Earth. 
The collection of marine organisms was limited to shore wading and shallow diving 
before the advent of SCUBA enabled greater access to the marine environment. This 
allowed collection of organisms down to depths of about 40 metres. Collection below 
this depth can only be achieved by dredging, which by its nature is non-targeted, or by 
using remote operated vehicles or specialist manned submersibles such as the Johnson 
Sealink. 
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Data from the National Cancer Institute (NCI) m the USA, compiled by Dr Peter 
Murphy of the Australian Tnstitute of Marine Sciences (AIMS) in 1992,5 further 
illustrate the value in screening marine natural products for potential pharmaceutical 
leads. The number of anticancer leads from various sources in the NCT's in vitro 
preclinical antitumour drug screen are displayed in Figure 1 The high propoliion of 
anticancer leads coming from marine animals relative to other sources is clearly 
illustrated. Australian results trom AIMS) indicate more specifically that the marine 
invertebrate phylum Porifera (sponges) provides a rich source of cytotoxic marine 
natural products, with greater than 11 % of specimens in this phylum displaying 
significant cytotoxicity. 
Absoll/te number screened in italics 
Terrestrial Animals 
Terrestrial Plants 
654{) 
rVlarine Animals 
rVlarine Plflnts 
Microorganisms 
a 2 
Percentage 
Figm'c 1.2.2 Percentage of Anticancer Leads with Significant Selective Cytotoxic 
Activity in the NCI Preclinical Anti tumour Drug Discovery Screen.s 
I Bioactivc Marine Nahantl Products 
The ara-nucleosides spongouridine (1.1) and spongothymidine (1.2) isolated from the 
Caribbean sponge CrJlplolhelhia cry pia in the early 1950s by Bergmani ) were among the 
('!tUfJle!' I -llllmelllelioll 5 
Ii !"st hio(1cLi ve marIne natural producls to be chmaclerised. The related cytosine 
arabinose (Ant-C) was eventually developed as a clinically useful anticancer drug. 
Ilowever lhe systematic invesllgaUon or marine environments as sources of novel 
biologically active agents only began in earnest in the mid 1970s.7 A review of the 
marine natural products liLerature up to early 19868 reported 185 bioactive compounds. 
i\ 1993 review by Scll mitz el al commented on an additional 400 compounds.') A 
surveyor MarinLit l1J reveals that this trend has continued with 46% of all cytotoxic 
compounds in the database having been reported since 1993. This overview will focus 
solely on promising allticancer compounds isolated from marine organisms. 
spongouridine (1.1) spongothymidine (1.2) 
No compound isolated from a marine source has yet reached clinical use as an 
anticancer agent, although several are in various stages of clinical testing. Didemnin B 
( 1.3), isolated from the lunicale Trididemnum so lidulll , was the tIrst marine-derived 
compound to enter elinical trials. I I Phase II clinical trials on didemnin B (1.3) were 
discontinued because of a failure to show reproducible activity against a range of 
tumours, while always exhibiting toxicity. A related compound, dehydrodidel1l11in B 
(1.4), isolated from the tunicate AplidiulIl albicans, is even more potent than didemnin 
8,12 This depsipeptide is currently in Phase I clinical trials in the US and Europe. 
( '/w/J/er / -- /1l/J'Odllc:liOI1 6 
clidemnin B (1.3) 
dehydrodidemnin B (1.4) 
A number of ecteinascidins have been isolated from the tunicate Ec/einascidia 
/lJrbina/a l ] including ecteinascidin 743 (1.5).14 This antimitotic agent exhibits 
significant in vivo activity against the murine B 16 melanoma and human MX -1 breast 
carcinoma models and is currently in Phase II trials in the US and Europe. 
ecteinascidin 743 (1.5) 
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A protein kinase C modulator isolated from the bryozoan Bugula neritina, blyostatin 1 
(1.6),15 showed promising activity against melanoma in Phase I trials. 7 This compound 
progressed to Phase II trials but was withdrawn in late 1998. 
o 
bryostatin 1 (1.6) 
Dolastatin 10 (1.7) was originally isolated from the sea hare Dolabella auricularia. 16 
The low yield (~ 1 mgll 00 kg wet weight) of dolastatins from this organism hindered 
the development of 1.7. However dolastatin 10 has since been synthesised,17 and has 
progressed to Phase I clinical trials. 
dolastatin 10 (1.7) 
Halichondrin B (1.8), initially isolated from the sponge Halichondria okadai in 1985,18 
and kahalalide F (1.9),19 isolated from a marine mollusc, are currently in preclinical 
development. Halichondrin B is an antimitotic agent, inhibiting the polymerisation of 
tubulin. 
('I/(IIJIe!' I 1I1II'odl/(;lioll 8 
halichondrin B (1.8) 
H2N~ ? ly 
Q, yl ~O 
,,(I'JH ~ NH ~ ~o-(:{,C 
o NH 0 HNfO oJ :~ NH 
nN 0 ~ NH ~Y-< Ho:t~iO 0 0 
\"NH ~ ~ 
o~ 
kahalalide F (1.9) 
A number of other compounds exhibit promising in vivo anticancer activity, 
Eleutherobin (1.10), isolated from the Australian soft coral Elellthel'obia sp., stabilises 
lllicrotubuies preventing tubulin depolymerisation, and is cytotoxic to cancer cells with 
an IC 511 similar to that of paclitaxeeo This compound has been synthesised by 
Nicolaou21 and Danishefsky,22 The sarcodictyins, isolated by Pietran from a soft coral, 
arc a related series or compounds that also act by stabilising microtubules. Sarcodictyin 
A (1.11) and B, and a library of analogues have been synthesised by Nicolaou,24 A third 
compound, discodermolide (1.12), also possesses tubulin stabilisation properties,25 
('hap/a I - In/roducthm 9 
Discodermolide (loU) was isolated from the deep water sponge Discodermia dissoluta 
by Gunasekera,2() 
°1°'(" 
"""~ 
OH 
OH 
0---\ OH OCH3~ 
° OAc 
eleutherobin (1.10) 
sarcodictyin A (1.11) 
OH 
-
OH 
c1iscodermolide (1.12) 
Isolated from the blue-green algae Nos/oc sp. GSV the cryptophycins27 are a family 
of c\epsipeptides showing highly potent cytotoxic activity. The recently synthesised 
cryptophycin I (L 13)2R acts as a microtubule poison. Interest in the compound has been 
heightened by the discovery that cryptophycin I (1.13) shows reduced susceptibility to 
the multidrug resistance pump, and shows no reduction of activity in a number of c1rug-
resistant cell lines.1!) Further examples of antimitotic marine natural products include 
curacin A (1.14), isolated by Gcrwick10 from the blue-green alga LynRhya maillscula, 
arenastatin A (1 isolated from the Okinawan sponge Dysidea ([renaria,JI and 
hemiasterlin (1. t (), isolated from Hemiaslel'ef/(/ minor by Kashman and coworkers . .l2 
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o 
cryptophycin 1 (1.13) 
S 
H N==( ./' 
H"\7"H 
curacin A (1.14) 
~ 0 
o I 6r O HNX""~ ~O HN 0 ~OCH ON 3 
arenastatin A (1.15) 
hemiasterlin (1.16) 
10 
The spongistatins, exemplified by spongistatin 1 (1.17), were reported independently by 
three research groups in 1993/3 and have since been synthesised by several groupS.34 
The spongistatins are potent antimitotic agents, acting at the vinca domain. 
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OH 
spongistatin 1 (1.17) 
Sponges35 
Sponges are members of the phylum Porifera ("pore-bearing"). They seem to have 
travelled an independent evolutionary route from other members of the animal kingdom 
and as such are sometimes placed in a subkingdom of their own, the Parazoa ("beside 
the animals"). Sponges differ from all other groups of invertebrates which occupy 
similar ecological niches in that they maintain an almost protozoan independence for 
their constituent cells, while at the same time ensuring that the entire cell mass pumps 
sufficient water to effect all essential exchanges.36 There are approximately ten thousand 
of sponge, grouped into four classes according to their skeletal structure. 
Sponges are benthic organisms that can be found in any situation, from upper intertidal 
to hadal depths (down to 8600m), in fresh and brackish water, in caves and in full 
illumination.3? 
Adult sponges are sessile hollow filter feeders. Water containing food patticles is drawn 
into the internal cavity of the sponge, the atrium, through numerous perforations known 
as incurrent pores. The water is strained of food particles and leaves the atrium through 
one or more large excurrent pores (osculum). The flow of water is maintained by a 
combination of the sucking effects of the flow of local currents across the osculum and 
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by the beating of protmding from the collars of choanocyies which line the 
interior cavi ty of the sponge. 
The sessile nature of sponges makes them a prime target for fouling or overgrowth by 
other organisms. Their continued existence points to the evolution of a complex 
chemical defense. 
1.2.3 The Group 
The Marine Chemistry Group at the University of Canterbury was formed in 1975. The 
prime objective of the Group was the isolation and identification of biologically active 
marine natural products.38 
The Group has an extensive and ongoing collection of New Zealand marine organisms. 
Extracts of two gram sub-samples of every organism collected are screened in the 
Maline Chemistry Group's in-house anti tumour, antiviral and antimicrobial assays. 
Organisms producing extracts that exhibit favourable biological activity are extracted on 
a larger scale. These bulk extracts undergo bioactivity-guided chromatographic 
fractionation to isolate the active components. The success of this approach is 
illustrated in Section 1.2.3 
1.2.3.1 The P388 Antitumour Assay 
The in vitro "antitumour" assay uses the P388 cell line (murine leukemia cells) and is up 
to a hundred times more sensitive to cytotoxicity effects than the antiviral 1 cell 
line. The P388 assay is therefore a cytotoxicity-based assay against a specific leukemia 
cell type. The 1C50 result obtained from this assay represents the concentration of the 
test compound at which the number of viable cells is reduced by fifty per cent relative to 
the control. 
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A two-fold dilution series of the sample of interest is incubated with P388 cells and 
MTT, a yellow tetrazolium salt, in small plastic wells. After seventy-two hours of 
incubation the concentration of the sample required to reduce the number of viable cells 
by fifty per cent relative to a control (P388 cells, MTT, media and solvent) is calculated. 
The mitochondria of viable leukemia cells reduce the yellow dye MTT to a purple 
formazan derivative. 39 By measuring the light absorbance at 540 nm in each well, a 
direct quantification of formazan formation and therefore the number of viable cells is 
able to be determined. The absorbance is expressed as a percentage cell viability 
relative to the control, and is plotted against the logarithm of the sample concentration 
in the well to generate a sample concentration vs cell viability curve. The antilogarithm 
of the concentration producing a fIfty per cent reduction in the number of viable cells 
gives the rC50 result, which is usually expressed in units of ng/mL. 
The P388 cell line represents a rapidly dividing cell type, thus its efficacy in finding 
products with activity against the predominantly occurring slow growing solid tumours 
such as lung, colon, breast, skin and kidney cancers is strictly limited.40 However, it is 
important to consider that a P388-active compound may still display selective activity 
against these types of turn our. 
1.2.3.2 The National Cancer Institute (NCI) Anticancer Screen 
An in vivo P388 murine leukemia screen was employed as the primary anticancer screen 
at the NCr from 1975 to 1985.41 In 1985 the NCr began investigating a disease-
orientated in vitro screen using a wide variety of human tumour cell lines because of 
concern that the P388 screen was only highlighting agents with activity against 
leukemia-type cancers. Routine operation of the in vitro screen began in 1990. In the 
primary screening, each compound is tested over a broad concentration range (five 10-
fold dilutions starting from 10.4 M) against each of the sixty cell lines in the paneL 
Three different target responses may be chosen to quantitate the data: by the G150, LC50 
or TGl response. The Gl50 represents the drug concentration producing an apparent 
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fifty per cent decrease in the number of tumour cells relative to an appropriate non-drug 
control at the end of the drug incubation.42 The LC50 is defined as the concentration of 
drug producing an apparent fifty percent reduction in the number of tumour cells in 
reference to an appropriate non-drug control at the start of the ineubation. The TGI is 
the concentration at which the number of tumour cells remaining at the end of the 
incubation is the same as at the beginning of the incubation. 
A mean-graph format can be constructed to display the data. This graph displays 
horizontal bars for each individual cell line for any of the desired target responses (for 
example, the negative 10glOTGI results) relative to the averaged response (negative 
10glOTGI) over all cell lines. The mean graph therefore provides a characteristic 
"fingerprint" for a given compound, depicting individual cell lines that are 
proportionally more sensitive than average (bars to the right of the average response) or 
less sensitive than the average (bars to the left of the average response). The mean 
graph for norhomohalichondrin B (4.17) is displayed in Figure 1.2.3. 
> 
•••• .. ~ ••••• w •••• ~ ... ~~··~·· 
Figure Mean Graph Profile for Norhomohalichondrin B (4.17) 
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Compounds that exhibit differential cytotoxicity for specific cell lines or panels in the 
screen are of most interest as they may represent a new class of disease-specific 
compounds and/or a new mechanism of action. The distinctive mean-graph 
"fingerprint" can also give an indication of the mechanism of action of a particular class 
of compounds. NCI developed a pattern recognition algorithm, COMPARE, that 
enables the evaluation of patterns of cytotoxicity against the 60 cell lines obtained ·with 
a test agent to be compared to those obtained with all other agents in their data base.43 A 
COMPARE correlation coefficient indicates the degree of similarity between the 
pattems of two agents. Seed compounds with known mechanisms of action can be used 
to predict the mechanism of action of test agents. For example, halichondrin B (1.8) 
correlated most closely to known antimitotic agents (see Section 1.2.4.2 for further 
discussion) . 
1.2.3.3 Bioassay-Guided Isolations 
Bioassay-guided isolation of the active components from the Otago Harbour sponge 
ivlycale sp. yielded mycalarnide A (L18) and mycalamide B (1.19).-14,45 The 
mycalamides exhibited antiviral activity but proved too cytotoxic to be effective ant-
viral agents. The mycalamides were also rejected as antitumour agents after in vivo 
trials highlighted problems with toxicity. 
R=H mycalamide A (1.18) 
R=CH3 mycalamide B (1.19) 
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The discorhabdins, a series of iminoquinones, were isolated from New Zealand species 
of the highly pigmented sponge Latrunculia.46.47,48 discorhabdins exhibited 
promising in vitro activity against the P388 cell line (in the order 0[20 ng/mL), but only 
discorhabdin D (1.20) exhibited (modest) in vivo activity (TIC 132% at 20 mg/kg).48 
discorhabdin D (1.20) 
Bioassay-guided purification of the active components from an extract of 
Lamellomorpha strongylata yielded calyculinarnides A (1.21) and B, swinholide 
(1.22), a mixture of the previously reported calyculins A, B, and F 49,5Q and a mixture , 
of theonellapeptolides. 51 The theonellapeptolides were subsequently characterised by 
Shangxiao Li.52 Swinholide H and the calyculinamides were shown to have differential 
antitumour activity against the NCI's 60 cell line primary screen. Theonellapeptolide 
HIe (1.23) exhibited modest in vitro cytotoxicity (7.4 ).lg/mL) against the P388 cell 
o 
~ /, 
N 
q'p-OH 
I "-HO 0." 
OH OH OCH3 
calyculinamide A (1.21) 
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swinholide H (1.22) 
theonellapeptolide lIIe (1.23) 
Bioactivity~guided fractionation of an extract of the Kaikoura sponge LissodendOlYx sp. 
yielded several members of the halichondrin family including halichondrin B (1.8). 
These potent antitumour polyether macrolides are discussed in more detail in Section 
1.2.4. 
1.2.4 The Halichondrins 
1.2.4.1 Discovery 
Norhalichondrin A (1.24) was the in a series of potent antitumour compounds 
reported by Uemura et al in 1985. 18 The isolation of a further seven halichondrins from 
the same Japanese sponge (Halichondria okadai Kadota) was subsequently reported in 
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1986.53 halichondrins: norhalichondrin A (1.24), Band C, halichondrin B (1.8) 
and C, and homohalichondrin A, B (1.25) and C represent three classes of halichondrin. 
The A, Band C families are distinguished by the ~_,.,~ __ of oxidation at C12 and Cl3 
(Figure 1.2.4). Within each family variation occurs beyond the C45 position. 
norhalichondrin A (1.24) 
H :: 
a~27# 0 G :: 22('" 25"CH3 
Illftl 
______ -,11 
halichondrin B (1.8) 
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9H3 
H 
-
H H 
0 0 M 55 0 N 47 
HO 0 
OH H H CH3 
homohalichondrin B (1.25) 
A family B family C family 
Halichondrin A, Band C Families 
The structures are characterised by a novel 2,6,9-trioxatricyclo(3.3.2.03•7]decane system 
(rings C-E), a 22-membered lactone ring (CI-C30), two exocyclic olefinic groups and 
several pyranose and furanose rings. 
Comparison of the cytotoxicity of all of the halichondrins isolated against the in vitro B-
16 melanoma cell-line (Table 1 1) showed that halichondrin B (1.8) was the most 
cytotoxic. Halichondrins with B-type C-E rings and homo- or hali-type terminal 
moieties gave the best results. 
('IWfJlcr I Il1troduction 
Tahlc I Cytotoxicity against 13-16 Melanoma cells (llg/mL) 
Compound ICso (ng/mL) 
IlomohaliclwlIlldn A 
Norhalicholldrin A (1.24) 
Ibllichondrin B (1.8) 
HOlllohalichondrin B (1 
Norhalichomldn B 
lIalichonddn C 
Iloll1ohalichonddn C 
Norhalichondrin C 
0.26 
5.2 
0.093 
0.1 
NR" 
0.35 
NR" 
NR" 
a Data not reported (NR) but result inferior to that for halicholldrin B.53 
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The in vivo antitumOLlI' activity of halichondrin B against B-16 melanoma, P388 
leukemia and L-1210 leukemia cell-lines was also determined. P388 leukemia infected 
mice treated with halichondrin B (1.8) experienced a 300% increase in median survival 
time relative to the control group. 
The isolation of halichondrin B (1.8) and hOl11ohalichondrin B (1.25) from an umelated 
sponge Axinclla sp" collected in Palau, was reported in 1991.54 Two new halichondrin 
compounds, halistatin 1 (1.26)55 and halislatin 2 (1.27),56 were reported by Pettit in 
1993. Halistatin 1 (1.26) is 10a-hydroxyhalichondrin Band halistatin 2 (1.27) is 10a-
hyciroxyholUohalichondrin B. Halistatin 1 (1.26) was isolated from an east Indian 
Ocean sponge Phakellia car/ert. Halichondrin B (1.8) and hOll1ohalichondrin B (1.25) 
were also isolated from this sponge. These three halichondrins were subsequently 
isolated from an extract of the Western Indian Ocean sponge Axinella cf. carleri Dendy 
together with balistatin 2 (1.27). Halistatin 1, halistatin 2 and halichondrin B were 
tested in the NCr's human tumour primary in vitro screen. The overall mean GI~(l values 
were 7.1 x to- Ifl M, 6.8 X 10- 111 M and 2.3 x 10-1(1 M respectively.56 
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halistatin 1 (1.26) 
frI H 43 
0 O~L M -
55 0 N :: 0 47 : 
37 
O~ 
II I A 15 H 
00· 
HO 0 
OH H H -CH3 
halistatin 2 (1.27) 
In 1987 halichondrin-like compounds were identified in two unrelated New Zealand 
species of sponge by Rob Lake. Trace quantities of halichondrins were detected in an 
extract of Ra.spalia agminata (order Axinellida, family Raspailiidae), a black shallow-
water sponge from the Leigh area of the North Island.57 A slimy yellow sponge 
obtained by benthic dredging (ca 100 m) ofT the Kaikoura coast was identified as one or 
more new species of the genus Lissodendoryx Topseht (class Demospongiae, order 
Poecilosclerida, family Myxillidae). 53 Kaikoura sponge is higher yielding (~ 1 mg 
total halichondrins/kg wet weight of sponge) than any of the other halichondrin-
producing sponges.53 ,54,55 
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A novel Iwliehondrin-type compollnd was isolaled by bioassay-directed fl'actionation of 
the first (smail) extract of LissodendOf)lX sp, Full characterisation of this compound was 
Ilot achieved. '7 Two olher Iwl ichondrins isolated iI'om the extract were identified as 
halidlolH.lrin B (1.8) ami hOlllohalichondrin B (1.25). A subsequent extraction of 
Lis,\'(){/elld(JI:Yx sp, by Marc LiLaudon yielded mg of the unidentified halichomlrin, 
This enabled lhe characterisation 01' the novel halichondrin using 2D NMR and MS 
lechniques, Isohomohalichondrin (1.28)59 was so named because it is isobaric to 
hOl11ohal ichondri n 13 (1.25). The diJlerence between the two compounds exists beyond 
('48, where isohol1lohalichondrin 13 (1.28) has the ring opened form of the terminal 
Ii.mlllosc unit of 1.25. 
11 
isohomohalichondrin B (1.28) 
A bulk extraction of co 200 kg of LissodendOlYx sp. yielded ha1ichondrin B (43 mg), 
IWl11ohalkhondrin B (45 mg) and isohomohalichondrin 13 (57 mg) together with 
110rhalichonclrin B (0.6 mg) and several novel minor halichondrin e0l11pounds. c1o Four of 
these minor compounds have been isolated and their structures established: 
Ilcol1orhalichondrin B (1.29, 0.9 mg), neohol11ohalichondrin B (1.30, 7 mg), 55-
methox y isohol11ohalichonclrin B (1.31, 0.7 mg) and 53-
I11clhoxyneoisohomohaiichondrin B (1.32, 15 mg). 
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neonorhalichondrin B (1.29) 
OH 43 
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53-methoxyneoisohomohalichondrin B (1.32) 
H 
During the investigations on 53-methoxyneoisohomohalichondrin B (1.32) it was noted 
that the IH NMR spectrum of a sample kept in CDCl3 without added CDsN slowly 
reverted to a spectrum characteristic of isohomohalichondrin B (1.28).60 In addition, a 
sample of 1.28 in CD30D was seen to revert over a period of time to 1.32. This would 
indicate that 1.32 is likely to be an artefact of the isolation process, where methanol 
used for both extraction and chromatography caused the conversion of 1.28 to 1.32. 
A compound isobaric with 1.32 was also isolated (1.33, 1.5 mg) from the Lissodendoryx 
sp. extract. Like 1.32, this compound was observed to revert to 1.28 in CDCI] solution 
(without added CD5N). The instability of 1.33 precluded the collection of a full set of 
spectroscopic data. The IH NMR spectrum of 1.33 was identical to that of 1.32 with the 
exception of resonances for H51 and 53-0CHJ , suggesting the structure to be 53 
methoxyneoisohomohalichondrin B. 60 
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53-epi-methoxyneoisohomohalichondrin B (1.33) 
The halichondrins isolated from LissodendolJ!X sp. were tested for antitumour activity in 
the Marine Chemistry Group's in-house P388 in vill'o murine leukemia assay, and 
against the NCI's 00 cell-line in vilm primary screen. The results are shown in Table 
1.2.2. 
Table 1.2.2 In Vitro Cytotoxicities of Halichondrins from Lissodendoryx sp. 
Compound P388 lCso 
halichondrin B (1.8) 
homohalicholldrill B (1.25) 
isohomohalichondrin B (1.28) 
I)orhalichondrin B 
IIcohomohalichondrin B (1.30) 
methoxyneoisohomohalichondrin B (1.32) 
methoxyisohomohalichonddn B (1.31) 
ncollorhalicholldrill B (1.29) 
(ng/mL) 
0.78 
0.18 
not recorded 
0.8 
0.1 
10.0 
0.4 
1.38 
3.16 
1.15 
29.50 
3.39 
2.00 
12.30 
Methoxyneoisohomohalichonurill B (1.32), isohomohalichondrin B (1.28) and 
neoholl1ohalichondrin B (1.30) have comparable cytotoxicities to those of halichondrin 
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B (1.8) and homohalichondrin B (1.25) in both assays. The NCr screen is relatively 
insensitive to neonorhalichondrin B (1.29) compared to the P388 cell-line. The opposite 
is true of methoxyisohomohalichondrin B (1.31), which exhibits comparable 
cytotoxicity to that of methoxyneoisohomohalichondrin B (1.32) in the NCI screen yet 
is a hundred-fold less active against the P388 cell line. 
Halichondrin B has since undergone further biological testing at the NCL It is highly 
potent and differentially active in the sixty cell line in vitro cancer screen run by the 
Development Therapeutics Program (DTP). Halichondrin B has been demonstrated to 
decrease tumour growth rates in several human tumour xenograft models, including 
LOX 1M IV (melanoma), NCI-H522 (lung), OVCAR-3 (ovarian) and MDA-MB-435 
(breast),61 and cUlTently has Decision Network IIA status with the NCI.62 The 
progression to Decision Network IIB status is unlikely to be made until arrangements 
for the purchase or supply of a bulk (10 g) quantity of the compound can be made. The 
implications of this are discussed in more detail in Section 1.2.4.3. 
1.2.4.2 Mode of Action 
An evaluation of the pattern of differential activity (mean-graph profile) of halichondrin 
B (1.8) against the NCI 60 human tumour cell line panel using the CO:rvtPARE43 
algorithm found that it most closely resembled those of the tubulin binding agents63 such 
as vincristine and taxol. This suggested that halichondrin B (1.8) was an antimitotic 
agent. 
Microtubules are tubulin polymers involved in many cellular functions including 
formation of the mitotic spindle required for chromosome segregation during cell 
division. Tubulin exists as a dimer consisting of IX and ~ subunits. Protofilaments are 
formed from the head to tail arrangement of heterodimers of IX and ~ tubulin, in the 
presence of guanosine triphosphate (GTP). These protofilaments group together to form 
a protein sheet that curls to form the microtubule.64 A third type of tubulin protein, y-
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tubulin is essential for microtubule growth in vivo. Two molecules of GTP are bound to 
the heterodimers, one of which is freely exchangeable with unbound GTP. It is widely 
thought that this exchangeable GTP molecule is involved in the regulation of tubulin 
function. 64 Microtubule destabilising agents tend to bind to the free dimer, preventing 
polymerisation. 
A signiiicant characteristic of a cancer cell is that it divides more frequently than a 
normal healthy cell. Since microtubules are involved in cell proliferation (mitosis), 
microtubule poisons are a potent tool in the fight against cancer. It should be noted that 
antimitotic agents interrupt microtubule assembly in all rapidly dividing cells. This 
indiscriminate action, typical of the current breed of cancer chemotherapeutics, IS 
responsible for the unpleasant side effects associated with cancer treatment. 
Drugs which bind to tubulin can be subdivided into separate classes depending on the 
effect that drug has on the binding of five well characterised tubulin binding agents to 
tubulin. The drugs are categorised depending on whether they prevent the binding of 
colchicine, the binding of the vinca alkaloids (vincristine and vinblastine) or the binding 
of rhizoxin and maytansine to tubulin. 64 Some drugs do not interfere with the binding of 
these agents, having affinity for a separate distinct region of tubulin. 
The vinca alkaloids vinblastine and vincristine, isolated from the periwinkle 
Catharanthus roseous, have been widely used as clinical agents in the treatment of 
leukemias, lymphomas and some solid tumours.64 Both these agents induce the 
destabilisation of polymerised tubulin by binding to a site recently localised on ~­
tubulin.64 The "vinca site" represents the region of tubulin where the vinca alkaloids 
and their competitive inhibitors (eg maytansine) bind. The peptide antimitotics 
dolastatin 10 and phomopsin A are non-competitive inhibitors of the vinca alkaloid 
binding to tubulin. This is interpreted as binding in a region physically near to, but 
distinct from, the vinca site. This site is termed the "vinca domain". 
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Investigations by Bai et al63 noted the accumulation of cells arrested in mitosis at 
cytotoxic concentrations of either halichondrin B (1.8) or homohalichondrin B (1.25) for 
L 121 0 murine leukemia cells in vitro. These compounds were found to inhibit the 
polymerisation of purified tubulin and microtubule assembly dependent on microtubule 
associated proteins. Halichondrin B was found to be a relatively weak inhibitor of 
tubulin polymerisation, despite its potent cytotoxicity. Bai63 speculated that tills was a 
reflection of either the highly efficient uptake of the drug or its intracellular metabolism 
to more potent compounds. Halichondrin B did not interfere with colchicine binding to 
tubulin, but was found to be a non~competitive inhibitor of the vinca alkaloid 
vinblastine. This suggested that halichondrin B was binding in the vinca domain of 
tubulin. Vinca domain drugs in11ibit tubulin-dependent GTP hydrolysis and also inhibit 
GTP/GDP exchange at the exchangeable nucleotide site of tubulin. Halichondrin B was 
found to inhibit net GTP hydrolysis and nucleotide exchange on tubulin. These 
observations verified the earlier COMPARE differential cytotoxicity analysis that the 
mode of action for halichondrin B was as an antinlitotic agent. 
Isohomohalichondrin B (1.28) has also been shown to break up the nlicrotubule network 
by direct interaction with tubulin, resulting in the decreased binding of GTP to the 
protein.65 Luduena et al66 suggest that halichondrin B (1.8) has a unique conformational 
effect on the tubulin molecule. 
1.2.4.3 Supply Issues 
The further preclinical development of halichondrin B (1.8) requires gram quantities of 
halichondrin B. The clinical use of halichondrin B would require ca 5 kg/year. This 
would necessitate the annual production and extraction of at least 5000 tonnes of 
LissodendOlYx Sp.68 The three main supply options are the harvesting of native sponge, 
synthesis of the target compound and sponge aquaculture. 
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Native 
The halichondrin material provided for testing to date has originated fi-om the extraction 
of native sponge. As mentioned previously (Section 1.2.4.1), LissodendOlYx sp. is high 
yielding relative to other halichondrin-containing sponges. Lissodendoryx sp. is, 
however, a rare water species found exclusively off the Kaikoura peninsula.67 An 
extensive environmental survey, conducted using an ROV and a benthic camera, 
established that the "sponge field" was only ~ 5 km2, with the mean biomass and 
abundance of sponge estimated to be 69 ± 21 g/m2 with 1.1 ± 0.1 individuals/m2 over 
the sponge field. 68 This survey gave a total estimate of LissodendOlJ'x sponge of 289 ± 
90 tonnes. 67,69 This result is significant, in that it means that the commercial supply of 
halichondrins from native Lissodendoryx sponge is not viable. 
Synthesis 
Halichondrin B (1.8) has received much attention due to its potent in vivo antiturnour 
activity. The scarcity of the material from natural sources has encouraged considerable 
synthetic effort in this area.70 The total synthesis of halichondrin B (1.8) and 
norhalichondrin B was achieved by Kishi and coworkers in 1991.71 
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,--- Yamaguchi lactonization 
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Figure 1.2.5 Strategic Couplings used in Kishi's Total Synthesis of Halichondrin B 
The strategically important couplings in Kishi's total synthesis of halichondrin B (1.8) 
are illustrated in Figure 1.2.5. The construction of the C13-C14, C38-C39 and C26-C27 
bonds was achieved by Nozaki-Hiyama-Kishi Ni(II)/Cr(II)-mediated coupling. This 
reaction was utilised several times in the synthesis. Yamaguchi lactonization was used 
to close the macrocycle. Simple sugars were used to provide ~ 50% of the stereo genic 
centres in halichondrin B. 
The major fragments utilised in Kishi's synthesis are shown in Figure 1.2.6. Fragment 
A was synthesised in eighteen steps from an L-ascorbic acid-derived lactone (fragment 
D). The synthesis of fragment B required fifty four steps from D-galactose glycal. 
Fragment C was obtained in sixteen steps from L-mannonic-y-lactone. Coupling of 
these fragments together via two Nozaki-Hiyama-Kishi (Ni(II)/Cr(U)) couplings and 
macrolactonisation followed by further manipulations gave halichondrin B (1.8) in ca 
120 steps. A twelve step synthesis of fragment C was reported in 1996.72 
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Figure 1.2.6 Major Fragments in the Kishi Synthesis of Halichondrin B (1.8). 
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It was recently reported that the right-half diol (1.34) exhibits the same activity pattern 
as the parent halichondrin B (1.8). The cytotoxicity of this truncated halichondrin was 
also within one order of magnitude of that exhibited by 1.8.73 This discovery has 
concentrated synthetic efforts on the C 1-C3 8 segment of halichondrin B. A new 
approach to C14-C38 segment was reported by Stamos et al in 1997.73 Although this 
strategy actually contains additional steps, it is an improvement in terms of a practical 
scalable synthesis. 
37 Cl HO : 
-
HO A 
right-half diol (1.34) 
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Significant contributions to the synthesis of halichondrin B have also been made by the 
groups of Salomon, Horita and Y onemitsu, and Burke.70 In some cases the synthesis of 
a particular halichondrin fragment is considerably more expeditious than in Kishi's total 
synthesis, but to date none of these fragments have been utilised in a total synthesis. 
Consequently it is difficult to comment on the viability of these approaches as a source 
of halichondrins. 
The commercial supply of halichondrin B (1.8) by total synthesis is clearly very 
lmlikely. However, the synthesis of the right-half diol (1.34) may offer the possibility 
of a commercially viable synthesis. 
Aquaculture 
The farming of marine organisms as a source of pharmaceuticals is still in its infancy. 
One success story is the aquaculture of Bugula neritina, a colonizing bryozoan, for the 
large scale production of the antitumour agent bryostatin I (1.6). It has been established 
that B. nerilina aquacultured by CalBioMarine Technologies off the southern 
Californian coast produces bryostatin 1 in comparable yield to the wild population.7 
The aquaculture of Lissodend01Yx sp. is currently being trialed by the New Zealand 
National Institute of Water and Atmospheric Research (NIWA). In a preliminary study 
explants of the sponge were relocated from the deep water off Kaikoura (ca 100 m) to a 
more accessible shallow water location in Wellington Harbour. These explants had at 
least doubled in size over four months at this site, and in some cases growth rates of up 
to 500% were recorded. 74 It was also noted that small samples that had broken off had 
recruited neighbouring sites.74 Further experiments were undertaken to establish 
optimal explant conditions and culture localities. It was quickly apparent that summer 
explants were not successful, with greater than 95% mortality.69 In contrast winter 
explants were generally successful, especially at greater depths, with impressive growth 
rates through to December, when a decline was observed as bryozoan overgrowth and 
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pathogen attack became excessive.69 critical temperature of 1SoC was identified, 
above which the sponges will not survive.69 
The aquacultured sponges are grown in a significantly different environment to their 
native habitat. It is therefore important to determine if the organism still produces the 
secondary metabolites of interest. Extracts of Lissodendoryx sp. grown by aquaculture 
at several different sites were investigated as part of this thesis (Chapter 3). 
Options 
Genome transfer to a vector appropriate for fermentation requires the identification of 
producing organism. This is not clear cut in the case of the halichondrins, with 
some thought that a symbiont could be responsible for their production. However, 
preliminary cell separation studies on Lissodendoryx sp. indicate that the halichondrins 
are associated with the sponge cells.75 It is hoped a cell separation study of 
Lissodendoryx sp. currently being undertaken in the Marine Chemistry Group will 
confirm this result. 
Sponge cell culture is also being investigated as a possible source of halichondrins. 
Attempts to develop long term, continuous cell lines from marine sponges are still very 
much in their preliminary stages. Indeed, it has recently been suggested that even the 
so-called long term cultures from several marine sponges are likely to be artefactual. 
The "sponge cells" that have been maintained in culture for an extended period of time 
have been identified as thraustochytrids. 76 
1.3 Immunoassay Development 
In addition to the supply problem, an impediment to further preclinical and clinical 
studies of halichondrin B (1.8) is the lack of an adequate assay method. The remarkable 
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potency of' halicholldrin B (1.8) and lhe chemical complexity of the sponge extracts 
impose demanding requirements on the sensitivity and specificity of an assay, 
TilL' hi l'iI'(} <lllliluillour Hclivily 01' halicholllirin 13 (Un imlicales lhal lhc dosage of' 
Iwl icllOndri n n will resul [ ill serul1I levels of 100 pg/mL or less. i ,) PIHIrmacokinctic 
sludies of halichondrin B and its metabolites will require a highly sensitive assay for 
determination of the parent drug and its major metabolites in serum and other body 
lluids. A highly sensitive assay is also required for the detection of contaminants in the 
drug preparation, such as other halichondrin congeners. 
The halichondrins do not possess a chromophore that can be readily exploited for 
detection by conventional UV or visible spectroscopic methods. HPLC with refractive 
index detection or UV detection at 199 11111 is the current detection method. This 
method requires several chromatographic steps prior to HPLC analysis, is time 
CO 11 Slllll ing, expensi ve, and not particularly accurate. The detection limit of HPLC 
nnalysis (> 0.01 mg/mL) cloes not meet the criteria of a suitable assay method for 
pharmacokinetic studies of halichondrin B (1.8). 
I Inmunoassays ofTer rapid, specific and cost-etTective means of identifying and 
quantitating trace amounts of biologically significant compounds such as proteins, 
hormones, peptides, drugs, pesticides and natural toxins in complex biological 
matrices. 77 Owing to the high antigen specificity of antibodies, crude biological extracts 
or t1 uids often require less purification prior to analysis. 78 
1.4 PoiY111er 
I Introd Ii 
The treatment of solid tumours USlllg conventional chemotherapeutics is often not 
possible because the toxic side effects of these <lntiproliterative drugs to surrounding 
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healthy tissue prevents administration of an efficacious dose. The polymer therapeutics 
approach of conjugating cytotoxic drugs to inactive polymers is providing a new class 
of anticancer agents that offer improved phannacokinetic properties and enhanced 
selectivity for twnour tissue. 
Ringsdorf first suggested the use of a water soluble polymer as a drug 
incorporating a biodegradable linker to facilitate controlled release of the drug at the 
tumour site in 1975.79 This area has been well studied since then, culminating in 
regulatory approval for two polymer-protein conjugates. conjugate of styrene-co-
maleic anhydride and the antitumour protein neocarzinostatin (S~'1ANCS) has been 
approved in Japan for the treatment of liver cancer. so In the USA, FDA approval has 
been granted for a conjugate containing the polymer poly(ethyleneglycol), (PEG)-L-
asparaginase, for the treatment of acute lymphocytic leukemia in children. so 
1 Definition 
A schematic of a polymer drug conjugate is shown III Figure 1.4.1. The major 
components of a polymer drug conjugate are the water soluble polymer, the 
biodegradable linker used to attach the drug, the drug itself, and an (optional) targeting 
residue. The specific requirements of the polymer, the linker and the targeting residue 
will be discussed in turn. 
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1.4.1 Features of a Polymer Drug Conjugate 
1.4.2.1 Polymer 
The polymer must be biocompatible. In other words it should not induce significant 
toxicity or immunogenicity. Unless the polymer is of sufficiently low molecular weight 
to permit excretion, the polymer must be biodegradable. Suitable functionality must be 
present within the polymer to permit conjugation to the bioactive agent via a linker 
whose chemistry does not impinge on the aforementioned requirement of. 
biocompatability. It is important that the polymer have sufficient drug carrying capacity 
for the potency of the drug to be delivered. From a commercial point of view the 
polymer must be amenable to economically viable production on a commercial scale, 
and must yield a well characterised, stable formulation that can be manufactured 
reproducibly and can be conveniently administered to patients.sl 
1.4.2.2 Linker 
The linker is required to be stable in circulation, enabling delivery of the drug 
specifically to the site of action. Once within the target cell, the . linker must be 
biodegradable in some manner. Linkers can be designed to cleave at a particular pH. 
Alternatively, the linker can be tailored for specific enzymatic cleavage. 
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1.4.2.3 Targeting Residue 
The incorporation of a targeting residue into the polymer dmg conjugate offers the 
possibility of targeting specific cell types. Carbohydrates, hormones and antibodies (or 
fragments there from) are used to direct polymer conjugates to specific cell subsets.82 
Targeting moieties coupled to HPMA copolymer conjugates include galactosamine, 
melanocyte-stimulating hormone, transferrin, and various monoclonal and polyc1onal 
antibodies. s3 An example of a polymer therapeutic incorporating galactosamine as a 
targeting residue is given in Section 1.4.5. 
The use of targeting residues is hindered by the lack of specificity of many so-called 
specific receptors or antigens. Many of the receptors proposed as candidates for specific 
cell targeting have a broad cellular distribution. This can result in the removal of a large 
amount of the polymer therapeutic from circulation prior to accessing the tumour by 
normal tissue-mediated uptake.S3 
Cellular Uptake 
The mechanism of cellular uptalce for polymer-bound dmg is contrasted with that of 
unbound dmg in Figure 1.4.2. 
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Figure 1.4.2 Comparison of Mechanism of Cellular Uptake of Free Drug and PDC 
Macromolecules such as polymer drug conjugates cannot enter cells by diffusion in the 
manner of unbound low molecular weight drugs. The nonnal mechanism whereby a 
polymer passes through the cell membrane is by the process of endocytosis. This 
represents polymer conjugate engulfment by an infolding of the plasma membrane. The 
initiation of endocytosis is influenced by several factors such as molecular weight and 
charge effects. 79 Endocytosis delivers the polymer conjugate to the endosomal and 
subsequently the lysosomal compartments of the cell. This offers two distinct methods 
for drug liberation. The drug linker could be designed to take advantage of the drop in 
pH that occurs (see Fi gure 1.4.2). Alternatively, the linker could be tailored to specific 
cleavage by lysosomal enzymes. 
1 effect 
The restriction of cellular uptake to endocytosis means that after intravenous 
administration the polymer drug circulates for longer in the blood stream. Consequently 
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[hc polymcr drug accumulates more errectively in tumour tissue relative to conventional 
low molccular weight chemotherapeutics, This phenomenon, discovered by Hiroshi 
Macda, is kl1owl1 as the enhanced pcrmeability and retention (EPR) effect. S•1 Figure 
1.4.J illustmles the two l11ain lflclors giving rise to thc EPR effect. The tUl110ur 
vasculaturc onen displays a discontinuous endothelium (ie is leaky) which allows 
macrolllolecular cxlravmmtiol1, Thc lack or clTcclivc lymphatic drainage within the 
tUIllOur leads to accumulation of the polymer therapeutic at the desired site of action. 
lower vasculature permeability 
in normal tissLie p [s [he 
PDe lhml escaping 
incomplete vasculature allows the 
PDC to escape into the tumour 
polymer drug conjugate 
poor lymphatic drainage in the tumour 
tissue leads to accumulation of POC 
Figul'e 104.3 Enhanced Permeability and Retention (EPR) Effect 
I HPlVlA Copolymer Conjugates 
N-(2-Hydroxypropyl)methacrylmllide (HPMA) copolymer conjugates have been studied 
extensively.BI HPMA is a biocompatible polymer originally developed as a plasma 
expandcr. 
Bioactive compounds (and targeting residues) containing an a111mo group can be 
conjugated to the reactive polymeric precursor in a simple aminolysis reaction. The 
antitu111011r agents are covalently bound to HPMA copolymers via peptidyl spacers 
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designed to limit drug release in plasma and serum, but be amenable to degradation by 
lysosomal proteases. 81 
Several compounds from this family are now in clillical study.85 PKI (1.35) is a simple 
HPMA copolymer conjugate containing the antitumour agent doxombicin bound to the 
polymer backbone by a Gly-Phe-Leu-Gly peptidyl spacer.85 Preclinical tests showed 
that PKI was 10 times less toxic than free doxorubicin and displayed improved 
antitumour activity, particularly in solid tumour models.85 Phase II trials are currently in 
progress. 
o OH 0 
PKI 
An HPMA copolymer conjugate containing doxorubicin and employing the targeting 
residue galactose, PK2 (1.36) localises a large percentage of the doxombicin dose in the 
liver.85 It is hoped that this copolymer conjugate, currently in Phase I clinical testing, 
will be useful in the treatment of primary and secondary liver cancer. 
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1.5 Proj ect Aims 
The main focus of this thesis was the further development of the halichondrins with 
respect to their clinical viability. The importance of halichondrin B (1.8) as a potent in 
vivo anti tumour agent is well established. Any modification to the halichondrins that 
improves their pharmacokinetic properties, increases selectivity, and reduces the 
required plasma concentrations has to be regarded as advantageous. 
The development of a polymer therapeutic was viewed as a means of improving the 
chances of the future clinical development of halichondrin B (1.8). To this end, the 
development of a synthetic route to a halichondrin amine from homohalichondrin B 
(1.25) formed a major part of this thesis. 
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An selective and sensitive detection halichondrin assay would be required 
should halichondrin B (1.8) advance to clinical testing. The fom1ation of haptens 
designed for antibody recognition of the macrocyclic portion of the halichondrins was 
undertaken. Presentation of the terminal end of the halichondrins giving rise to 
congener specific antibodies necessitated attachment of a linker somewhere in the 
lactone portion of the halichondrin skeleton. An important aspect of this thesis was the 
development of chemistry to facilitate the selective oxidation of one of the two 
exocyclic oietinic groups thus providing a functional group conducive to linker 
attachment 
Aquaculture seems to be a promising prospect for overcoming the problem of bulk 
supply of halichondrin B. It was important to establish if Lissodendoryx sp. grown by 
aquacultme still produced the desired halichondrins. The investigation of sponge grown 
in aquaculture for halichondrin content formed another aspect of this project. 
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2.1 Introduction 
Halichondrin-like species were first isolated from LissodendOlJlX sp. in 1985 by Rob 
Lake. s7 Extraction of further material by Marc Litaudon enabled the structural 
assignment of one of these halichondrin species as isohomohalichondrin B (1.28).86 It 
\"'as found that this compound, if left in an NMR tube in deuterated methanol for several 
weeks, translormed itself into another compound 53-methoxyneoisohomohalichondrin 
B (1.32). This transformation was characterised by the shiH of the H47 resonance from 
(SI' 3.27 to 811 3.25 (in CD]OD) and the change in position of the resonances for 
methylenes 52, 54 and 55. At ambient temperature the transformation was complete in 
It was subsequently ascertained that this was transformation of 
isohomohalichondrin B (1.28) to the cyclic methoxy acetal 1.32. 
A joint venture between NIWA, New Zealand Pharmaceuticals and the Marine 
Chemistry Group was set up in 1994 to undertake the collection and extraction of one 
tonne of LissodendOlJlx sp. with the aim of supplying a quantity of halichondrin B (1.8) 
to the National Cancer Institute (NCl) for preclinical trials. The extraction and 
purification of 1.8 was undertaken by NZ Pharmaceuticals with technical support in the 
lorm of P388 assays <md 'H NMR spectroscopy provided by the Marine Chemistry 
Group. A total of 310 mg of halichondrin B was supplied to the NCI for lise in in vivo 
testing. All the side fractions from the purification of halichondrin B (1.8) were the 
property of the Marine Chemistry Group. Some of the hOll1ohalichondrin B (1.25) 
isolated from these side fractions was Llsed in the experimental work described in this 
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thesis. The isohomohalichondrin B (1.28) was supplied to PharmaMar, who hold the 
patent for 1.28 and were partners in the joint venture. 
Fractions containing isohomohalichondrin B (1.28) were identified by comparing their 
HPLC chromatograms to those of authentic standards, and by characteristic IH NMR 
resonances. Gel permeation chromatography on LH20 eluted with CH2Cl2 was utilised 
to concentrated fractions of 1.28. Analysis of the fractions from the LH20 
chromatography by reverse phase (CIS) HPLC indicated that, in addition to 
isohomohalichondrin B (1.28), a significant amount of a less polar halichondrin was 
present. A characteristic methoxy singlet at OH 3.23 in the I H NMR spectrum of some of 
these fractions confirmed the less polar component was 1.32. An improved yield of 
1.28 would be possible if the equilibrium position between these two halichondrins 
could be controlled in favour of 1.28. 
The previously observed interconversion of 1.28 to 1.32 in deuterated methanol, but not 
in deuterated chloroform containing 0.1 % d5-pyridine, gave an indication as to the 
equilibrium relationship between these two compounds. It had also been noted that the 
IH NMR spectrum of a sample of 1.32 kept in a CDCl3 solution (without added CsDsN) 
slowly reverted to a spectrum characteristic of isohomohalichondrin B (1.28).86 It was 
thought the addition of acid would facilitate the rapid attainment of equilibrium between 
1.28 and 1.32. 
treatment of halichondrins with acid had to be approached with some care, as a 
of reactions by Joanne Hart had illustrated the vulnerability of halichondrins 
under acid conditions. 87 Treatment of homohalichondrin B (1.25) with 1.7 equivalents 
ofTFA resulted in both furan formation, as a consequence of the opening of ether bonds 
at positions 9 and 1 and/or epimerisation at C3S, shown for epi-homohalichondrin B 
furan 87 The equilibrium relationship between some of these acid products was 
demonstrated. Homohalichondrin B (1.25) was shown to be stable to treatment with 
one equivalent of pyridinium p-toluene sulfonate (PPTS), as long as reaction times were 
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less than 72 hours. Treatment of 1.25 with a large excess of p-toluene sulfonic acid 
(PTSA) in CH2Cl2 for 48 hours had no affect. 
CH3 
HO 
o H H a 4Jd~ " 
o N ~LO~9 0 
47 - H A 34 A 
H 
55 
OH 
epi-homohalichondrin B furan (2.1) 
2.2 Formation and Isolation of2.2 
Conversion of 1.32 to the more desirable isohomohalichondrin B (1.28) was attempted 
using dilute HCI04• The conversion was initially followed by reverse phase (C 18) 
analytical HPLC. A 100 flg fraction containing a mixture of 1.28 and 1.32 was treated 
with 5:1 CH3CNIHCI04 (120 flL, 0.035%). After 5 minutes, analysis of a 20 flL aliquot 
revealed the total absence of 1.32 in the sample. A short reaction time was preferential 
as further reaction resulted in the formation of another compound of similar polarity to 
1.32. 
The reaction was repeated on a 1 mg scale to allow confirmation by IH NMR analysis. 
The reaction was halted after 5 minutes by diluting the sample with H20 and applying it 
to a reverse phase (C 18) cartridge. The acid was washed through with H20 and the 
, 
product stripped with CH3CN and CH2CI2. An increase in intensity of the characteristic 
triplet resonances of H54 and H55 of isohomohalichondrin B (1.28), a clean methyl 
region, and the absence of a methoxy singlet in the IH NMR spectrum of the product 
confirmed the transformation of 1.32 to 1.28. 
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The reaction was scaled up for the conversion of Imger amounts (200 mg) of 1.32 to 
1.28. The same concentration of acid (0.035%) was used as for the NMR trial. HPLC 
analysis of the product showed that in addition to the expected 1.28, there was a second 
component 2.2 of similm polmity to 1.32. The lack of a methoxy resonance in the lH 
NMR spectrum confirmed the component was not 1.32. However, many resonances 
characteristic of the halichondrins were observed. 
Conversion of a mixed sample of 1.32 and 1.28 to purely 1.28 was attempted, again 
using 0.035% HCI04. The reaction time was reduced from 6 minutes to 1 minute, and 
the sample was loaded onto a C 18 cartridge as quickly as was possible. The HPLC 
chromatogram of the product indicated that only 1.28 was present. This was supported 
by the lH NMR spectrum of the product, which was compmable to the lH N:tvIR 
spectrum of a standard sample of 1.28. 
Reverse phase (C18) HPLC (90% CH3CNIH20) was utilised to sepmate 2.2 (4.0 mg) 
from 1.28 (2.2 mg). 
2.3 Structural Elucidation 
The UV spectrum of 2.2 (eluting off the analytical C 18 column at ca 1000 s in 90% 
CH3CN/H20) indicated this compound contained no UV chromophore, with end 
absorption at A 193 nm; a UV spectrum identical to isohomohalichondrin B (1.28). 
High resolution F ABMS gave a parent ion corresponding to a molecular formula of 
C6oH86019' isobaric with that of 1.28. 
The lH NMR spectrum of2.2 is displayed in Figure 2.3.1. The absence of resonances at 
8H 5.95 and 8H 6.19 together with the lack of a UV chromophore was indicative that a 
furan-type species, as observed in the homohalichondrin B series upon acid treatment,87 
had not been formed. A comparison of this spectrum with the IH NMR spectrum of 
1.28 showed some differences. The doublet resonance of CH3-42 had merged with that 
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of CH3-31, the H32 resonance had moved upfield ca 8H 0.1 and the isolated H41 triplet 
resonance was no longer evident. 
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A full array of NMR experiments were performed on 2.2 viz COSY, 2D-TOCSY 
(mixing time 80 ms), HSMQC, HIVIBC, NOESY and APT (Figure 2.3.2) experiments. 
These data enabled the assignment of the majority of the lH and all of the 13C NMR 
spectral data of 2.2 to be achieved. The 'H and l3C NMR data are collated in Table 
2.3.1 and Table 2.3.2 respectively, and the important correlations from the 2D 
experiments are shown in Figure 2.3.3. 
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Table 2.3.1 IH NMR Data for epi-Isohomohalichondrin B (2.2) 
Proton" o ppmb Proton" o ppmb Proton" o ppmb 
H2 2.37 H21 1.40 H39 2.03 
H2' 2.59 H21' 1.87 H39' 2.30 
H3 3.88 H22 1.62 H40 3.93 
H4 1.39 H22' 1.62 H41 3.84 
H4' 1.76 H23 3.51 H42 2.25 
H5 1.39 H24 1.05 CH3-42 0.99 
H5' 2.11 H24' 1.74 H43 1.37 
H6 4.34 H25 2.20 H43' 1.48 
H7 2.94 CH3-25 1.07 H45 1.37 
HS 4.31 26=CH2 4.76 H45' 1.49 
H9 4.06 26'=CH2 4.81 H46 2.10 
HI0 4.19 H27 3.52 CH3-46 0.91 
Hll 4.60 H28 1.94 H47 3.23 
H12 4.68 H2S' H48 3.71 
H13 1.95 H29 4.20 H49 1.84 
H13' 2.13 H30 4.66 H49' 2.13 
HI5 1.62 H31 2.04 H50 3.51 
H15' CH3-3I 0.99 H5I 3.81 
H16 1.41 H32 3.12 H52 2.62 
H16' 2.17 H33 3.77 H52' 2.93 
H17 4.09 H34 2.06 H54 2.73 
HI8 2.26 H34' 2.25 H54' 2.73 
H18' 2.80 H35 4.07 H55 3.83 
19=CH2 4.92 H36 4.14 H55' 3.83 
19'=CH2 4.99 H37 2.24 
H2O 4.38 H37' 2.24 
a Tile symbol' represents the less shielded proton of a geminal pair. 
b Data recorded at 23°C in CDCI) at 300 MHz with chemical shifts in ppm and referenced to CRCI), OH 
7.26. 
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DC NMR Data for epi-Isohomohalichondrin B (2.2) 
<5 ppm" Carbon <5 ppma 8 ppm" 
170.9 C2l 29.4 C39 44.6 
40.4 C22 32.1 C40 71.8 
C3 73.7 C23 74.9 C41 78.3 
30.7 C24 43.3 .4 
30.1 C~CH3-25 36.0 C-CH3-42 17.8 
C6 68.2 C-CH3-25 18.1 C43 36.9 
C7 77.7 26C==CH2 15l.7 C44 97.0 
CS 74.3 26C=CH2 103.9 C45 37.4 
C9 73.8 C27 73.4 C-CH3-46 
CIO 76.5 C28 36.9 C-CH3-46 17.0 
1 82.0 C29 71.2 C47 
Cl2 81.0 C30 77.1 C48 66.3 
Cl3 48.4 C-CH3-3I 36.3 C49 34.4 
C14 110.0 C-CH3-3I 14.9 C50 66.3 
34.4 C32 77.3 C5I 76.4 
CI6 28.2 C33 67.2 C52 
CI7 75.2 C34 29.7 C53 210.4 
CIS 38.7 C35 77.2 C54 46.0 
151.3 C36 76.8 C55 57.9 
I9C=CH2 104.3 C37 44.0 
C20 .2 C38 113.9 
a Data recorded at 23°C in CDCl) at 75 MHz with chemical shifts in ppm and referenced to CHCll , Oc 
77.0. 
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The COSY 
The homonuc1ear COSY (COrrelation SpectroscopY) experiment was the tint 
experiment used for the assignment of the protons in the NMR spectrum of epi-
isohomohalichondrin B (2.2). From the COSY experiment, correlations between 
adjacent (geminal and vicinal) protons can be observed. of the coupling 
between protons is reflected in the intensity of correlation observed in the COSY 
spectrum. This is particular relevant to the assignment of NMR spectra of 
halichondrins. The halichondrin skeleton contains several cis fused rings. The coupling 
between protons at these ring junctions is small, and as a consequence COSY 
correlations between such protons are not always observed. 
The use of the COSY experiment is illustrated in the assignment of the H2/2'-H13/13' 
protons (Figure 2.3.4). The isolated proton resonance of HI 1, and the partially obscured 
H7 and H2' protons provided a starting point for the assignment of the spin system. A 
correlation was observed between H11 and two methine protons HIO (OH 4.19) and H12 
(OH 4.68). The H12 proton was coupled to one ofthe C13 methylene protons, H13 (OH 
1.95). This proton, in tum, was coupled to the geminal H13' proton (OH 13). Moving 
back around the spin system, the HI 0 proton was coupled to H9 at OH 4.06. Coupled to 
the H9 proton was the H8 proton at OH 4.31. From the H7 proton a single correlation 
was seen to a methine proton. From this correlation, there were observed correlations to 
a me thine proton (H9), and to methylene protons (H5, 0H 1.39 and , OH 2.11). The 
observation of a single correlation from H7 was due to the similarity in chemical shift of 
the H8 (OH 4.31) and H6 protons ()H 4.34). The overlapping nature of the methylene 
region of the COSY spectrum made it impossible to observe the correlations between 
the methylene protons of C4 and C5. Working back toward H5 from , an intense 
correlation was observed between the H2' proton (OH 2.59) and the geminal H2 proton 
(OH 2.37). A correlation was also observed from the H2' proton to a methine proton (H3, 
0H 3,88). In tum, the H3 proton was correlated to another methylene proton (H4, OH 
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1.39). remammg protons m the CI-Cl4 spm system were assigned from the 
TOCSY spectrwn. 
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Figure 2.3.4 COSY Spectrum of epi-Isohomohalichondrin B (2.2) 
Experiment 
The TOCSY (TOtal Correlation SpectroscopY) experiment is an extension of the COSy 
experiment that allows the connectivity of protons within a spin system to be probed. 
The appearance of a TOCSY correlation is dependent on the magnitude of the coupling 
constant for the transfer of magnetisation through the spin system. The length of the 
mixing time, during which the magnetisation is transferred, also has an effect on the 
TOCSY signal. A longer mixing time will allow transfer of magnetisation further 
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through a spin system, but the advantage of this has to be weighed against a decrease 
the signal to noise ratio as relaxation occurs. 
The 2D-TOCSY spectrum for epi-isohomohalichondrin B (2.2) is displayed in Figure 
.5. The assignment of the CI-C14 spin system is used once more to illustrate the use 
of the TOCSY experiment in the assignment of the IH NMR spectrum of2.2. 
Looking along the HII cross section (Figure 2.3.6), correlations can be seen to HI2, 
H8, HlO, H9, H13' and H13. From both H7 and H2' TOCSY correlations are seen to 
H5' (8H 2.11), H4' (8H 1.76) and a methylene proton at 8H 1.39 (H4 and HS). 
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Figure 2D-TOCSY Spectrum of epi-Isohomohalichondrin B (2.2) 
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Figure Cross-section of 2D-TOCSY Spectrum through HII 
The 1 D-TOCSY is a related experiment that is performed by selectively irradiating 
individual signals in the IH NMR spectrum. Generally this experiment requires the 
signals to be isolated, but it may be possible to dereplicate a ID-TOCSY obtained by 
the irradiation of two overlapping signals. The 1 D-TOCS Y spectrum is essentially the 
same as a cross-section through the 2D-TOCSY spectrum. The major advantage of the 
ID-TOCSY experiment is the reduction in time required to obtain a given signal to 
noise ratio. The resolution, and hence coupling information, of the ID-TOCSY 
experiment is superior to that of the 2D-TOCSY experiment. An array of mixing times 
may be used for a given irradiated proton to give a range of ID-TOCSY spectra that 
enable a picture of the connectivity relative to the irradiated proton to be established. 
An example of the ID-TOCSY experiment with variable mixing times is given in 
Section 6.3 
The HSQC Experiment 
The HSQC (Heteronuclear Single Quantum Coherence)experiment is a proton-detected 
experiment that indicates carbons directly attached to protons. This experiment was 
particularly useful in the indirect assigmnent of the 13C spectrum of halichondrin 
derivatives where there was inadequate mass for a 13C or APT spectrum to be obtained. 
The HSMQC (Heteronuclear Single and Multiple Quantum Coherence) experiment was 
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used to obtain the same one bond carbon to proton information as the HSQC experiment 
for some of the earlier work described in this thesis. 
Con-elations to methylene protons in the COSY and TOCSY spectra are sometimes 
difficult to see due to the complex, overlapping nature of this region of the spectrum, so 
the HSQC experiment gives a useful indication of the chemical shift equivalence or 
otherwise of methylene protons. In the assignment of epi-isohomohalichondrin B (2.2), 
the HSMQC experiment showed that the C39 carbon was correlated to methylene 
protons of distinct chemical shift (OH 2.03 and OH 2.30), whereas the protons con-elated 
to the C37 carbon had equivalent chemical shifts (OH 2.24) (Figure .7). 
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Figure 2.3.7 HSMQC Spectrum of epi-Isohomohalichondrin B (2,2) 
The HMBC Experiment 
20 10 
The HMBC (Heteronuclear Multiple Bond Coherence) experiment shows con-elations to 
carbons two and three bonds removed from a proton. This experiment is useful in 
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establishing cOlmectivity. In cases where there was insufficient material for obtaining a 
DC spectmm, this experiment offered the only means of assigning the lJC chemical shift 
of the non-protonated carbons of the halichondrin skeleton, viz the lactone Cl, and the 
spiro ketal C 14, C38 and C44 carbons. HMBC correlations traverse heteroatoms, which 
is particularly useful in the case of the halichondrins for the observation of three bond 
correlations through ether bonds. The HMBC spectmrn of epi-isohomohalichondrin B 
is displayed in Figure 2.3.8. 
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Figure 2.3.8 HMBC Spectrum of epi-Isohomohalichondrin B 
A cross section through the quaternary C14 carbon shows correlations to H12, H11 
(through oxygen), H8, 13' and H13 (Figure 2.3.9). The HSQC and HMBC 
experiments are run using a narrowed carbon window to reduce the time required to 
obtain the equivalent signal to noise ratio. A reasonably wide window was used for 
acquiring the HMBC spectrum of but the typical spectral window used was Dc 80 to 
Chapter 2 epi-Isohomohalichondrin B 
Oc 10. Conelations to the lactone carbon (CI, Oc 170.9) from H30, 
as a foldback to Oc 60.9. 
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Figure 2.3.9 Cross-section ofHMBC Spectrum through C14 
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Using the experiments described above to assign the IH and l3C NJ:v1R spectra of 2.2 it 
was possible to confinn the connectivities and NMR shifts around the CI-C30 and C47-
C55 regions were identical to those of 1.28. A COSY correlation from the isolated H32 
resonance to OH 3.78 allowed the assignment of the chemical shift of the H33 proton. A 
correlation to OR 2.06 in the COSY spectrum from the H33 resonance allowed the 
assignment of the chemical shift of the H34 proton. The chemical shift of the H34' 
proton (OR 2.25) was assigned from a correlation in the COSY spectrum from the 
geminal H34 resonance. From the and the H33 proton resonances a correlation 
was seen in the 2D TOCSY spectrum to OH 4.07. This resonance was assigned to the 
H35 proton. An HMBC correlation from the C38 spiro carbon resonance (oc 113.9) to 
OH 4.14 allowed the assignment of the chemical shift of H36. Further HMBC 
correlations were observed from C38 to H35, H40 and to unassigned proton resonances 
at OH and OH 2.30. In the HSQC spectrum, the proton at OR 2.30 and another 
resonance at OR 2.03 were correlated to a carbon at Oc 44.6. A COSY correlation from 
the H40 resonance (OR 3.93) to OR 2.30 allowed the assignment of H39' and hence of 
H39 (OR 2.03). The remaining resonance (OB 2.24) was attributed to H37. A COSY 
correlation from the H40 resonance to a proton resonating at OII 3.84 allowed the 
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assignment 01' the chemical shin of the 1-141 methine proton. A correlation from the 
C Hl-42 resonance to a proton resonating at 811 2.25 allowed the assignment of the 
chemical shin or the H42 proton. The 2D-TOCSY showed correlations from the H41 
IllClhine resonance to prolol1s resonating at 011 1.37 and 011 1.48. These resonances were 
assigned to the H43 and H43' protons. An HMBC correlation 11'0111 the C44 spiro 
carbon to this pair of methylene proton resonances supported this assignment. A COSY 
correlation rrom the ClJ l -46 (0.91) resonance to DB 2.10 allowed the assignment of the 
cllemical shift of H46. H45 and H45' were assigned from the observation of a 
correlation 1'1'0111 811 0.91 (CHl-46) to Dll 1.37 and Dll 1.49. 
The assigned NMR data for were compared to those of 1.28.59 Significant chemical 
shiH differences (2:: 811 0.5) were observed for most protons in the region of C32-C46. 
Carbon chemical shift differences were centred on C38. 
In terms of specitic chemical shift differences, the H41 proton (DII 3.84) exhibited a 
large downfield shift of DI1 0.20 relative to 1.28. The H39 (DH 2.03) and H39' (Dll 2.30) 
protons appeared as two separate resonances. This was in contrast to the H39/H39' 
methylene pair of 1.28 that had a chemical shift of DII The converse was true of 
the H37/H37' methylene pair. The H37 and H37' lH NMR resonances of were 
equivalent (Dll 2.24) whereas they appeared as separate signals (DlI 1.92 and DB 2.37) in 
the 1 H NMR spectrum of isohomohalichondrin B (1.28). The C38 spiro carbon 
exhibited a change in DC NMR chemical shift of 8e 1.5 downfield. 
The observed changes in 'H and DC NMR chemical shifts described above are 
consistent with epimerisation at C38 to give epi-isohol11ohalichondrin B (2.2). 
('lwpler 2 epi-/so/iolllolwiid1OI1drin B 59 
epi-isohomohalichondrin B (2.2) 
2.4 Acid Equilibria 
The equilibrium character of the C38 epimerisation was investigated. It was envisaged 
the addition of a trace amount of acid would catalyse the rapid achievement of 
equilibrium between 2.2 and 1.28. The determination of the position of equilibrium 
between 1.28 and was desirable, as it would allow the possibility of obtaining 
rurther 1.28 to be assessed. 
Treatment of 2.2 with HCl04 (0.035%) was monitored by reverse phase (CI8) HPLC, 
eluted with 90(Yo CH,CN/I-I20. The relative amount of 1.28 in the sample increased to a 
maximum or 50(% ailer 3 hours. Analysis of the reaction after 4 hours conf1nned the 
equilibrium ratio of 1.28:2.2 was 1: 1. The acid conditions were apparently not strong 
enough to cause opening of the trioxadecalin ring system as observed in the earlier work 
011 homohalichondrin B.87 
2.5 Biological Activity 
The biological activity of was evaluated in the in vitro P388 assay. Control samples 
of 1.28 and were assayed in the same batch to allow a valid comparison of activity 
('/JUfJtel' 2 - epi-iso/7oI110/1Olichondl'in B 60 
dutu. These data are cited in Table 2.1 along with those for the equivalent acid products 
in the hOl11ohalichonclrin B series. 
Table 2.1 Cytotoxicity of Related [-[alichonclrills 
Compound 
isoho1l1ohalichonclrin 8 (1.28) 
53 -methoxyneoisohomohalichondrin B (1.32) 
epi-isohomohalichondrin B (2.2) 
h01l1ohalichondrin B (1.25) 
epi-homohalichondrin B (2.3) 
P3881C5o (ng/mL) 
0.20 
2.9 
3.4 
0.22 
15.0 
From the above data it can be concluded that epimerisation at C38 has a detrimental 
affect on the cytotoxicity of the haJichondrin series. The C38 epimer 2.2 is 17-fold less 
active relative to the parent 1.28. This reduction in cytotoxicity is similar to the 
equivalent result for the homohalichondrin B epimer 2.3 and the parent 
homohalichondrin B (1.25). 
2.6 Discllssion 
Conditions for the conversion of 1.32 to 1.28 have been established. It was found that 
the most important consideration was the time of acid contact with the halichondrin 
mixture. The largest scale reaction was performed using the same overall concentration, 
but less molar equivalents of perchloric acid than the NMR trial reaction and a 
subsequent successful reaction. The notable difference was re'action time and the time 
taken to load the diluted reaction mixture onto a larger CI8 column. Subsequent large 
scale (cu 100 mg) transformations utilised a 1 g reverse phase (C 18) cartridge for acid 
removal. SH This allowed the diluted reaction solution to be loaded rapidly onto the C 18 
column and the acid washed out with water. The epimer 2.2 was fully characterised, 
and the equilibrium relationship between 2.2 and 1.28 established. 
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3.1 Introduction 
The options for halichondrin B supply are collection of native sponge, synthesis or 
aquaculture. The native supply of Lissodendoryx sp. is inadequate to cater to the needs 
of clinical supply in a sustainable manner. As yet synthesis is not a commercially viable 
option for the production of halichondrin B for clinical use, although efforts in this 
direction are ongoing.73 The aquaculture of Lissodendoryx sp. appears to be the most 
viable method of producing the quantities of halichondrin B required should it enter into 
clinical use as a chemotherapeutic agent. 
Sponge aquaculture has been recorded as early as the 18 th century in the 
MeditelTanean. s9 However sponge aquaculture for the production of biologically active 
metabolites is still in its infancy. Sponge cultivation essentially consists of cutting 
pieces from a sponge and attaching these explants to some type of submerged anchor to 
allow regeneration to occur. Factors affecting sponge growth include depth, light 
intensity, temperature, water movement and nutrient conditions.90 
The successful aquaculture of Lissodendoryx sp. by NIW A is discussed In Section 
1.2.4.3. The investigation and quantification of halichondrin content in Lissodendoryx 
sp. grown in aquaculture is presented in this chapter. 
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3.2 Sponge Production 
Sponge expJants were grown in the Marlborough Sounds (Beatrix Bay) and Banks 
1'<.:lIillsula (I\karo<l). I\t each location two silcs, between lilly lo one hundred metres 
apart, were used. Sponge samples were grown in tiered lanterns at shallow (-5 to -7 111), 
mid depth (-10 to -15 111) and deep (-25 Lo -30 111) positions. Sixty nine sponge samples 
classified in terms of site number, depth and tier were harvested from the aquaculture 
si les at Beatrix Bay and Akaroa. To allow halichondrin detection to be feasible, the 
samples were combined on the basis of depth at each of the two sites, giving tlu-ee 
BeaLrix Bay samples (shallow, mid depth and deep) and two Akaroa samples (shallow 
and deep). 
3.3 Extraction and Purification 
Each of the five sponge samples was blended with MeOH, stirred overnight, filtered, 
and then repeatedly extracted with MeOH. The MeOHIH20 ratio was adjusted to 4:1 
before partitioning against petroleum ether (PE). With the exception of the Beatrix Bay 
deep extract, the aqueous MeOH partitions were evaporated in vacuo, and the residue 
coated onto Celite and subjected to reverse phase (C 18) "flash" chromatography.'11 A 
step gradient elution from 1: I MeOH/H20 to MeOH then 1: 1 MeOH/CH2Cl2 was 
utilised, before stripping the column with CH2CI2 and MeOH. In the case of the Beatrix 
l3ay deep sample, the MeOH was evaporated from the aqueous methanol partition to 
afford an aqueous extract. This extract was partitioned against EtOAc in order to reduce 
the mass of the sample, before evaporating the solvent invacuo, coating the residue onto 
Celite and purifying by reverse phase (C 18) chromatography as described above. All 
three Beatrix Bay samples exhibited identical separation profiles, with activity 
concentrated in a single fraction (90';10 MeOH/1l20). In contrast, the two extracts 
originating from Akaroa had reduced activity spread over several fractions. 
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The P388 active fractions in each series were combined and subjected to further 
fractionation by size exclusion chromatography on LH20 eluted with CH2Cl2• TLC 
(DIOL, 1% MeOHlCH2C12) of the active fractions from LH20 revealed the presence of 
the desired halichondrin B (1.8), homohalichondrin B (1.25) and isohomohalichondrin 
B (1.28). However, it was not possible to observe halichondrin peaks in the HPLC 
chromatograms of the active fractions due to coeluting UV -acti ve components. 
In an attempt to remove these impurities one of the active fractions was subjected to a 
trial purification using nonnal phase (DIOL) chromatography. The DIOL cartridge (250 
mg) was eluted with benzene, 1: 1 benzene/CH2Cl2, 1 :99 MeOHlCH2Cl2, 1:9 
MeOH/CH2C12 and MeOH. TLC (DIOL, 1% MeOH/CH2Cl2) indicated that the 
nonpolar impurities eluted with benzene and the halichondrins were eluted with 1: 1 
benzene/CH2C12 (largely 1.28) and CH2Cl2 (1.8 and As a consequence of this 
result the remaining active fractions were combined within each series and subjected to 
purification by normal phase (DIOL) chromatography. The elution scheme was 
subsequently simplified to benzene, CH2Cl2, 1:9 MeOHlCH}Cl2 and 1: 1 MeOHlCH2Cl2• 
The halichondrins were concentrated into the CH2Cl2 fraction in each case. 
3. 4 Analysis 
The five samples were analysed by reverse phase (C 18) HPLC for halichondrin content. 
This involved comparing the retention time of halichondrin-type (end absorption only) 
peaks to those of standard samples for halichondrin B (1.8), homohalichondrin B (1.25) 
and isohomohalichondrin B (1.28). A typical HPLC chromatogram of the purified 
aquaculture extracts is displayed in Figure 3.4.1. 
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Figure 3.4.1 HPLC Chromatogram of a Purified Lissodendoryx Extract 
The mass of the individual halichondrins in each sample was determined by comparing 
the integral of halichondrin peaks with that of a known amount of halichondrin B. The 
estimation of isohomohalichondrin B (1.28) content in both the Akaroa and Beatrix Bay 
deep samples was hindered by the coelution of a UV -active impurity. The presence of 
1.28 in these samples was shown by TLC (DIOL, 1 % MeOHlH20). The mass of 1.28 in 
the Beatrix Bay sample was estimated indirectly from the halichondrin ratio exhibited 
by the two other samples originating from this site. It was not possible to estimate the 
amount of 1.28 contained in the Akaroa sample. 
The results are shown in Figure 3.4.2. In addition to the aquacultured sponge, a sample 
of native (Kaikoura) Lissodendoryx sp. was extracted and purified in the same manner 
as described for the aquacultured sponge samples in Section This control extract 
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enabled a comparison or halichondrin content Lo be made between the native and the 
aq llacul tu red sponge. 
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Figure 3.4.2 Halichondrin Levels in LissodendOlYx Samples 
Two conclusions can bc drawn immcdiately. llalichondrins, and more especially 
halichondrin B (1.8) are produced by Lissodendoryx sp. grown in aquaculture. The 
levels of total halichondrins produced by aquacultured sponge are less than those of the 
nativc sponge. Il is interesting to nole that in the cases of the Akaroa shallow sponge 
and the Beatrix Bay mid depth sponge, the levels of halichondrin B (1.8) are not 
dissimilar to those of the native sponge. This result is encouraging, and may indicate it 
is possible to ini1uence the production of individual halichondrins by manipulation of 
the aquaculture environment. 
Halichondrin production is not the only variable to be considered in determining 
optimum conditions for the aquaculture of LissodendOlJ/x sp. In order for the 
production of halichondrins by harvest of aquacultured sponge to be viable, sponge 
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survival and growth rates must also be maximised. A comparison between halichondrin 
production (J-.lg kg wet weight of sponge) and sponge yield is illustrated in Figure 
3.4.3. 
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Figure 3.4.3 Comparison of Halichondrin Production against Sponge Yield 
The highest rate of halichondrin production is negatively correlated with growth. A 
possible explanation for this observation is that halichondrin production increased in 
sponges suffering from stress. 
3.5 Discussion 
This is the first proof that extracts of Lissodendoryx sponge grown In aquaculture 
produce halichondrins. The quantity of halichondrin, and the ratio of the three 
halichondrins detected varied depending on the site and depth at which the sponge was 
grown. NIW A are examining the reasons for these differences and developing 
techniques for increasing both sponge growth rate and halichondrin content. Land-
based aquaculture trials are also being undertaken to examine the factors responsible for 
fast growth and halichondrin production.92 It is hoped that these experiments will 
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facilitate better understanding of the processes involved 111 the biosynthesis of 
halichondrin B. 
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4.1 Haptens - An Introduction 
In the event that halichondrin B proceeds to further trials, an effective means of 
detecting halichondrins in biological matrices will be required. The extreme potency of 
halichondrin B requires any selected method to have the ability to detect halichondrins 
down to the pg level. The development of an Enzyme Linked Immunosorbent Assay 
(ELISA) was perceived as the best means of achieving these requirements. 
In the case of low molecular weight compounds such as the halichondrins, the 
development of an immunoassay normally requires synthesis of a protein-reactive 
derivative (hapten) of the compound to allow conjugation to an immunogenic carrier 
protein. To allow for the possibility of both class-specific halichondrin assays 
(distinction between the A, Band C families) and congener specificity (distinction 
between halichondrin B and other congeners in the B family) the site of conjugation has 
to be carefully selected. It is generally observed that the portion of a hapten most distal 
to the conjugation site most profoundly affects antibody recognition.93 Immunogenic 
proteins conjugated at the terminal site of any member of the B series of halichondrins 
should elicit antibodies that recognise the macrocyclic portion of the molecule (ie will 
distinguish between the A, Band C families). Similarly, antibodies elicited by 
immunogenic proteins conjugated distal to the terminal site of a B series halichondrin 
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should discriminate between the B series congeners (halichondrin B, homohalichondrin 
13, isohomohalichondrin Rete.). 
Tile haptens were prepared in collahoration with (he Ilawnii Biotechnology Group Inc 
(IIIH;). ;\ t the time the haptens were synthesised it was expected that HBO would 
prepare the hapten carrier conjugates and undertake the development of a halichondrin 
immunoassay. The linkers used in the preparation of hap tens were recommended by 
HBO.'M The use or the hydroxy reactive p-maleimidostyryl isocyanate (PMSI) linker 
(PfvISL 4.1)" to synthesise haptens from homohalichondrin B (1.25) and 
isol1ol11ohalichonclrin B (1.28) is described in Section 4.2. The closely related p-
l1laJeimiclophenyl isocyanate (PMPl, 4.2) linker was used to create haptens ii-om 
halichondrin B (1.8) and homohalichondrin B (1.25) and is discussed in Section 4.3. 
The terminal diol moiety of was cleaved to furnish norhomohalichondrin B (4.13). 
This enabled the synthesis of an alternatively linked hapten, while still incorporating the 
common maleimide functionality, which is discussed in Section 4.5. 
4.2 PMSI Linker-derived Haptens 
4.2.1 Introduction 
PMSI (4.1) consists of a hydroxy reactive isocyanate functionality, a styryl spacer group 
and a sulfhydryl-reactive maleimide moiety. The maleimide hapten will react readily 
with the sul1l1ydryl residues of proteills thiolated with 2-iminothiolane to yield a stable 
lhiodher linkage. 
i\ The donation of PMSI by Hawaii Biotechnology Group Inc. is gratefully acknowledged. 
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PMSI (4.1) 
Reaction of Isohomohalichondrin B (1.28) with (4.1) 
Isohomohalichondrin B (1.28, 2.5 mg) was initially treated with 4.1 for 8 hours. TLC 
(DIOL, 3% MeOHlCH2CI2) of the reaction mixture showed that both 1.28 and 4.1 were 
still present. After reaction for a further 19 hours resonances characteristic of 1.28 and 
4.1 could still be seen in the IH NMR spectrum of the reaction mixture. 
Isohomohalichondrin B (1.28) and 4.1 were kept III the NMR tube in 0.1% 
CsDsN/CDCI3 Cea 150 ilL) for 4 days. Changes to resonances in the IH NMR 
spectrum of the reaction mixture after 4 days indicated the reaction had gone to 
completion. The characteristic H54/54' and H55 triplet resonances of 1.28 were no 
longer observed. The H2' resonance was observed as a clean doublet of doublets, with 
the previously overlapping resonance moving downfield by iSH 0.21. Ine most 
obvious evidence for reaction of 4.1 having occurred was the shift in the resonance for 
the styryl protons from iSH 6.61 and DH 6.43 to DH 5.92 and DH 7.18 respectively. 
Chromatography of the product mixture on LH20, using CH2Cl2 as the eluent, was used 
to isolate hapten 4.3 (2.0 mg) from PMSI-derived side products. 
The IH NMR spectrum of is displayed in Figure 4.2.1. A minimum of NMR 
experiments were performed on 4.3 to enable the location of key resonance changes viz 
HSMQC and 2D-TOCSY (mixing time 100 ms) experiments. These data were used to 
assign the majority of the IH NMR and DC NMR resonances of 
NMR data are collated in Table 4.2.1 and Table respectively, and the important 
correlations from the 2D experiments are shown in Figure 
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Figure 4.2.1 lH NMR spectrum of Isohomohalichondrin B PMSI Hapten (4.3) 
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Tahle 4.2.1 11-1 N MR DaLa for Isoholl101mlichondrin B PMSI Hapten (4.3) 
P"oton" () PPlll h Pn)ton" () ppmh Proton" 8 ppmb 
112 2.]4 1122 I . () I 1142 2.29 
112' 2,5<) 1122' I . () I CIIJ -42 0.95 
H3 3.88 H23 3.51 H43 1.34 
H4 1.37 H24 H43' 1.53 
114' 1.74 H24' 1.69 H45 1.49 
1-15 1.41 H25 2.20 H45' 1.49 
115' 2.10 CHJ -25 1.06 H46 2.16 
1-16 4.35 26=CH2 4.76 CH3-46 0.89 
H7 2.94 26'=CHz 4.80 H47 3.23 
HS 4.31 H27 3.52 H48 3.74 
1-19 4.05 H28 H49 1.84 
1-110 4.19 H28' H49' 2.13 
1-111 4.59 H29 4.19 H50 3.52 
H12 4.68 H30 4.65 H51 3.82 
H13 \.94 1-131 2.02 H52 2.81 
1-113' 2.15 CH3-31 0.99 H52' 2.81 
HIS 1.61 H32 3.18 H54 2.83 
HIS' H33 3.80 H54' 2.83 
H16 2.16 H34 1.78 H55 4.38 
H16' 1.42 H34' 2.14 H55' 4.45 
HJ7 4.09 H35 4.10 H2' 6.83 
HIS 2.26 H36 4.09 H3' 6.83 
H18' 2.79 H37 1.90 H6' 7.23 
19=CHz 4.91 H37' 2.34 H7' 7.34 
19'=CHz 4.99 H39 2.21 H9' 7.34 
H2O 4.37 H39' 2.21 H10' 7.23 
[-121 1.40 H40 3.93 H11' 5.92 
H21' H41 3:63 H12' 7.18 
" The symbol' represents the less shielded proton of a geminal pair. 
h Data recorded at 23°C in CDCl) at 300 MHz with chemical shifts in ppm and referenced to CHCIl , bH 
7.26. 
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Table 4.2.2 13C NMR Data for Isohomohalichondrin B PMSI Hapten (4.3) 
Carbon 8 ppm" Carbon 8 ppm" Carbon 8 ppm" 
CI C-CH3-2S 35.9 C-CH3-46 28.5 
C2 40.3 C-CH3-2S 17.8 C-CH3-46 16.8 
C3 73.6 26C=CHz C47 75.9 
C4 30.5 26C=CHz 104.1 C48 66.4 
CS 29.9 C27 73.5 C49 34.3 
C6 68.2 C28 36.8 CSO 66.1 
C7 77.6 C29 71.0 CSI 76.2 
C8 74.3 C30 76.8 C52 45.4 
C9 73.8 C-CH3-31 36.6 CS3 
CIO 76.5 C-CH3-31 14.8 C54 42.5 
Cll 82.0 C32 77.4 CS5 60.7 
C12 81.1 C33 66.4 CI' 
C13 48.2 C34 29.0 C2' 134.2 
Cl4 C35 75.2 C3' 134.2 
CIS 34.3 C36 76.2 C4' 
Cl6 28.1 C37 43.4 CS' 
Cl7 75.2 C38 C6' 126.1 
Cl8 38.6 C39 42.4 C7' 125.8 
19C=CH2 C40 71.1 C8' 
19C=CH2 104.4 C41 79.0 C9' 125.8 
C20 75.3 C-CH3-42 25.7 ClOt 126.1 
C21 29.3 C-CH3-42 17.5 Cll' 109.6 
C22 32.0 C43 36.9 C12' 
C23 74.7 C44 C13' 
C24 43.2 C4S 37.1 
a Data recorded at 23°C in CDC!] with chemica! shifts in ppm, assigned from an HSMQC spectrum at 
300 MHz. 
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The lH and DC NMR spectral data in the region of the A-N rings of hapten 4.3 were 
consistent with those of isohomohalichondrin B (1.28). The most notable differences in 
chemical shift for relative to were observed for the H52/52' and H55/55' 
methylene resonances. The H55/55' proton resonances, observed at a coincident 
chemical shift in 1.28 (OH 3.86) were seen as 2 distinct resonances for 4.3 (OR 4.38, OR 
4.45). The H52/52' protons appeared as a single resonance (DR 2.81). The assignment 
of the H52/52' proton resonances was confilmed by the observation of a TOCSY 
correlation between the H51 resonance (OR 3.82) and the resonance at DR 2.81. The 
equivalent protons in 1.28 had separate resonances (DH 2.93 and OR 2.62 respectively). 
H54/54' methylene proton resonances (OB 2.83) were also different to those of the 
parent 1.28 (OR 2.74). A significant change in 13C chemical shift data was apparent for 
C54, with a shift difference relative to C54 of 1.28 of oe 3.6 upfield. The C55 
resonance of 4.3 at 60.7 was downfield compared to the C55 resonance of 1.28 (oe 
57.8). The chemical shift of C52 for 4.3 was not significantly different to that of the 
parent 1.28, confirming that the C52 hydroxy group did not react with The 
downfield styryl proton resonance (OR 7.18) was located from a 2D-TOCSY correlation 
to this resonance from the isolated up field styryl proton resonance at 0H 5.92. 
4.2.3 Homohalichondrin Band PMSI 
Homohalichondrin B (1.25, 1.3 mg) was treated with an equimolar quantity of 4.1. The 
reaction was monitored by lH NMR spectroscopy. It was deemed to be complete after 5 
days, at which time the styryl proton resonances of 4.1, and the H55/55' resonance of 
1.25 were no longer observed in the IH NMR spectrum of the reaction mixture. The 
presence of several maleimide proton resonances was indicative of the formation of a 
mixture of products. Reverse phase (C 18) HPLC using 60% CH3CNIH20 as the mobile 
phase was used to separate the product mixture into four fractions. The most polar 
fraction was identified as the starting material by comparison of its retention time 
and NMR spectrum to those of an authentic sample. Of the remaining three 
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fractions, two were similar in polarity (4.4, 4.5), and one was notably polar (4.6). 
The molecular formula of the less polar 4,6 was determined as C87H)0202SN4 by 
HRF ABMS. This was consistent with the addition of linkers to both hydroxy 
groups of The polarity of 4.6 relative to 1.25 was also consistent with the masking 
of the polar diol of 1 The isobaric 4.4 and 4.5 were found to have a molecular 
formula of C74H94022N2 by HRF ABMS. This molecular formula was consistent with the 
attachment of a single 4.1 linker at the C54 hydroxy group, or the C55 hydroxy group of 
1.25. The lack of material precluded the use of 2D NMR experiments to assign the H54 
and resonances. The major differences in the IH NMR spectrum of 
compared to that of were in the region of OH 4.00-4.25. The distinct H55 resonance 
(OH 3.69) was not observed. The predominant product 4.5 is likely to be the result of 
reaction of the primary C55 hydroxy group of 1.25 with 4.1 (see also Section .2). 
9H3 9H3 H 1:1 37 1:1 H : 0 H 
o 0 M H 
47 0 A A 
55 0 N 
o HO 
homohalichondrin B PMSI hapten (4.4) 
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homohalichondrin B PMSI hapten (4.6) 
The ratio of haptens formed was determined by the integration of their peaks in the 
chromatogram of the product mixture. The ratio of 4.4:4.5:4.6 was determined to 
be 11: This is comparable to the ratio of products obtained in the reaction of 
with the phenyl linker (Section 4.3.2). 
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4,3 Linker-derived Haptens 
Within the structure of PMPI (4.2) is an hydroxy-reactive isocyanate functionality, a 
phenyl spacer group and a sulfhydryl reactive maleimide moiety. The male imide 
haptens will react readily with sulfhydryl residues in proteins thiolated with 
iminothiolane to form a stable thioether linkage. 
o 
GN-o-N~C~O 
o 
PMPI (4.2) 
of Homohalichondrin Band PMPI 
In order to obtain predominantly monoconjugated product, an equimolar amount of 
PMPI (4.2) was reacted with homohalichondrin B (1.25, 0.9 mg). The progress of the 
reaction was monitored by IH NMR spectroscopy. No further change in the IH NMR 
spectrum of the reaction mixture was seen after 64 hours. That more than one product 
had been formed was evident from the complex nature of the methyl region of the 
spectrum. Semipreparative HPLC using a reverse phase (CI8) column eluted with 60% 
CHJCN/H20 was utilised to separate the product mixture into four fractions. The most 
polar fraction was identified as starting material 1.25 by comparison of its retention time 
and NMR spectrum to those of an authentic sample of 1.25. The major product 
eluted at 600 s, just after one of the minor products. The third, minor product was 
considerably polar, with a retention time of ca 1200 s. The relative polarities of the 
products indicated it was likely, as expected, that the more polar fractions were 
monoconjugated and that the much less polar fraction was diconjugated 1.25. 
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The appearance of a doublet of doublets (OH 6.33), and a decrease in intensity of the 
characteristic male imide proton resonance a ca OH 6.S was observed in the lH NMR 
spectrum of the major product This indicated that the maleimide olefm was no 
longer intact. Analysis by reverse phase (CIS) HPLC showed 4.7 was more polar than 
the product peak collected under identical conditions. The molecular formula of 4.7 
(C7JH96N2023) determined by HRF ABMS was consistent with the addition of MeOH to 
the double bond of the maleimide. This was supported by the observation of a methoxy 
resonance (OH 3.49) in the lH spectrum of 4.7. The addition of MeOH seems most 
likely to have occurred when MeOH was used for transferring purified fractions into 
storage vials. In hindsight this was obviously a very poor choice of solvent. 
55 
o 
o 
o 
H H 
H 
N 
o 
H 
47 H H 34 H 
methanol addition product (4.7) 
The addition of an equimolar amount of PMPI (4.2) to (2.5 mg) was repeated. The 
reaction was deemed to be complete after 5 minutes, when no further changes were 
observed in the NMR spectrum of the reaction mixture. The HPLC chromatograph 
of the mixture was comparable to that obtained for the previous reaction. 
Semipreparative reverse phase (CIS) HPLC was used to separate the four components. 
Chapter 4 Terminal Haptens 80 
4.3 1 Characterisation of 4.8 
The lH NMR spectrum (Figure 4.3.1) of the least polar component 4,8 contained two 
male imide proton resonances, consistent with the addition of to both hydroxy groups 
of There were two notable additions to the IH NMR spectrum relative to that of 
the parent compound; a multiplet resonating at 6H 5.14 and a resonance at ca 6H 4.4. 
Pat1ial IH NMR assignments were made fi'om spectral data collected from a 2D-TOCSY 
(mixing time 80 ms) experiment. The assigned data are listed in Table 4.3.1 and the 
important 2D-TOCSY correlations are shown in Figure 4.3.2. 
Figure 4.3.1 IH NMR Spectrum of Homohalichondrin B PMPI Hapten (4.8) 
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Table 'H NMR Data for Homohalichondrin B PMPI Hapten (4.8) 
ProtonU () ppmb Protona () ppmb Pro toni () ppmb 
H2 2.35 H39 2.20 
H2' 2.60 1.88 H39' 2.20 
H3 3.88 1.61 H40 3.92 
H4 1.61 H41 3.59 
H4' 1.73 3.53 H42 2.35 
H5 CH3-42 0.93 
HS' 10 H24' 1.69 H43 1.30 
H6 2.21 H43' 1.46 
2.95 1.07 H4S 
H8 4.32 4.77 H4S' 1.44 
H9 4.05 4.82 H46 2.17 
HIO 4.19 H27 3.53 CH3-46 0.92 
Hll 4.60 H28 H47 3.08 
4.69 H28' H48 3.54 
H13 1.94 4.19 H49 1.79 
H13' 15 H30 4.66 H49' 
HIS H3I 2.03 HSO 3.91 
HIS' CH3-31 1.00 HSI 4.04 
Hl6 3.19 HS2 1.87 
H16' 2.18 H33 3.81 H52' 10 
Hl7 4.10 H34 1.79 HS3 4.42 
Hl8 2.26 H34' 2.16 H54 5.19 
H18' 2.80 H35 4.11 4.41 
19=CHz 4.93 H36 4.10 4.41 
19'=CHz 5.00 H37 
H2O 4.38 H37' 2.35 
a The symbol' represents the less shielded proton of a geminal pair. 
b Data recorded at 23°C in CDCl] at 300 MHz with chemical shifts in ppm and referenced to OH 
7.26. 
Chapter 4 
-
Term
inal H
aptens 
82 
Figure 4.3.2 
H
om
ohalichondrin B
 PM
PI H
apten 
-
Im
portant 2D
-TO
C
SY
 C
orrelations 
c 
Chapter 4 Terminal Haptens 83 
The spectral window used for the experiments was limited to the halichondrin region 
of the spectnun. Consequently, data for the linker portion of 4.8 are not available. 
These data confirmed the connectivity and chemical shift of the rIngs were 
identical to those of the parent 1.25. A TOCSY correlation between the H51 resonance 
(OB 4.04) and a resonance at OH 4.42 allowed the assignment of H53. A correlation 
between the H53 proton resonance and a proton resonating at OH 5.19 allowed the 
assignment of H54. The H55 proton resonance was assigned from the observation of a 
TOCSY cOlTelation between a doublet resonance at OH 4.41 and the H54 resonance. No 
mass spectrometry data could be obtained for 4.8. HRF ABMS data were obtained for 
the related 4.6 (Section 4.2.3) which has two PMSI (4.1) linkers to attached to 1.25. 
The product 4.6 is similar in polarity to 4.8. The relative polarity of 4.8, the pair of 
maleimide resonances observed in the lH NMR spectrum of 4.8, and the HRFABMS 
result for the related 4.6 are all consistent with formation of the disubstituted product 
4.8. 
H H 
o 
55 o N 
o 
M 
47 
CH3 
I:lo~ 
II I A .5 H 
00· 
H 34 H 0 
homohalichondrin B PMPI hapten (4.8) 
4.3 Characterisation of 4,9 
The molecular formula of the major component 
by HRF ABMS, indicating attachment of a single linker 4.2.. The major differences in 
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the IH NMR spectrum of (Figure 4.3.3) compared to that of were ,the 
appearance of extra resonances at 8H 4.2 and 8H 3.8, and the absence of the characteristic 
H55/H55' resonance at 8H 3.69. 2D-TOCSY (mixing time 80 ms) and HSMQC 
experiments were run to quickly obtain a rna'Ximum amount of spectral data. The 
partially assigned IH NMR and 13C NMR data are collated in Table 4.3.2 and Table 
4.3.3, and important 2D correlations are shown in Figure 4.3.4. 
Figure 4.3.3 NMR Spectrum of Homohalichondrin B PMPI Hapten (4.9) 
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Tahle 4.3.2 III NMR Data for Homohalichonclrin B PMPI Hapten (4.9) 
Proton" o I1pmh Proton" 8 ppmh Proton" 8 ppm" 
112 2,J5 1122 1,61 1142 2,J4 
112' 2JlO 1122' IJll CII.1-42 0,93 
113 3,S8 H23 3,54 H43 1.28 
114 1.38 1124 1.04 1-143' 1,48 
114' 1.74 H24' 1.69 B4S 1.37 
H5 B25 2.21 H4S' 1.49 
H5' 2.09 CH3-25 1.07 H46 2,17 
1-16 4.36 26=CHz 4.77 0.92 
H7 2.95 26'=CHz 4.82 3,08 
118 4.32 3.53 3.54 
119 4.05 H28 H49 1.80 
II I () 4.20 H28' H49' 2.18 
1111 4.60 H29 4.19 H50 3.90 
Hl2 4.69 H30 4.66 4.05 
H13 1.94 H31 2.03 
HB' 2.15 CH3-31 l.00 
HIS 1.61 H32 3.18 HS3 4.21 
HIS' 2.17 H33 3.81 HS4 3.76" 
BI6 1.42 H34 1.79 4.23" 
B16' 2.17 H34' 2.15 4.23 c 
II t 7 4.1 0 l135 4.11 6,84 
Hl8 H36 4.11 6,84 
H18' 2.80 H37 1.88 H6' 7.27 
19=CHz 4.92 H37' 2.35 H7' 7,49 
19'=CH2 5.00 H39 2.20 H9' 7,49 
H2O 4.38 H39' 2.20 H10' 7.27 
H2t 1.89 H40 3.93 
H2l' 1.89 H41 3.59 
"Tile symbol' represenls the less shielded proton of a geminal pair. 
h Data recorded at noc in CDCI) at 300 MHz with chemical shifts in ppm and referenced to CHC!) Of! 
7,26. 
" Assignment of H54 and H55/55' tentative - may be interchanged 
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1Jc NMR Data for Homohalichondrin B PMPI Hapten (4.9) 
Carbon 8 ppm" Carbon 8 ppm" Carbon 8 ppm" 
C21 29.2 C39 42.4 
C2 40.2 31.8 C40 70.7 
C3 73.6 C23 74.9 79.5 
C4 30.5 C24 43.2 25.4 
CS 29.8 C-CH3-25 35.8 C-CH3-42 17.4 
C6 68.2 17.8 C43 36.9 
77.6 26C=CH2 C44 
C8 74.3 26C=CH2 103.9 36.9 
C9 73.9 C27 73.6 C-CH3-46 28.7 
CIO 76.6 C28 C-CH3-46 16.9 
Cll 81.9 C29 71.2 C47 73.0 
Cl2 80.8 C30 77.1 C48 63.5 
C13 48.2 C-CH3-3I 36.6 C49 31.0 
Cl4 C-CH3-3I 14.8 C50 74.6 
CIS 34.2 C32 77.6 CSI 76.6 
CI6 28.0 C33 66.5 C52 
CI7 C34 28.9 77.8 
CI8 38.6 C35 C54 67.3b 
19C=CHz 151.3 C36 C55 71.7b 
19C=CH2 104.3 C37 43.2 
C20 75.2 C38 
a Data recorded at 23°C in CDC13 with chemical shifts in ppm, assigned from an HSMQC spectrum at 
300 MHz. 
b Assignments tentative - may be interchanged 
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The carbons of the linker portion of 4.9 were not assigned owing to the narrowed 
window (bH 5.2-0.8) used for the 2D NMR experiments. The majority of the methlne 
carbons of were assigned by direct comparison of the HSMQC data to those of 
homohalichondrin B (1.25). Three carbon resonances remained unassigned: be 71 be 
77.8 and .be 67.3. These carbon resonances were correlated to protons resonating at bH 
3.76, bH 4.21 and bH 4.23 respectively. It was not possible to assign any of the 
H54 or H55/H55' protons from the available spectral data. No TOCSY correlation was 
seen between H50 and any of these resonances. A correlation between the H9 
resonance (bH 4.05) and the resonance of HlO (bB 4.20) overlapped with any possible 
correlation between the H51 resonance (bH 4.05) and either of the two protons 
resonating at ca bH 4.2. The carbon resonating at be 77.8 was assigned to C53 on the 
basis of chemical shift arguments. An attempt to assign the remaining two 
carbon/proton resonances was made by comparison of chemical shift differences. The 
change in chemical shift upon converting an alcohol to a carbamate was compared for 
the a-methylene protons of 1.25/4.9 and 2,3-di-O-methyl-L-ascorbic acid and its PMPI 
reaction product. However the differences observed were not consistent with either 
assignment ofC54/H54 and C55/H55/55'. 
H 
o 
55 o N 47 
o A 
H 
homohalichondrin B PMPI hapten (4.9) 
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The available spectral data confirmed the structure of 4.9 to be the result of reaction at 
the primary C55 hydroxy group. 
4.3 Characterisation of 4.10 
The observation of a single maleimide proton (8H 6.84) in the lH NMR spectrum of 4.10 
was indicative of the addition of a single PMPI (4.2) linker to 1.25. The IH NMR 
spectrum of 4.10 contained a distinctive new multiplet resonating at 8H Other new 
resonances were observed at bH 3,90 and under the 1 resonance (8H 4.92). A 2D-
TOCSY (mixing time 80 ms) experiment and an HSMQC experiment were run to obtain 
comlectivity information. The partially assigned lH NMR and DC NMR data are 
collated in Table 4.3.4 and Table 4.3.5. The important 2D NMR con-elations are shown 
in Figure 4.3.5. 
55 
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homohalichondrin B PMPI hapten (4.10) 
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IH NMR Data Homohalichondrin B PMPI Hapten (4.10) 
Proton:l 8ppmb 8 ppmb Proton3 8 ppmb 
2.34 2.20 
2.60 2.20 
3.87 1.60 3.93 
1.60 3.62 
1.74 3.53 2.33 
0.96 
2.10 1.69 1.28 
4.35 2.21 1.49 
2.95 1.07 
HS 4.32 4.77 H45' 1.44 
H9 4.05 4.82 H46 2.16 
HIO 4.18 3.54 CHl -46 0.92 
Hll 4.60 H47 3.08 
4.69 H2S' H4S 3.54 
1.94 4.19 H49 
2.15 H30 4.66 
H3I 2.02 H50 3.93 
1.00 4.04 
HI6 3.19 2.06 
H16' 2.16 H33 3.81 2.06 
4.09 1.78 H53 4.52 
2.26 2.16 H54 4.92 
HIS' 2.81 4.11 H55 3.90 
4.92 H36 4.10 H55' 3.90 
19'=CH2 5.00 
H2O 4.38 H37' 2.35 
n The symbol' represents the less shielded proton of a geminal pair. 
b Data recorded at noc in CDC!} at 300 MHz with chemical shifts in ppm and referenced to CHCI), OH 
7.26. 
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Table DC NMR Data for Homohalichondrin B PMPI (4.10) 
Carbon 8 ppm" 8 ppm" 8ppma 
Cl C2l C39 42.4 
C2 31.7 C40 70.8 
C3 73.4 74.9 C4l 79.3 
C4 
CS C-CH3-2S 17.4 
C6 68.0 C-CH3-2S 17.8 C43 37.1 
C7 77.3 26C=CH2 C44 
CS 74.5 26C=CHz 103.9 C45 37.1 
C9 C27 73.4 C-CH3-46 28.4 
CI0 76.4 C2S C-CH3-46 17.0 
Cll 81.8 C29 C47 72.9 
Cl2 C30 77.0 C4S 63.5 
C13 C-CH3-3I C49 
CI4 C-CH3-3I 14.7 CSO 74.0 
CIS C32 77.5 CSI .5 
CI6 C33 66.6 CS2 36.6 
CI7 C34 CS3 
CIS C35 CS4 74.8 
I9C=CH2 C36 CS5 64.0 
I9C=CH2 104.3 C37 
C20 75.5 C3S 
a Data recorded at 23°C in CDCl) with chemical shifts in ppm, assigned from an HSMQC spectrum at 
300 MHz. 
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The spectral window used for the 2D experiments was limited to the halichondrin region 
of the spectrum. Consequently data for the linker portion of 4.10 are not available. A 
correlation between the HS I resonance (OH 4.04) and OH 4.52 allowed the assignment of 
H52/H52' methylene resonance was assigned from the observation of a 
TOCSY correlation from both the H51 resonance and the H53 resonance to OH 2.06. 
The resonance was also correlated to OH 4.92 and OH 3.90. The upfield (OH 3.90) 
proton resonance was correlated to a carbon resonating at Oc 64.0 allowing the 
LjO,L.UU'wLH of H55. The proton resonating at 01-1 4.92 was thus assigned as An 
HSMQC correlation was observed from this proton resonance to Oc 74.8. The 
difference in chemical shift for C54 in 4.10 relative to the parent (oe downfield) 
supported the assignment of 4.10 as being the secondary hydroxy-linked hapten. 
Halichondrin Band PMPI 
Halichondrin B (1.8, 1.5 mg) was treated with an equimolar amount of in CDCI3 . 
No fmiher changes were observed in the IH NMR spectrum of the product mixture after 
hours. The product mixture was analysed by reverse phase (CI8) using 60% 
CH3CN/H20 as the mobile phase. The mixture contained two major components (1.8, 
s, 4.11, 374 s) and several minor components of varying polarity. The relative 
polarities of the components were indicative of the formation of mono-, bis- and tri-
substituted halichondrin B derivatives. Integration of the product peaks showed the 
major component was ca 80% of the product mixture. This would be the lower bound 
of the estimate as the bis and trisubstituted components have a more intense UV 
chromophore. Semipreparative reverse phase (CI8) HPLC was used to separate the 
mixture into six components . 
. 3.1 Characterisation 
The most polar fraction was identified as the starting material 1.8 by comparison of its 
NMR spectrum with that of an authentic sample of 1.8. 
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The nu~jor component 4.11 was found to have a molecular formula of C11H92022N2 by 
IIRFAI3MS, consistent with the addition of a single 4.2 linker. In order to determine 
the position of the linker, a 10 TOCSY experiment was run on both a standard sample 
01' I.H (mixing limc IO() ms, FigLlfc 4.3'()) ami 4./1 (mixing time gO illS). The H51 
pro[ol1 «)II 3.g0) was irradiated to probe Lhe spin system around to 1154. The H51 
resonance overlapped with tbe 1133 resonance (also ()II 3.80) hence the need to fully 
assign the 1 TOCSY spectrum of 1.8. The H54/H54' pair of doublet of doublets was 
observed to shift from Oil 3.54 and Oil 3.61 to ca Oil 4.10 and (\I 4.20. This change in 
chemical shirt is consistent with the addition of a PMPI (4.2) linker to the C54 hydroxy 
group. Attachment of the 4.2 linker at the C53 hydroxy group would be expected to 
cause a shirt down field by at least 011 0.6 of the H53 resonance. This change in chemical 
shi ft was not observed in tbe ID TOCSY spectrum of 4.11. 
halichondrin B PMPI hapten 
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/\ minor componenl 4.12 was fOllnd to be isobaric to 4.11 by l-IRFABMS. This is 
consistent with the order of elution hom C 18. Compound 4.12 was the 1110st polar of 
the products isolated. The single 4.2 linker could be attached at the C51 hydroxy group 
or the C53 hydroxy group. An unmasked diol (linker attached at the C5l hydroxy 
group) would possibly give rise to the more polar compound. A lack of material 
prevented the use ofNMR techniques to confirm this supposition. 
halichondrin B PMPI hapten (4.12) 
The three remaining fractions were aU of a low mass « 0.1 mg) which precluded the 
use of I H NMR spectroscopy. These samples were submitted for MS analysis but no 
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The three remaining fractions were all of a low mass « 0.1 mg) which precluded the 
use of IH NMR spectroscopy. These samples were submitted for MS analysis but no 
useful results were obtained. The more polar of these fi'actions eluted from C 18 in 346 
s, after 1.8 (229 s) and 4.12 (346 s) but before (374 s). The relative polarity of this 
component is consistent with the addition of a single linker to the C53 (or CS1) 
hydroxy group. A combination of three compounds, eluting from 467 s to 523 s, was 
collected as a single fraction. It is possible that this fraction contains a mixture of 
disubstituted 1.8. The remaining fraction was relatively less polar, eluting at 692 s. 
This fraction may be the result of linker attachment at all three hydroxy groups of 1.8. 
4.4 Norhomohalichondrin B Aldehyde 
4.4.1 Introduction 
Modification of the terminal diol of homohalichondrin B (1.25) was desirable, as this 
would create another option for linker attachment. Sodium periodate was chosen as the 
reagent for diol cleavage because it had been used previously to successfully treat olefm 
modified halichondrins.95 
4.4.2 Diol Cleavage 
A small quantity of homohalichondrin B (1.25) was stirred with an aqueous solution of 
sodium periodate at room temperature ovemight. A doublet resonance at ()H 9.69 in the 
I H NMR spectrum of the product indicated formation of the aldehyde 
The reaction was repeated on a larger scale to provide enough material for thorough 
structure elucidation. 
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The molecular formula of was determined as C6oHs20lS by HRF ABMS. The IH 
NMR spectmm of 1S displayed in Figure 4.4.1. Irradiation of the aldehyde 
resonance (6H 9.69) was used to locate the decoupled H53 proton resonance at 6H 4.51. 
10 7 6 5 3 1 ppm 
Figure 4.4.1 'H NMR Spectrum of Nor hom ohali chondrin B Aldehyde (4.13) 
A full array of NMR experiments were performed on 4.13 viz COSY, 2D-TOCSY 
(mixing time 80 ms), HSMQC, HMBC, NOE and APT (Figure 4.4.2) experiments. 
These data enabled the complete assignment of the IH NMR and 13C NMR resonances 
of 4. to be achieved. The IH and 13C spectral data are listed in Table 4.4.1 and Table 
4.4.2 respectively, and the important correlations from the 2D experiments are shown 
Figure 
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Tahle 4.4.1 III N MR Dntu 101" Norhol11ohalichondrin B Aldehyde (4. B) 
Proton" () ppm l• Pnlton" () ppmh Proton" () 1111mb 
112 2.11 1120 4.J7 rIJ7 I.Rt) 
112' g 1121 I.J8 1137' 
113 3.87 1 ' 1.88 H39 
114 1 1-122 1.60 H39' 
114' 1.72 tl22' 1.60 H40 3,92 
1.37 H23 3.53 H41 3.58 
US' 2.07 1124 1.03 H42 
H6 4.35 H24' 1.69 CH3-42 0.91 
117 2.94 H25 2.19 H43 
118 4.31 CH3-25 1.06 H43' 1.41 
119 4.04 26==CH2 4.75 1,42 
H10 4.18 26'==CHz 4.80 H45' 1.42 
Hll 4.59 H27 3.52 H46 2.17 
H12 4.68 H28 1.93 CH3-46 0.91 
H13 1.94 H28' 2.03 3.08 
HB' 2.14 H29 4.19 H48 3.55 
H15 1.60 H30 4.65 H49 1.84 
HIS' 2.17 H31 2.01 H49' 
H16 1.42 CH3-31 0.99 H50 3.97 
II 16' 2.16 H32 3.l7 H51 4.06 
1117 4.09 H33 3.80 H52 1.97 
IU8 2.25 H34 1.80 H52' 
H18' 2.79 H34' 2.14 H53 4.51 
L9=CHz 4.91 H35 4.11 H54 9.69 
4.98 H36 4.11 
" The symbol' represents the Jess shieJded proton of a geminal pair. 
h Data recorded at 23°C in CDCI] at 300 MHz with chemical shifts in ppm and referenced to CHCll • DB 
7.26. 
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Tllble 4.4.2 13C NMR Data for Norhomohalichondrin B Aldehyde (4.13) 
Carbon i5 ppma Carbon i5 ppmu Carbon i5 ppma 
Cl 171.0 C20 75.3 C37 43.5 
C2 40.5 C21 29.5 C38 11 
73.7 C22 32.1 C39 42.6 
30.8 74.8 C40 70.8 
CS 30.1 43.4 C41 79.3 
C6 68.2 CmCH3~2S 36.0 C-CH3m42 25.8 
C7 77.7 C-CH3~2S 18.1 C-CH3-42 17.7 
C8 74.3 151.6 C43 37.0 
C9 73.9 26C=CHz 104.1 C44 96.7 
CIO 76.5 C27 73.5 C45 37.0 
Cll 82.1 C28 37.0 C-CH3-46 28.8 
C12 81.1 C29 71.2 C-CH3-46 17.1 
cn 48.4 C30 77.0 C47 .3 
CI4 110.0 C-CH3-31 36.6 C48 63.3 
CIS 34.5 C-CH3-31 15.1 C49 31.1 
C16 28.2 C32 77.6 C50 75.8 
CI7 75.4 C33 66.6 CSI 76.0 
CI8 38.8 C34 29.1 C52 36.2 
19C=CH2 151.4 C35 75.0 82.0 
I9C=CH2 104.4 C36 76.3 202.7 
Data recorded at 23°C in CDCl) at 75 MHz with chemical shifts in ppm and referenced to eHCl], Oc 
77.0. 
140 100 
Figure 4.4.2 APT Spectrum of Nor hom ohali chondrin B Aldehyde (4.13) 
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Thesc data cOlllirmed the eonncctivities ~1IH.1 NMR shins of the A-M rings were identical 
10 those of Itomohalichondrin B (1.25). Correlations in the COSY spectrum from the 
previously assigned 1153 resonance (on 4.51) to resonances at 011 1.97 and oft 2.27 
allowed the (lssignmcnt or II and 1152'. ;\ correlation in thc 21)-TOCSY spectrum 
between the 1I53 resonance and 0" 4.06 allowed the assignment or 1. The 1-:151 
resonancc W,lS correlated to u resonance at 011 3.97, cnabling the assignmenl of 1-150. A 
COSY correlation between the H48 resonance (0" 3.55) and 8" 1.84 allowed the 
assignment of the H49 resonance. The remaining H49' resonance was assigned from the 
observation of a COSY correlation between 0Il 1.84 (H49) anu 8f! 2.24. 
norhomohalichondrin B aldehyde (4.13) 
4.4.4 Stereochemistry 
4.4.4.1 Introduction 
The relative stereochemistry of 1-153 in homohalichondrin B (1.25) has an element of 
uncertainty associated with the assignment. The formation of 4.13 provided an 
opportunity to examine and assign this relative stereochemistry as the H53 proton was 
now observed as an isolated resonance in the IH NMR spectrum of 4.13. Unfortunately, 
no NOE enhancements were observed between protons across the 0 ring. Modelling of 
this five membered showed that the lack ofNOE enhancements was to be expected. 
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4.4.4.2 Proton Ikcollpling Experimcnt 
Irradiation or the [[54 aldehyde resonance in a III decoupling experiment allowed the 
coupling belwecn II and the 1152/1152' methylene pail' to be observcd. The observed 
coupling cons[,lllis CJIIIJ were 6,46 Hz between H52 and H53, and 10.26 Hz between 
1152' Hllli 1153. 
4.4.4.3 Molecular Modelling 
The M, Nand 0 rings of 4.13 were generated in ChemDraw Pro, incorporating the 
known stereochemistry and the cis and Irans options for H53. The structures were 
transferred via Chem3D Pro to MacroModeL The energies of the two structures were 
minimised using an MM2* forcefield, incorporating solvent effects (CHCI3). Vicinal 
coupling constants were collected in MacroModel for the minimised structures and 
compared to the experimentally obtained 3JHH coupling constants. The coupling 
constants derived from the modelled structures (Figure 4.4.4, 6.2 Hz, 10.7 Hz) most 
closely resembled the experimental values for the trans configuration. The 3JHH 
coupling constants extracted 11'0111 MacroModel for the cis configuration (1.4 Hz, 8.2 
Hz) were not consistent with the experimentally observed coupling constants for HSJ. 
3 JHH (H53-H52)=1.4 Hz 
3 JHH (H53-H52')=8.2 Hz 
3 JHH (H53-H52)=6.2 Hz 
3 JHH (H53-H52')=1 0.7 Hz 
Figure 4.4.4 Models ofthe Two Possible Configurations of the C53 Stereocentre 
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A recent paper has presented views on the stereochemistry of the stereo centre in 
conflict with that originally proposed. Uemura reported that the relative stereochemistry 
of homohalichondrin B had been deduced from spectral data and biogenic 
considerations (Figure 4.4.5),96 
~H3 
H 
37 
H H 
H 0 0 M H 55 0 N ~ " 47 HO "", 0 
OH H H -CH3 
Figure Stereochemistry of Homohalichondrin B Reported by Uemura 
As part of the synthesis of the left half of the homohalichondrins, Kishi constructed all 
possible stereoisomers with respect to the C53 and C54 positions of homohalichondrin 
B (1.25),97 Only diastereomer 4.14 exhibited IH NMR data close to that of the data 
reported for the natural product. It should be noted that Uemura's proposed 
stereochemistry for C53 is opposite to that found by Kishi. 
~HHO _ OCH 3 HO H 0 :: 
HO H H CH3 
Kishi's diastereomer (4.14) 
The stereochemistry of C53 determined in this thesis by comparison of experimental 
and modelled coupling constants agrees with that reported by Kishi for the left hand 
portion of homohalichondrin B. 
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The biological activity of norhomohalichondrin B aldehyde (4,13) was evaluated in the 
in vitro P388 murine leukemia assay, and in the NCr's primary 
Included with the results in Table 4.4.3 below are those of the parent halichondrin 
and halichondrin B (1.8). The GIso-centred mean graph profile of halichondrin B (1.8) 
was used as the for the calculation of COMPARE cOLTelation coefficients. 
Table 4.4,3 In Vitro Cytotoxicities of Selected Halichondrins 
Compound P388 ICso NCI GIso 
(nglmL) (x10-10 M) Correlation 
halichondrin B (1.8) 0.78 1.38 1.00 
bomohalichondrin B (1.25) 0.22 3.16 0.95 
norhomohalicbondrin B 0.33 3.02 0.98 
aldebyde (4,13) 
The derivative possesses activity comparable to that of the parent halichondrin 
1.25. The mechanism of action of 4.13 is also very closely cOLTelated to that of the 
"seed" compound, 1.8. This result is not unexpected, as it has been observed 
previously9s that alteration of the terminal diol of 1.25 has little on the biological 
activity. 
4.5 Linker-derived Haptens 
E-Maleimidocaproic acid hydrazide (EMCH, 4.15) is a carbonyl-reactive linker. It 
consists of a sulfhydryl reactive maleimide for subsequent conjugation of the hapten to a 
protein, an amino caproic acid spacer unit, and the nucleophilic hydrazide. 
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o 
GN~~'NH2HCI 
o 
EMCH (4.15) 
4.5.2 Norhomohalichondrin Aldehyde 
105 
The reaction conditions for coupling the aldehyde 4.13 to EMCH (4.15) were first 
established using butyraldehyde in place of 4,13. 
Norhomohalichondrin B aldehyde (4.13) was treated with one equivalent of 4,15 and 
two equivalents of sodium acetate ovemight. The absence of the characteristic 4.13 
H53 and H54 resonances in the NMR spectrum (Figure 4.5.1) of the freeze dried 
reaction mixture indicated reaction of the aldehyde 4.13 was complete. 
Figure 4.5.1 lH NMR Spectrum ofEMCH Hapten (4.16) 
4.5.2.1 Characterisation of 4.16 
The molecular formula of 4,16 was determined as C7oH95020N3 by HRF ABMS. 2D-
TOCSY (mixing time 80 ms), COSY and HSMQC NMR experiments were performed 
on 4,16. These spectral data were used to partially assign the lH and l3C resonances of 
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These assigmnents are listed in Table 4.5.1 and Table 4.5.2 respectively. 
important cOlTelations from the 2D experiments are shown in Figure 
54 
HN/ )10' 
o 
I ~ 
EMCH hapten (4.16) 
106 
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Table IH NMR Data for EMCH Hapten (4,16) 
Proton" <5 ppmb Proton il <5 ppmb Proton" <5ppmb 
2.33 1.41 H39 2.18 
2.58 1.87 H39' 2.18 
H3 3.87 1.60 H40 3.91 
H4 1 H22' 1.60 H41 3.57 
H4' 1.73 H23 3 H42 2.32 
1.38 H24 CH3-42 0.89 
HS' 2.08 H24' 1.69 H43 
H6 4.35 H2S 2.18 H43' 
H7 2.94 CH3-25 1.06 H45 
H8 4.31 26==CH2 4.76 H45' 
H9 4.04 26'=CH2 4.81 H46 2.17 
HIO 4.19 H27 3.53 CH3-46 0.90 
Hll 4.59 H28 1.93 H47 3.08 
HI2 4.68 H28' H48 3.55 
1.94 H29 4.20 H49 1.83 
HB' 2.15 H30 4.65 H49' 2.16 
HI5 1.61 H3I 2.01 H50 3.92 
H15' CH3-3I 0.99 H5I 4.03 
HI6 1.42 H32 3.17 HS2 1.97 
H16' 2.17 H33 3.79 HS2' 2.25 
HI7 4.09 H34 1.78 H53 4.71 
HI8 2.25 H34' 2.14 7.00 
HIS' 2.79 H3S 4.10 H2' 6.67 
I9=CH2 4.91 H36 4.10 H3' 6.67 
I9'=CH2 4.98 H37 1.88 
H2O 4.36 H37' 2.33 
n The symbol' represents the less shielded proton of a geminal pair. 
b Data recorded at 23°C in CDCI] at 300 MHz with chemical shifts in ppm and referenced to CHelj, OH 
7.26. 
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NMR Data for EMCH Hapten (4.16) 
Carbon a ppm" Carbon a ppm" a ppm" 
Cl C21 29.3 C39 42.5 
40.3 31.9 C40 70.7 
C3 73.6 74.7 79.3 
C4 30.6 C24 43.4 25.7 
C5 30.0 C-CHJ-25 35.9 C-CHJ-42 17.1 
C6 68.2 C-CHJ-25 17.8 C43 
C7 77.6 26C=CHz C44 
C8 74.3 26C=CH2 104.1 C45 
C9 73.7 C27 73.6 C-CHJ-46 28.6 
CIO 76.5 C28 36.8 C-CHJ-46 17.4 
Cll 82.2 C29 71.1 C47 73.1 
CI2 81.1 C30 76.8 C48 63.4 
C13 48.2 C-CHJ-3I 36.6 C49 31.1 
CI4 C-CH3-3I 14.9 C50 74.6 
CI5 34.3 C32 77.5 C5I 76.2 
CI6 28.0 C33 66.5 C52 38.8 
CI7 C34 29.0 C53 
CI8 38.7 C35 C54 
I9C=CHz C36 C2' 134.0 
I9C=CHz 104.4 C37 43.3 C3' 134.0 
C20 75.3 C38 
a Data recorded at 23°C in CDCI) with chemical shifts in ppm, assigned from an HSMQC spectrum at 
300 MHz. 
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The chemical shifts and connectivities of rings A-L were identical to those of 1,25. The 
doublet resonance at OH 7.00 was assigned as the hydrazone proton H54. The remaining 
protons of the halichondrin skeleton (H52-H54) were assigned from COSY and TOCSY 
couelations to this resonance. The H54 resonance was couelated to a resonance at OH 
4.71 in the COSY spectrum, allowing the assignment of H53. A TOCSY correlation 
from the H54 resonance to OH 1.97 and OH 2.25 allowed the assignment of the H521H52' 
methylene pair. 
4.6 Reduction ofNorhon10halichondrin B Aldehyde 
4.6.1 Introduction 
The reduction of norhomohalichondrin B aldehyde (4.13) to the alcohol 4.17 would 
facilitate the formation of a single product upon reaction of 4,17 with the phenyl or 
styryl linkers. This would both eliminate the purification step required when making 
haptens from the diol 1.25, and improve the yield. 
4.6.2 Reduction 
Norhomohalichondrin B aldehyde (4.13, 3.9 mg) was reduced to the alcohol 4.17 upon 
treatment with an excess of sodium borohydride in IP A for 1 hours. The reaction was 
quenched with aqueous NH4CI, diluted with water and run through a reverse phase 
(CI8) cartridge. The cartridge was washed with water before stripping with MeOH. 
The solvent was evaporated to give (3.8 mg). 
Structural Elucidation 
The molecular formula of C6oHs4018 determined by HRF ABMS confirmed that 
reduction had occurred to give 4.17. 
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9H3 
H 
H H 
0 0 M 
f:f 9H3 37 
- f:f : - 011 -
0 N 47 
O~ 
0 
H 34 H 
OH H H CH3 
norhomohalichondrin B (4.17) 
The IH NMR spectrum of 4.17 is displayed in Figure 4.6.1. The most obvious 
differences in the IH NMR spectrum of 4.17 compared to that of 4.13 were the absence 
of the H54 aldehyde resonance and the shift of the H53 resonance from an isolated 
position at OH 4.51. The region between OH 3.45 and OH 4.15 had also undergone subtle 
changes. A doublet of doublets resonating at OH 3.79 were thought to belong to the 
newly formed H54/H54' methylene pair. 
A full array of NMR experiments were performed on 4.17 viz HSMQC, HMBC, 2D-
TOCSY (mixing time 100 ms), COSY and APT (Figure 4.6.2) experiments. These data 
allowed the full assignment of the IH and l3C resonances of 4.17 to be made. The IH 
and l3C spectral data are collated in Table 4.6.1 and Table 4.6.2, and the important 
correlations from the 2D-NMR experiments are shown in Figure 4.6.3. 
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Figure 4.6.1 lH NMR Spectrum of Norhomohalichondrin B (4.17) 
Figure 4.6.2 APT Spectrum of Nor hom ohali chondrin B (4.17) 
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Table 4.6.1 I H NMR Data for N orhomohalichondrin B (4.17) 
Protona oppmb oppmb oppmb 
2.34 4.39 1.90 
2.60 lAO 2.34 
3.88 1.89 2.19 
1.38 1.61 2.19 
H4' 1.74 H22' 1.61 3.93 
1.39 3.52 3.58 
H5' 2.08 H24 1.03 2.35 
H6 4.33 H24' 1.68 0.92 
2.94 2.21 1.30 
H8 4.32 1.07 1.43 
4.06 4.77 1.43 
HI0 4.18 26'=CHz 4.81 1.43 
H11 4.60 3.52 H46 2.19 
H12 4.69 1.94 CH3-46 0.92 
H13 1.94 H28' 2.01 H47 3.07 
H13' 2.14 H29 4.19 3.54 
HIS 1.60 H30 4.66 H49 1.81 
HIS' 2.17 2.03 H49' 2.15 
H16 1.43 1.00 3.88 
H16' 2.17 3.18 4.03 
H17 4.10 3.80 1.95 
2.26 1.79 1.95 
H18' 2.80 2.15 4.32 
19=CHz 4.92 4.11 3A9 
19'=CH2 4.99 4.11 3.79 
a The symbol' represents the less shielded proton of a geminal pair. 
b Data recorded at 23°C in CDCI] at 300 MHz with chemical shifts in ppm and referenced to CHCI" OH 
7.26. 
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Table 4.6.2 lJC NMR Data for Norhomohalichondrin B (4.17) 
Carbon (5 ppm" Carbon (5 ppm" Carbon (5 ppm" 
CI 171.1 C20 75.4 C37 43.5 
C2 40.5 C21 29.5 C38 112.3 
C3 73.7 C22 32.1 C39 42.6 
C4 30.8 C23 74.8 C40 70.7 
C5 30.1 C24 43.5 C41 79.4 
C6 68.3 C-CH3-25 36.0 C-CH3-42 25.8 
C7 77.7 C-CH3-25 18.1 C-CH3-42 17.8 
C8 74.4 26C=CHz 151.7 C43 37.1 
C9 73.9 26C=CHz 104.1 C44 96.7 
CIO 76.5 C27 73.6 C45 37.1 
Cll 82.1 C2S 37.0 C-CH3-46 28.8 
Cl2 81.1 C29 71.2 C-CH3-46 17.2 
C13 48.4 C30 77.1 C47 73.1 
Cl4 110.0 C-CH3-31 36.6 C4S 63.7 
Cl5 34.5 C-CH3-31 15.1 C49 31.5 
Cl6 28.3 C32 77.6 C50 74.4 
Cl7 75.3 C33 66.6 C51 77.2 
CIS 38.8 C34 29.1 C52 36.0 
19C=CHz 151.4 C35 75.1 C53 78.3 
19C=CH2 104.4 C36 76.3 C54 64.3 
a Data recorded at 23°C in CDCI) at 75 MHz with chemical shifts in ppm and referenced to CHCI), Oc 
77.0. 
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The full assignment of the lH and 13C NMR spectral data confirmed the chemical shift 
and connectivity of 4.17 was identical to that of for the A-N rings. A correlation in 
the HSMQC spectrum between the proton resonating at OH 3.79 and a methylene carbon 
resonance at 64.1 allowed the assignment of this proton as H54'. The geminal H54 
proton was assigned from the observation of a COSY correlation between the H54' 
resonance and a resonance at OH 3.49. The assignment of H54 was supported by a 
correlation in the HSMQC spectrum between the C54 resonance and a resonance at OH 
3.49. A COSY correlation from both the H54 and H54' proton resonances to a 
resonance at OH 4.32 allowed the assignment ofH53. The H53 resonance was correlated 
to a resonance at OIl 1.95 in the COSY spectrum. The H51 resonance (OIl 4.03) was also 
cOlTelated to a resonance at OH 1.95 in the COSY spectrum. Both 
attributed to this resonance. 
4.6.4 Biological Activity 
and H52' were 
The biological activity of 4.17 was evaluated in both the in-house P388 assay and the 
NCI's in vitro 60 cell line primary screening assay. The results are presented in Table 
4.6.3, along with those of reference halichondrins for comparison of activity. 
Table 4.6.3 In Vitro Cytotoxicities of Selected Halichondrins 
Compound P388 ICso COMPARE 
(nglmL) (XlO-IO M) Correlation 
halichondrin B (1.8) 0.78 1.38 1.00 
homohalichondrin B (1.25) 0.22 3.16 0_95 
norhomohalichondrin B (4.17) 0.64 1.23 0.99 
The in vitro biological activity of norhomohalichondrin B (4.17) is comparable to that 
of the natural halichondrins 1.8 and 1.25, both in the magnitude of the cytotoxicity and 
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in the mode of action. This is hardly suprising considering the degree of structural 
similarity between the compounds. 
Norhomohalichondrin B (4.17) has been refelTed to the Biological Evaluation 
Committee for further testing. 
4,7 Norhomohalichondrin Band PMSI 
4.7.1 Reaction of Norhomohalichondrin B with PMSI 
Norhomohalichondrin B (2.4 mg, 4.17) and PMSI were dissolved in CDCl3 (with 0.1 % 
CDsN) and the reaction monitored by IH NJ'vIR spectroscopy. Evidence of reaction was 
observed after 14 hours with a reduction in the H54 resonance and changes to the 
methyl region of the IH NMR spectrum of the reaction mixture. After 42 hours the 
integral of the upfield styryl proton (HIli, OH 5.95) relative to that of H32 and HI8' 
indicated that the reaction was complete. The solvent was evaporated and the residue 
dissolved in CH2Cl2 and chromatographed on LH20 to remove excess reagent. The 
column was eluted with CH2Cl2 and thirty fractions collected. The fractions containing 
solely halichondrin material were identified by TLC (DIOL, 4% MeOWCH2CI2) and 
combined to give the product (4.19, 2.5 mg). 
4.7.2 Structural Elucidation 
The appearance of a resonance at OH 5.95 in the IH NMR spectrum of 4.19 was 
consistent with attachment of the PMSI linker to norhomohalichondrin B (4.17) (refer to 
Section 4.2). COSY, 2D-TOCSY (mixing time 100 ms), HSQC and HMBC 
experiments were performed on 4.19. These data enabled the assignment of the 
majority of the IH and DC NMR resonances of 4.19. The IH and l3C NMR data are 
collated in Table 4.7.1 and Table 4.7.2 respectively, and the important correlations from 
the 2D experiments are shown in Figure 4.7.1. 
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Table IH NMR Data for Norhomohalichondrin B PMSI Hapten (4.19) 
Proton" (3 ppmb Proton' (3ppmb Protona oppmb 
H22 1.60 2.37 
2.60 1.60 CH]-42 0.92 
H3 3.88 3.53 H43 1.30 
H4 1.37 H24 1.04 1.43 
H4' 1.73 H24' 1.68 1.43 
1.38 H25 2.20 H45' 1.43 
H5' 2.09 1.07 H46 2.18 
H6 4.32 26=CH2 4.77 CH3-46 0.92 
H7 2.94 26'=CHz 4.81 H47 3.07 
4.34 H27 3.52 H48 3.54 
4.05 H2S 1.99 H49 1.80 
HIO 4.19 H28' 2.09 H49' 2.19 
Hll 4.60 H29 4.19 H50 3.91 
Hl2 4.69 H30 4.66 4.04 
1.93 H31 2.02 H52 1.76 
HB' 15 1.00 H52' 2.09 
Hl5 1.61 3.18 H53 4.45 
Hl5' 2.17 H33 3.80 H54 
Hl6 1.42 H34 1.78 
H16' 2.18 H34' 2.14 ill' 6.84 
Hl7 4.09 4.11 H3' 6.84 
Hl8 2.25 H36 4.10 H6' 7.24 
H18' 2.80 H37 1.90 7.35 
19=CHz 4.92 H37' 2.34 H9' 7.35 
19'=CH2 4.99 H39 2.19 HIO' 7.24 
H2O 4.37 H39' 2.19 Hll' 5.95 
H21 1.40 H40 3.91 7.24 
1.89 H41 3.57 
" The symbol' represents the less shielded proton of a geminal pair. 
b Data recorded at 23°C in CDCl, at 300 MHz with chemical shifts in ppm and referenced to CHCl" OH 
7.26. 
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DC NMR Data for Norhomohalichondrin B PMSI Hapten (4.19) 
Carbon {) ppm" {) ppm" Carbon {) ppm" 
Cl 171.1 35.6 
40.1 17.7 
C3 73.7 151.7 C47 73.1 
C4 30.4 103.7 63.5 
30.4 73.4 C49 30.9 
C6 68.0 C28 36.5 CSO 74.2 
C7 77.8 C29 71.2 CSl 77.0 
C8 74.3 C30 76.9 36.5 
C9 73.9 36.5 75.6 
CIO 76.5 14.8 
Cll 81.7 77.5 CI' 169.5 
C12 80.6 C33 66.5 C2 1 134.0 
C13 48.1 C34 28.8 C3' 134.0 
Cl4 109.9 75.1 b C4' 169.5 
CIS 34.3 C36 76.2b CS' 
Cl6 27.6 C37 43.1 C6' 126.0 
Cl7 C38 C7' 125.8 
Cl8 38.4 C39 42.3 CS' 
19C=CHz C40 70.6 C9' 126.0 
104.3 C41 79.5 CIO' 
C20 75.0 C-CH3-42 25.7 Cll' 109.3 
C21 29.3 16.9 C12' 147.2 
C22 31.7 C43 36.8 C13' 
C23 74.7 C44 
C24 43.1 C45 36.8 
a Data recorded at 23°C in CDCl3 with chemical shifts in ppm, assigned from an HSQC spectrum at 300 
MHz. 
b Assignment tentative - may be interchanged. 
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These data confirmed the connectivity and chemical shift of 4.19 were identical to that 
of 4.17 for the A-N ring's. A methine proton at iSH 4.45 showed a COSY correlation to a 
pair of methylene protons (iSH 1.76, 2.09). A TOCSY correlation from this methine 
proton to the H51 proton resonance (iSH 4.04) allowed the assignment of H53. The 
methylene proton resonances were assigned as H52 and H52'. The C52 resonance (iSe 
36.5), assigned from the observation of a correlation with the H52 proton in the HSQC 
spectrum, supports the assignment of the methylene pair as H52 and H52' rather than the 
oxygenated methylene protons H54 and H54'. It was not possible to assign H54 and 
H54' as no COSY or TOCSY correlations to the methylene pair were seen from H53. 
9H3 9H3 H I:l 37 : I:l H H 0 
0 -0 
/0 M H N 0 47 A 34 0 
0 A 
norhomohalichondrin B PMSI hapten (4.19) 
4.8 Summary 
The formation of haptens "presenting" the macro cyclic portion of the halichondrin 
skeleton has been investigated. A series of haptens were constructed utilising the 
linkers PMSI, PMPI and EMCH attached to one or more of hom ohali chondrin B (1.25), 
isohomohalichondrin B (1.2S) and norhomohalichondrin B aldehyde (4.13). Reduction 
of the aldehyde 4.13 to norhomohalichondrin B (4.17) provided the starting material for 
an improved route (in terms of yield) to a PMPIIPMSI hapten. 
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5.1 Introduction 
As discussed in Section 4.1, antibodies elicited in response to an immunogenic protein 
conjugated distal to the terminal site of a B series halichondrin should discriminate 
between the B series congeners. The New Zealand sponge Lissodend01Yx sp. is 
cUlTently the most likely source of halichondrins for future preclinical trials.62 To date 
only B series halichondrins have been isolated from this sponge. The development of 
an immunoassay with the ability to distinguish between the B series analogues would be 
a valuable tool for assessing the purity of drug preparations. 
The possible sites for attachment of a linker distal to the terminus of the halichondrin 
skeleton are limited to the C 1-C30 lactone and the CH2= 19 and CH2=26 exocyclic 
methylenes. The lactone was not regarded as a good option, as it was preferable to 
maintain the integrity of the halichondrin skeleton to gain maximum antibody 
recognition. The exocyclic methylenes were considered the most likely site at which to 
achieve linker attachment. 
Diketone 5.195 was a readily accessible compound for reaction with the linker 
(Section 4.5). However attachment of a single linker at one of either C19 or C26, with 
retention of the remaining olefin, was preferable. The differential reactivity of the 19 
and 26 exocyclic methylenes observed previously during the formation of the dikctone 
indicated that selective derivatisation of the olefinic groups may be possible. The 
X-ray structure ofnorhalichondl'in A (Figure 5.1.1)98 and the solution conformations of 
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homohalichondrin B indicated by NMR spectroscopy95 suggest that the 9 group is 
orientated into the lactone ring and thus is less exposed (greater steric hindrance) than 
the CH2=26 group which points towards the outside of the lactone choice ofa 
sterically demanding reagent could be expected to enhance this difference in reactivity. 
9H3 
H 
0 H H 
II 0 0 M 
/c" 55 ° 
N 
H3C 0 47 
52 
H 
H3C, /0 H CHs 
C 
II 
0 
o 18 
homohalichondrin B diacetate diketone (5.1) 
Figure 5.1.1 The X-ray Structure of No rhali chondrin A98 
5.2 Hydroboration-oxidation 
Hydroboration-oxidation of the methylene would be expected to give a hydroxy 
derivative. Haptens could be produced from this derivative upon reaction with PMPI 
(4.2) or PMSI (4.1). 
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9-Borabicyclo[3.3.lJnonane (9-BBN, 5.2) was chosen as the hydroborating agent 
because of its and because it was readily available in a stable crystalline form. 
HBtf 
9-BBN (5.2) 
5.2.1.1 Reaction of ~-Pinene with 
The reaction conditions for hydroboration were established using ~-pinene as a model 
compound. ~-Pinene was treated with 5.2 in THF for 18 hours before the addition of a 
basic solution of hydrogen peroxide. The reaction was stirred for a further 2 hours 
before quenching with potassium carbonate. A IH NMR spectrum of the organic extract 
indicated the reaction was nearly complete as the exocyclic methylene resonances were 
barely visible. 
5.2.1.2 Acetylation of 
The protection of the terminal diol of homohalichondrin B (1.25) was necessary before 
hydroboration to limit the possible sites of reaction for the PMPI (4.2) or PMSI (4.1) 
linkers to the newly formed alcohoL Compound 1.25 was acetylated with acetic 
anhydride in pyridine at room temperature for 16 hours. The reaction was quenched 
with H20 before extraction with EtOAc. The IH NMR spectrum of the organic extract 
was identical to that of an authentic sample ofhomohalichondrin B diacetate 
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CH3 
homohalichondrin B diacetate (5.3) 
5.2.1.3 Reaction of with 9-BBN 
Homohalichondrin B diacetate 0.6 mg) was treated with 9-BBN in 
for 8 hours. A basic solution of hydrogen peroxide was added and the reaction stirred 
for a further 2 hours. The IH NMR spectrum of the EtOAc extract indicated that the 
starting material 5.3 was intact. 
The reaction was repeated and allowed to react for 5 days before the addition of basic 
hydrogen peroxide. After a further 6 hours the reaction mixture was extracted with 
EtOAc. The exocyclic methylene resonances were still visible in the NMR spectrum 
of the organic extract. Comparison of the integrals of these olefinic resonances with the 
H54 methine resonance confirmed that no reaction had occurred. 
The reaction was repeated using a twenty-fold molar excess of 9-BBN to negate any 
influence that trace amounts of moisture might be having on the reaction. Once again 
starting material 5.3 was recovered. It was concluded that 9~BBN was simply too large 
to react with the sterically hindered exocyclic methylenes of homohalichondrin B 
diacetate (5.3). 
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A smaller hydroborating agent was required. Borane dimethyl sulfide was chosen 
because of its and availability. Reaction conditions were again established using p-
pinene as a model compound. 
5.2.2.1 Hydroboration of 
A THF solution of borane dimethyl sulfide was added to (0.5 mg) in dry CDCI) in 
an NMR tube filled with argon. The reaction was monitored half hourly by 'H NMR 
spectroscopy, and when no change to the exocyclic methylene resonances was observed 
a further aliquot of borane dimethyl sulfide (2 ilL) was added. such additions 
were made with no effect on the starting material. It was thought that the scale of the 
reaction may be enhancing the detrimental effect of any residual water in the solvent or 
in the NMR tubes used. To negate this problem excess reagent was used. This did give 
rise to some reaction as a small change in the chemical shift and intensity of the 
exocyclic methylene resonances was observed, along with the disappearance of the H32 
resonance. solution was oxidised (HzO/NaOH) and the product extracted with 
EtOAc. The complexity of the methyl region of the 'H NMR spectrum indicated that 
the extract contained a mixture of products. The shift in the exocyclic methylene 
resonances could not be explained but if hydroborationloxidation had occurred there 
should be no resonances in this region of the spectrum. There was inadequate material 
for further investigation. 
It was decided to change the solvent used to the more conventional THF and to use 
reacti-vials to facilitate dry reaction conditions. Borane dimethyl sulfide was added to 
homohalichondrin B diacetate (5.3, 0.5 mg) dissolved in dry (100 ilL) and stirred 
for 16 hours. Ethanol was added to destroy the borane before adding basic hydrogen 
peroxide. Stirring was continued for 6 hours before extracting the product with EtOAc. 
The absence of the CH2=26 methylene resonances and a reduction in the CH2=19 
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methylene resonances in the IH NMR spectrum of the extract indicated that the reaction 
had been successful. The incomplete derivatisation of the CH2=19 olefin was promising 
as it gave an indication that it may be possible to refine the reaction conditions to enable 
hydroboration of the CH2=26 methylene only. The extract was resubmitted to 
hydroborationloxidation to complete oxidation of the CH2= 19 olefmic group. 
It was planned to employ semipreparative reverse phase (C 18) HPLC to purify the 
product mixture. However no peaks were observed in the HPLC chromatogram of the 
product mixture. The lack of UV visibility could be attributed to loss of a chromophore 
from the molecule, in the form of the exocyclic methylenes. TLC (DIOL, 3% 
MeOHlCH2CI2) showed that there was a mixture of products, of similar polarity to 
homohalichondrin B (1.25). Introduction of a UV chromophore to 1.25 in the form of a 
phenyl-derived protecting group was necessary to enable purification of the subsequent 
hydroboration product mixture. 
5.2.2.2 Protection of 1.25 with a UV -active Protecting Group 
Several factors had to be considered when selecting a suitable protecting group. The 
use of acid conditions had to be avoided as previous experience had shown the 
halichondrins were not stable to acid treatment.95 The halichondrins were relatively 
stable to dilute alkaline solutions, but less stable in the presence of more nucleophilic, 
Lewis bases, such as sodium methoxide.95 Subsequent reaction of the 
hydroborationloxidation product with an isocyanate linker would produce a carbamate 
functionality. Conditions used for the cleavage of the protecting group could not affect 
this coupling. The protecting group, while cleavable in mild conditions, needed to be 
stable to hydroboration and basic hydrogen peroxide. Careful consideration of these 
requirements led to the choice of benzoate ester for the protection of homohalichondrin 
B. 
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Homohalichondrin B 0.3 mg) was treated with benzoic anhydride and N, N-
dimethylaminopyridine (DMAP), in dry pyridine for 42 hours before extracting with 
EtOAc. The solvent was evaporated in vacuo to give a mixture of the product and 
DMAP. This mixture was dissolved in water and applied to a reverse phase (CIS) 
cartridge. The cartridge was washed with H20, eluted with MeOHlH20 (1:1) to remove 
the DMAP and stripped with MeOH to give the product 
homohalichondrin B dibenzoate (5.4) 
The absence of the H55/55' methylene resonances (8R 3.69) and the appearance ofa new 
resonance at 8H 5.55 together with two full sets of phenyl-type resonances in the 'H 
NMR spectrum of the MeOH fraction supported the assignment of homohalichondrin B 
dibenzoate (5.4). The 8H 5 resonance was assigned to the H54 proton, analogous to 
the downfield shift observed for the H54 resonance of homohalichondrin B diacetate 
(5.3). The H54 proton resonance was irradiated in a ID TOCSY experiment (mixing 
time 80 ms) to probe the chemical shifts of other protons in the same spin system. The 
HS51SS' and H53 proton resonances were found to overlap in the region of OH 
The upfield resonance (8H 1.67) was assigned to the H52/52' methylene protons. 
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Figure 5.2.1 ID-TOCSY Correlations from H54 of 5.4 
5.2.2.3 Deprotection of 5.4 
In a trial reaction to establish conditions for the cleavage of the benzoate protecting 
groups, the dibenzoate 5.4 was treated with 1 % K2C03 in MeOH for 24 hours. The 
removal of both benzoate protecting groups was confirmed by TLC (DIOL, 3% 
MeOH/CH2Cl2). It was realised that the use of MeOH would not be possible due to the 
reactivity of the maleimide linker that would be present at the deprotection step 
(discussed in Section 4.3.2). It was found that using acetonitrile in place of methanol 
gave the same result. The stability of the carbamate linker to the cleavage conditions 
was established using a 2,2-dimethylpropanol/PMPI derivative as a model. 
5.2.2.4 Hydroboration of 5.4 
Homohalichondrin B (1.25, 1 mg) was protected as the dibenzoate by treatment with 
benzoic anhydride and DMAP in dry pyridine for 40 hours. The reaction was quenched 
by the addition of saturated NaHC03 and the product extracted with EtOAc. Excess 
DMAP was removed from the organic extract as described previously by passing it 
through a reverse phase (CIS) cartridge. A 'H NMR spectrum of the MeOH fraction 
eluted off the cartridge was comparable to the spectrum obtained previously for 5.4. 
Compound 5.4 was stirred with borane dimethyl sulfide in THF for 17 hours. The 
borane was quenched by the addition of a few drops of ethanol before basic hydrogen 
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peroxide was added. The reaction mixture was stilTed for a further 6 hours before 
extraction of the product with EtOAc. The 19 and 9' methylene resonances 
were observed in the NMR spectrum of the product mixture. Integration of these 
methylene resonances relative to the H54 resonance indicated that ca 13% of the mono-
derivatised product was present in the mixture. It appeared that both benzoate 
protecting groups were still intact. Reverse phase (CIS) HPLC, using 60% CH3CNIHzO 
as the mobile phase, was used to separate the mixture into seven fractions, five of which 
were found to contain halichondrin-derived species. absence of the characteristic 
exocyclic methylene resonances in the iH NMR spectrum of the most polar fraction 
(403 s) was consistent with the formation of a hydroboration product. The loss of one 
of the benzoate groups was evident from the iH NMR spectmm. A fraction of similar 
polarity (520 s) was found to be halichondrin in character but a lack of mass prevented a 
more in depth analysis. The iH NMR spectmm of the major component (2197 s) 
showed that the exocyclic methylenes were no longer intact, with no resonances 
observed in the region of OH 4.75-5.05. The presence of the H54 resonance at OH 5.65 
indicated that both benzoate protecting groups were intact. The molecular formula of 
C7sH98023 was consistent with formation of the desired oxidation product. 
H H 
0 
M 
0 N 47 
52 0 H H CH3 
hydroboration-oxidation product (5.5) 
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The complicated nature of the methyl region in the IH NMR spectrum of another non 
polar fraction (23 s) indicated that it contained a mixture of dibenzoate hydroboration 
products. The mixture included some (50%) intact 19 methylene derivative. further 
non polar fraction (2886 s) was too small to allow the deduction of anything other than 
its halichondrin character. 
The loss of the benzoate protecting group was initially attributed to the oxidation 
process, which uses basic hydrogen peroxide, although benzoate protection was chosen 
because it is usually stable under these conditions.99 The purity of the starting material 
was also questionable. A small amount of mono-protected homohalichondrin B may 
have been present which could have given rise to the more polar of the hydroboration 
products. It is impossible to be sure which of the above occurred but there are problems 
with both scenarios. Benzoate cleavage during oxidation would affect product yield. 
Alternatively, there was a mixture of mono- and di-protected hydroxy groups in the 
starting material after 42 hours reaction, the ease with which the dibenzoate is formed is 
. questionable. Benzoate protection was put to one side while other protection methods 
were investigated. 
5.2.2.5 Protection of 1.25 with t-Butyldiphenylsilyl Chloride 
The stability to hydroborationloxidation conditions has been reported for t-
butyldiphenylsilyl (TBDPS) and t-butyldimethylsilyl protected compounds. 100,101 
common method for the removal of this class of protecting group is treatment with 
HF Ipyridine in 
Homohalichondrin B (1 mg) was stirred with TBDPSCI and pyridine for 42 hours at 
room temperature. The reaction mixture was diluted with hexanes/toluene (1 :1) and 
loaded onto a DIOL cartridge. The cartridge was eluted with a gradient elution scheme, 
from hexanes/toluene (1: 1) through to CH2CI2• Halichondrin-type resonances were 
observed in the IH NMR spectra of the toluene and toluene/CH2C12 (1 :1) fractions. TLC 
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(DIOL, 3% MeOH/CH2CI2) of these combined fi:actions produced two spots that 
coloured brown with PMA spray, characteristic of halichondrin compounds. 
Semipreparative reverse phase (CI8) HPLC using a mobile phase of 60% CH)CNIH20 
was used to separate the mixture into three fractions. No halichondrin-like material was 
found in any of these fractions. The HPLC column was stripped with MeOH. A 'H 
NMR spectrum of the column strip contained halichondrin-derived components. The 
complicated nature of the methyl region indicated that more than one compound was 
present. The characteristic H551H55' methylene resonance was no longer visible, 
consistent with reaction of the diol group. 
The difficulties encountered with the ease and reliability of protection, and subsequently 
deprotection, of homohalichondrin B lead to the investigation of alternative methods for 
exocyclic methylene derivatisation. 
5.3 Osmium tetroxide 
The reaction of homohalichondrin B diacetate (5.3) with osmium tetroxide followed by 
cleavage with sodium periodate to produce the 19,26-diketone was established by 
Hati.95 Evidence of differential reactivity between the CH2=19 and CH2=26 olefinic 
groups was observed. It was thought that the reaction of with just one molar 
equivalent of osmium tetroxide might result in selective oxidation of the CH2=26 olefin. 
5.3.1 Reaction of 5.3 with 0804 
Homohalichondrin B diacetate 3.4 mg) was stirred with an ethereal solution of 
osmium tetroxide in pyridine for 4.5 hours. Sodium metabisulfite in water/pyridine was 
added to the reaction mixture and stirring continued for a further 30 minutes. The 
product was extracted with CH2Cl2 and dried over MgS04• The observation of the H54 
resonance (OB 5.14) in the 'H NMR spectrum of the product mixture indicated the 
acetate protecting groups were still intact. The CH2=26 resonances were completely 
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absent, and the CH2= 19 olefinic resonances were reduced to ca 60% of their original 
area relative to comparing their integral to that of the H54 resonance. The 
appropriate resonances for the osmate esters95 (OH 4.56, 4.61, 4.74) were not 
observed which suggested that the diol had been formed. TLC (DIOL, 3% 
MeOHlCH2CI2) showed the mixture contained two products, of similar polarity to 
homohalichondrin B (1.25). The product mixture was purified on DIOL, eluting with 
hexanes/toluene (1: 1), toluene, toluene/CH2Cl2 (1: 1) and CH2Clz' Fractions identified 
by TLC as containing solely the diol 5.6 were combined (1.2 mg). The remaining 
halichondrin-containing fractions were combined and re-osmylated to produce the 
tetraol 5.7 (1.5 mg). 
Characterisation of 5.6 
The molecular formula for 5.6 of C65Hn023 determined by HRF ABMS was consistent 
with diol formation. 
o 
o 
52 
homohalichondrin B diacetate 26-diol (5.6) 
There were several notable differences between the 'H NMR spectrum of 5.6 (Figure 
.1) and that of 5.3. The most significant difference was the absence of the CH2=26 
olefinic resonances. A change in chemical shift was seen for the H2' methylene 
resonance (upfield OH 0.1) and the resonance (upfield OH 0.06). New resonances 
were observed at OH 3.38 and ca OH 4.2. 
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5.3.1 lH NMR Spectrum of Homohalichondrin B Diacetate 26-Diol (5.6) 
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A full array of NMR experiments were performed on 5.6 viz COSY, 2D-TOCSY 
(mixing time 100 ms), HSMQC and HMBC experiments. These data enabled the 
assignment of the majority of the 'H NMR and DC NMR resonances of to 
achieved. and 13C NMR data are collated in Table 5.3.1 and Table 5.3 and the 
important correlations from the 2D experiments are shown in Figure 5.3.2. 
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Table IH NMR Data for Homohalichondrin Diacetate 26-Diol (5.6) 
Proton" (5 ppmb Proton3 (5 ppd) Proton3 (5 ppmb 
HZ 2.28 H21 1.43 H39 2.20 
2.45 H39' 2.20 
3.84 3.92 
H4 1.30 H22' 3.60 
H4' 1.66 H23 3.56 H42 2.35 
1.35 H24 1.11 CH3-42 0.95 
HS' 2.09 1.56 1.30 
H6 4.24 1.77 1.45 
H7 2.89 CH3-25 1.00 H45 1.45 
H8 4.29 26-CH2 3.38 H45' 1.45 
H9 4.03 26'-CH2 3.88 H46 2.15 
HIO 4.18 3.15 CH3-46 0.92 
Hll 4.58 H28 1.84 3.06 
H12 4.68 H28' 2.03 H48 3.52 
H13 1.96 H29 4.17 H49 1.74 
H13' 13 H30 4.56 H49' 15 
HI5 1.60 1.96 H50 3.88 
HIS' 2.20 CH3-31 1.04 H51 4.01 
H16 1.39 H32 3.37 H52 1.74 
H16' H33 3.94 H52' l.98 
HI7 4.10 H34 4.35 
H1S 2.24 H34' 5.13 
HIS' 2.78 H35 H55 4.18 
I9=CH2 4.92 H36 4.14 H55' 4.28 
I9'=CH2 5.00 H37 1.90 540COCH3 2.10 
H2O 4.31 H37' 2.37 550COCH3 2.04 
a The symbol! represents the less shielded proton of a geminal pair. 
b Data recorded at 23°C in CDCl) at 300 MHz with chemical shifts in ppm and referenced to CHCIJ , OH 
7.26. 
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13C NMR Data for Homohalichondrin Diacetate 26-Diol (5.6) 
Carbon 8ppma Carbon 8ppma Carbon 8ppma 
Cl 171.2 C22 C41 79.4 
40.1 C23 75.3 25.4 
C3 74.6 38.6 1 
C4 C-CH3~25 40.8 37.1 
C5 29.8 C-CH3-25 14.7 C44 96.3 
C6 68.0 26C-CHz 70.9 C45 36.7 
C7 77.8 26C-CHz 58.3 C-CH3-46 28.5 
C8 74.0 79.3 C-CH3-46 16.9 
C9 73.7 C28 C47 72.7 
CI0 76.5 C29 69.0 C48 63.6 
Cll 82.2 C30 74.3 C49 31.0 
C12 80.9 C-CH3-31 37.6 C50 74.3 
C13 48.3 C-CH3-31 15.4 76.2 
C14 109.5 C32 75.9 C52 36.4 
Cl5 34.5 C33 68.0 C53 76.2 
Cl6 C34 C54 72.1 
C17 75.6 C35 75.9 63.7 
Cl8 38.9 C36 75.9 540COCH3 170.6 
19C=CH2 151.9 C37 43.6 540COCH3 20.7 
19C=CHz 103.8 C38 112.3 550COCH3 170.6 
C20 74.0 C39 42.3 550COCH3 20.7 
C21 C40 70.6 
a Data recorded at 23°C in CDCl] with chemical shifts in ppm, assigned from HSMQC and HMBC 
spectra at 300 MHz. 
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Significant changes in chemical shift were observed for the H20 to H33 proton 
resonances. The connectivity and chemical shifts of the remaining protons were readily 
established using the information obtained from the COSY and 2D-TOCSY 
experiments. Correlations in the COSY spectrum from the downfield H30 resonance 
(OH 4.56) to protons resonating at OH 4.17 and OH 1.96 allowed the assignment of H29 
and H31 respectively. A COSY correlation between the H31 resonance and OH 1.04 
allowed the assignment of CH3-31. This allowed the remaining methyl resonance (OH 
1.00) to be assigned to CH3-25. The H31 resonance was correlated to OH 3.37 in the 
COSY spectrum, allowing the assignment of H32. A TOCSY correlation between the 
H30 resonance and OH 3.15 allowed the assignment ofH27. H28 (OH 1.84) and H28' (OH 
2.03) were assigned from the observation of COSY correlations between these 
methylene resonances and the H27 resonance (OH 3.15). A COSY correlation between 
the CH3-25 methyl resonance and OH 1.77 allowed the assignment of H25. TOCSY 
correlations were observed between the CH3-25 resonance and OH 1.77 (H25), OH 1.56 
and OH 3.56 allowing the assignment of H24' and H23 respectively. A COSY 
correlation to the H24' resonance from OH 1.11 allowed the assignment of H24. A 
correlation in the HSMQC between a pair of methylene proton resonances (OH 3.38 and 
OH 3.88) and a carbon resonating at Oc 58.3 allowed the assignment of CH2-26 and CH2-
26'. 
5.3.3 Further Osmylation of 5.3 
The osmylation reaction was repeated on a larger scale, using a freshly prepared batch 
of 5.3, to check the reproducibilty of the result. The reaction was to provide material for 
complete characterisation of the 26-keto derivative, for methylenation attempts, and for 
future hapten production should this be required. Homohalichondrin B (1.25, 14.4 mg) 
was stirred with acetic anhydride in dry pyridine for 16 hours at room temperature. The 
reaction was quenched with water and extracted with EtOAc to give the diacetate 5.3 
(15.4 mg). 
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The protected halichondrin 5.3 was stirred with osmium tetroxide in pyridine for 4.5 
hours. Sodium metabisulfite in water/pyridine was added and the reaction stirred for a 
further 20 minutes. A IH NMR spectrum after work-up showed that ca 30% of the 
product mixhlre contained intact 9 olefin. This result is possibly atttibutable to 
the difficulties involved in adding small volumes of the OS04 solution. 
The product mixture was purified by normal phase (DIOL) chromatography with elution 
by toluene through to CH2CI2• The fractions were analysed using 'H NMR spectroscopy 
as the lack of a UV chromophore precluded the use of analytical HPLC. The 'H NMR 
spectra of several fractions contained two pairs of exocyclic methylene resonances. 
Only a single pair of resonances for the CH2=19 methylene protons was observed for the 
product mix hIre before DIOL chromatography. This would seem to indicate that some 
change had occurred during the chromatography. 
Fractions 14, 15 and 16, eluted with CH2CI2, were combined on the basis of their 
identicallH NMR spectra to give 5.7 (3.4 mg). 
5.3.4 Characterisation of 5.7 
The 'H NMR spectrum of 5.7 is displayed in Figure 5.3.3. The most obvious difference 
between this spectrum and that of the starting material 5.3 is the absence of the 19 and 
26 methylene resonances. The H18' resonance is no longer clearly visible, and there are 
additional resonances in the region of OR 3 .5. 
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5.0 2.5 1.5 1* a ppm. 
Figure 5.3.3 'H NMR Spectrum of Homohalichondrin B Diacetate 19,26-Tetraol (5.7) 
An array of 2D NMR experiments were performed on COSY, TOCSY (mixing 
time 80 ms), HSMQC and HMBC experiments. The IH and l3C NMR data extracted 
from these experiments are listed in Table 5.3.3 and Table 5.3.4 respectively. The 
important correlations from the 2D experiments are shown in Figure 5.3.4. 
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Table IH NMR Data for Homohalichondrin B Diacetate 19,26-Tetraol (5.7) 
Proton" oppmb Protona oppmb Proton3 oppmb 
2.42 H21 1.68 H39 1 
2.42 H2I' 1.81 2.21 
H3 3.91 1.56 H40 3.95 
H4 1.37 H41 3.61 
H4' 1.73 H23 3.61 H42 2.36 
1.39 H24 1.15 CH3-42 0.95 
2.11 H24' 1.57 1.30 
H6 4.25 H25 1.77 H43' 1.43 
H7 2.93 CH3-25 1.00 H45 1.44 
H8 4.35 26-CHz 3.45 H45' 1.44 
H9 4.06 26'-CH1 3.87 H46 2.15 
HlO 4.18 H27 3.15 CH3-46 0.93 
Hll 4.60 H28 1.75 H47 3.07 
Hl2 4.67 H28' 2.15 H48 3.52 
1.96 H29 4.01 H49 
H13' 2.11 H30 4.57 H49' 2.15 
HIS 1.56 H31 2.06 H50 3.87 
HIS' 2.26 CH3-31 1.06 H51 4.02 
HI6 1.45 H32 3.36 H52 1.75 
H16' H33 3.91 H52' 1.98 
Hl7 4.12 H34 2.09 H53 4.35 
HI8 1.71 H34' 2.09 H54 5.14 
Hl8' 2.21 H35 4.14 HS5 4.18 
I9-CHz 3.70 H36 4.06 H55' 4.27 
I9'-CHz 3.70 H37 1.93 540COCH3 2.10 
H2O 3.72 H3T 2.38 550COCH3 2.04 
a The sym bol ! represents the less shielded proton of a geminal pair. 
b Data recorded at 23°C in CDCI) at 300 MHz with chemical shifts in ppm and referenced to CHCl}, OH 
7.26. 
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Table 13C NMR Data for Homohalichondrin B Diacetate 19,26-Tetraol (5.7) 
Carbon is ppm" Carbon is ppm" Carbon 3 ppm" 
Cl 168.7 C22 30.6 C41 79.5 
C2 40.8 C23 25.4 
C3 74.8 38.8 17.4 
C4 30.6 C-CH3-25 40.8 36.9 
CS 30.1 C-CH3-25 14.7 C44 96.4 
C6 68.2 26C-CHz 71.0 C45 36.9 
C7 78.1 59.1 C-CH3-46 . 28.7 
C8 74.2 C27 79.8 C-CH3-46 16.9 
C9 73.7 C28 30.6 C47 72.9 
CIO 76.4 C29 79.8 C48 63.5 
Cll 82.2 C30 75.1 C49 30.9 
C12 80.6 C-CH3-31 36.9 C50 74.2 
C13 48.4 C-CH3-31 15.5 CSI 76.2 
Cl4 108.9 C32 75.9 CS2 36.3 
CIS 35.3 C33 67.1 C53 76.2 
Cl6 28.7 C34 27.6 C54 72.3 
Cl7 74.5 63.8 
Cl8 44.9 C36 75.6 540COCH3 170.4 
19C-CH2 81.2 C37 44.0 540COCH3 20.7 
19C-CHz 67.4 C38 112.5 550COCH3 170.4 
C20 77.5 C39 42.9 550COCH3 20.4 
C21 23.2 C40 71.0 
a Data recorded at 23°C in CDCl] with chemical shifts in ppm, assigned from HSMQC and HMBC 
spectra at 300 MHz . . ·c ... 
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The NMR data were consistent with those of the diol 5.6 in the region of the and K-
N rings. Some similarities in chemical shift were observed in the region of the 26-diol, 
but differences (?: OH 0.05) were seen for the H28, H28', H29, 1 and H33 resonances. 
This may reflect the proximity of these protons to the 19-diol. The CH2-19 and CH2-19' 
proton resonances (OH 3.90) showed HMBC correlations to C19 COc 81.2), CI8 (oc 44.9) 
and C20 (oc 77.5) resonances. A COSY correlation between the H20 resonance (OH 
3.72) and a resonance at OH 1.68 allowed the assignment of H21. The H21' resonance 
(iSH 1.81) was assigned from the observation of a COSY correlation between this proton 
resonance and the geminal H21 resonance. TOCSY correlations from the H20 
resonance were seen to the resonances of H21, H21', H22 and H23. 
The molecular formula of C6sH94025, determined by HRF ABMS, is consistent with the 
formation of 5.7. 
9H3 
H 
-
0 H H 
II 0 0 M 
/c'" 55 0 N 0 47 H3C 0 
0 52 H 
H3C, /0 H 
-
CH3 
C 
II 
0 
homohalichondrin B diacetate 19,26-tetraol (5.7) 
Periodate cleavage of osmylation 
A small amount (0.3 mg) of was retained for deprotection (Section 5.3.10). The 
remaining 0.9 mg was treated with 1.2 equivalents of aqueous NaI04 for 15 hours. 
Fractions containing intact CH2=19 olefinic groups, obtained from the second 
osmylation reaction (Section 5.3.3), were combined (2.7 mg) and treated likewise with 
Chapter 5 Double Bond Alteration 145 
NaI04 for 16 hours. The products were separately extracted with EtOAc. The complex 
nature of the methyl region of the IH NMR spectra of the EtOAc extracts indicated the 
presence of a mixture of products. Analytical reverse phase (CIS) HPLC, using a 
mobile phase of 60% CH3CNIH20, showed that three halichondrin-type components 
were present in the product mixtures. Two components were of similar polarity (419 s 
and 595 s), and the third component was significantly less polar (1340 s). The 5.6 
derived product mixture contained predominantly the more polar component, with trace 
amounts of the other two components. Semipreparative reverse phase (C18) HPLC, 
using 80% CH3CNIH20 as the mobile phase, was used to separate the product mixtures 
into three fractions S.8 (2.0 mg), 5.9 (0.8 mg) and 5.10 (~ 0.1 mg). 
5.3.6 Characterisation of 
The IH NMR spectrum of 5.8 (Figure 5.3.5) showed several changes relative to the 
spectrum of the dio15.6. The CH3-25 doublet was apparent at OH 1.11, in a less shielded 
position relative to 5.6 (OH 1.00), as expected for ketone formation. Resonances were no 
longer observed in the region of OH 3.35-3.50 as the resonance was absent and 
the H32 resonance had shifted to a more shielded position (OH 3.12). A new isolated 
resonance was observed at OH 4.45. 
o 
o 
52 
H 
47 
o 
A 34 H 
homohalichondrin B diacetate 26-ketone (5.8) 
3 
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5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 l.",0 p-pm 
Figure 5.3.5 IH NMR Spectrum of Homohalichondrin Diacetate 26-Ketone (5.8) 
A range of NMR experiments (COSY, 2D-TOCSY (mixing time 100 ms), HSMQC, 
HMBC, l3C and NOE) were performed on the ketone 5.8. The IH and l3C NMR data 
obtained from these experiments are listed in Table 5.3.5 and Table 5.3.6. The 
important NMR correlations from these experiments are shown in Figure 5.3.6. 
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5.3.5 IH NMR Data for Homohalichondrin B Diacetate 26-Ketone (5.8) 
Proton" 8 ppmb Proton" 8ppmb Proton" 8ppmb 
2.33 H21 1.48 H40 3.90 
2.49 H21' 1.85 3.59 
3.87 H22 1.70 
H4 1 1.70 CH3-42 0.95 
H4' 1.67 3.86 H43 1.30 
1.35 H24 1.60 1.42 
2.06 H24' 2.02 1.42 
H6 4.29 H25 2.43 H45' l.42 
H7 2.93 1.11 H46 2.13 
HS 4.33 H27 3.74 CH3-46 0.91 
H9 4.08 H28 H47 3.06 
HI0 4.20 H28' H48 3.52 
H11 4.60 H29 4.05 H49 1.75 
H12 4.68 4.62 H49' 2.16 
H13 1.94 H31 1.95 H50 3.84 
2.15 CH3-31 0.97 4.05 
H15 1.61 H32 3.12 H52 1.75 
HIS' 2.20 3.73 H52' 1.99 
H16 1.40 H34 1.68 H53 4.35 
H16' 2.13 H34' 2.13 5.14 
H17 4.08 H35 4.17 
H18 2.24 H36 4.12 H55' 4.28 
H18' 2.83 1.88 540COCH3 2.10 
19=CH2 4.97 H37' 2.34 550COCH3 2.04 
19'=CH2 5.02 H39 17 
H2O 4.45 H39' 2.17 
IT The symbol' represents the less shielded proton ofa geminal pair. 
\j Data recorded at 23°C in CDC I] at 300 MHz with chemical shifts in ppm and referenced to CHCI) OH 
7.26. 
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5.3.6 DC NMR Data for Homohalichondrin B Diacetate 26-Ketone (5.8) 
Carbon () ppm3 Carbon () ppm3 Carbon () ppm3 
C1 170.7 C22 30.9 25.7 
C2 40.0 C23 C-CH3-42 17.4 
C3 C24 41.8 C43 37.2 
C4 30.6 C-CH3-25 42.4 C44 96.6 
C5 30.0 C-CH3-25 14.7 C45 37.0 
C6 68.2 26C=O 209.3 C-CH3-46 28.8 
77.6 C27 77.6 C-CH3-46 16.8 
C8 74.4 C28 33.2 C47 73.0 
C9 73.8 C29 71.1 C48 63.6 
C10 76.5 C30 76.2 C49 31.2 
82.4 C-CH3-31 36.2 C50 
Cl2 81.2 C-CH3-31 14.4 C51 76.2 
Cl3 48.2 C32 78.2 C52 36.6 
Cl4 109.9 66.3 C53 76.2 
Cl5 34.7 C34 29.2 C54 72.3 
Cl6 27.9 C35 63.8 
Cl7 C36 540COCH3 170.6 
Cl8 38.5 C37 43.3 540COCH3 21.0 
19C=CH2 151.3 C38 112.3 550COCH3 170.7 
19C=CH2 104.9 C39 42.4 550COCH3 20.8 
C20 75.0 C40 70.8 
C21 30.3 C41 79.4 
a Data recorded at 23°C in CDC1} with chemical shifts in ppm, and referenced to CHCl}, Oc 77.0 ppm. 
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The I3C NMR contained a new resonance at oe 209.3, characteristic of a 
carbonyl resonance. correlation between this resonance and the resonance 
the HMBC spectrum of 5.8 confirmed the assignment of this resonance to the C26 
carbon. HMBC correlations from the CH3-25 resonance were also seen to the C24 and 
C25 resonances. new HSMQC correlation between oe 77.6 and OH 3.74 was assigned 
to C27 and respectively. The assignment ofH27 was confirmed by the observation 
of a TOCSY correlation between this resonance and the H29 resonance (OH 4.05). It 
was established that the connectivity of the remainder of the molecule was identical to 
that ofhomohalichondrin B (1.25). 
The molecular formula of 5.8 was determined as C64Hss022 by HRF ABMS. This is 
consistent with the expected loss of CH40 for diol cleavage. 
Characterisation of 5.10 
The less polar ketone 5.10 was found to be isobaric with 5.8 by HRF ABMS. A 
comparison of the [H NMR spectrum of 5.10 (Figure 5.3.7) with that of 5.8 revealed 
two major differences. The H32 resonance had shifted upfield OH 0.05 to overlap with 
the H47 resonance, and the broad singlet H41 resonance had shifted downfield from OH 
3.59. These changes in chemical shift were reminiscent of those observed previously 
for the homohalichondrin B epimer 2.3.95 COSY, 2D-TOCSY (mixing time 100 ms and 
120 ms) and HSMQC experiments were run on 5.10. The partially assigned [H and 13C 
NMR data are listed in Table 5.3.7 and Table 5.3.8. Important NMR correlation are 
shown in .8. 
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CH3 
H H ~37 0 II 0 o L K _- J M : -,-- 0 
/C"'" 
55 0 N 47 : 0 H 39 H3 C 0 A 
52 0 
H3C" /0 H 
H 
CH3 
C g 
38-epi-homohalichondrin B diacetate 26-ketone (5.10) 
Figure lH NMR Spectrum of 38-epi-Homohalichondrin B 26-Ketone (5.10) 
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IH NMR Data for 38-epi-Homohalichondrin B Diacetate 
(5.10) 
Protona 8ppmb Protona 8ppmb Proton" 8 ppmb 
2.34 H21 L50 3.92 
1 H21' 1.86 H41 3.80 
3.87 H22 1.67 H42 2.31 
1.40 H22' CH]-42 0.97 
1.67 H23 3.83 H43 1.30 
1.38 H24 1.60 H43' 1.42 
2.09 H24' 2.01 H45 1.28 
4.29 H25 2.45 H45' 1.40 
2.94 CH]-25 1.10 H46 2.07 
H8 4.34 3.74 CH3-46 0.93 
H9 4.06 H28 H47 3.06 
H10 4.18 H28' H48 3.50 
H11 4.60 H29 4.04 H49 1.75 
4.68 H30 4.60 H49' 17 
H13 1.94 H31 2.02 H50 3.87 
H13' 2.16 CH3-31 0.99 H51 4.00 
H32 3.07 H52 1.74 
H33 3.69 H52' 1.97 
H16 H34 2.06 H53 4.31 
H16' H34' H54 5.14 
4.10 H35 H55 4.18 
H18 2.25 H36 H55' 4.28 
H18' 2.84 H37 540COCH3 2.10 
4.97 H37' 550COCH] 2.04 
5.02 H39 2.03 
4.45 H39' 2.29 
The symbol I represents the less shielded proton of a geminal pair. 
b Data recorded at 23°C in CDCl] at 300 MHz with chemical shifts in ppm and referenced to CHCl], OH 
7.26. 
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5.3.8 13C NMR Data for 38-epi-Homohalichondrin B Diacetate 26-Ketone 
(5.10) 
(5 ppmu Carbon o ppm" Carbon oppma 
C-CH3-42 
40.1 17.6 
C3 C24 C43 
C44 
14.8 
C6 26C=O C-CH3-46 
C7 77.7 C27 77.5 C-CH3-46 17.1 
C8 74.4 C28 C47 72.9 
C9 73.8 C29 C48 63.6 
CIO 76.5 C30 76.4 C49 
Cll 82.2 C-CH3-31 C50 74.3 
81.0 14.4 C51 76.3 
C13 48.2 
Cl4 66.8 76.2 
CIS C34 C54 72.2 
Cl6 63.8 
Cl7 C36 540COCH3 
Cl8 38.6 C37 540COCH3 21.0 
19C=CHz C38 550COCH3 
19C=CH2 C39 550COCH3 20.7 
C20 C40 71.5 
C21 C41 78.8 
a Data recorded at 23°C in CDCI] with chemical shifts in ppm, assigned from HSMQC and Hl\1BC 
at 300 MHz. 
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The connectivity of 5.10 was established as being identical to that of the ketone In 
addition to the aforementioned changes in chemical shift, the H391H39' methylene 
protons were no longer eql}ivalent.'fhe chemical shift difference for these protons 
compared to those of 5.8 is consistent with the formation of the C38 epimer. 
Characterisation of 
The molecular formula of 5.9 was determined as C6sHn023 by HRF ABMS, isobaric to 
the dioI5.6. However the 'H NMR spectrum of5.9 (Figure 5.3.9) was not equivalent to 
that of 5.6. Subtle differences in chemical shift were observed in the methyl region of 
the spectrum, and the region of DH 3.7-4.2. The CH2=19 resonance had shifted upfield 
slightly, and the H42 resonance was no longer observed at DH 3.60. The change in 
chemical shift of the H42 resonance pointed once again to epimerisation at C38. 
5.3.9 'H NMR Spectrum of 38-epi-Homohalichondrin B Diacetate 26-Diol 
(5.9) 
An array of 2D NMR experiments were perfonned on viz COSY, 2D-TOCSY 
(mixing time 40, 100 and 120 ms) and HSMQC experiments. These data enabled a 
partial assignment of the 'H NMR and 13C NMR resonances of 5.9 to be achieved. The 
I Hand 13C NMR data are listed in Table 5.3.9 and Table 5.3.1 0 and the important NMR 
correlations are shown in Figure 5.3.10. 
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Table 5.3.9 IH NMR Data for 38-epi-Homohalichondrin B Diacetate 26-Diol (5.9) 
Proton" 8 ppmb Proton" 8 ppmb Proton" 8ppmb 
H2 2.30 H21 H39 2.02 
H2' 2.46 H21' H39' 2.29 
H3 3.85 H22 H40 3.94 
H4 1.31 H22' H41 3.86 
H4' 1.68 H23 3.53 H42 2.32 
H5 1.30 H24 1.09 CH3-42 0.98 
HS' 2.06 H24' 1.55 H43 1.35 
H6 4.25 H25 1.74 H43' 
H7 2.91 CH3-25 1.00 H45 1.30 
H8 4.31 26-CH2 H45' 1.42 
H9 4.02 26'-CH2 H46 2.06 
HI0 4.16 H27 3.12 CH3-46 0.94 
Hll 4.58 H28 1.77 H47 3.07 
HI2 4.67 H28' 2.00 H48 3.50 
H13 1.94 H29 4.11 H49 1.75 
H13' 2.12 H30 4.56 H49' 2.14 
HIS H31 1.98 HSO 3.88 
HIS' CH3-31 1.03 HSI 4.01 
HI6 1.39 H32 3.40 H52 1.74 
H16' H33 3.87 H52' 1.99 
HI7 4.08 H34 H53 4.33 
HI8 2.24 H34' H54 5.14 
HIS' 2.80 H3S H55 4.18 
I9=CH2 4.85 H36 H55' 4.29 
I9'=CH2 4.98 H37 540COCH3 2.10 
H2O 4.29 H37' 550COCH3 2.04 
" The symbol' represents the less shielded proton of a geminal pair. 
b Data recorded at 23°C in CDCl) at 300 MHz with chemical shifts in ppm and referenced to CHCI), 8H 
7.26. 
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Table 5.3.10 DC NMR Data for 38-epi-Homohalichondrin B Diacetate 26-Diol (5.9) 
Carbon a ppm" Carbon a ppma oppma 
C1 78.8 
C2 40.2 75.5 25.3 
C3 38.6 17.5 
C4 C~CH3~25 40.8 C43 37.0 
C5 C-CH3-25 14.7 C44 
C6 68.1 26C-CH2 C45 37.2 
C7 26C-CH2 C-CH3-46 28.8 
C8 74.1 C27 79.3 C-CH3-46 17.l 
C9 73.8 C28 C47 72.9 
CIO 76.6 C29 69.6 C48 63.5 
Cll 82.2 C30 74.1 C49 31.0 
Cl2 81.1 C-CH3-31 37.8 C50 
Cl3 48.2 C-CH3-31 14.7 76.5 
C14 C32 75.3 C52 
C15 34.8 C53 76.2 
C16 C34 C54 72.4 
C17 75.6 C35 C55 63.8 
C18 38.8 C36 540COCH3 170.6 
19C=CH2 C37 44.0 20.9 
19C==CH2 103.8 C38 170.6 
C20 C39 44.1 20.6 
C2l C40 71.5 
R Data recorded at 23°C in CDClJ with chemical shifts in ppm, assigned fiom HSMQC and HMBC 
spectra at 300 MHz. 
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The limited l3C NMR data obtained for the O-ring are in good <;Hl'T·PP.,'Yl with the data 
for the diol NMR data, while not identical, are consistent with the presence 
of a diol at C26. The changes in chemical shift, relative to for the H39', H41 
and CH3-42 resonances are consistent with epimerisation at C38. Further evidence for 
epimer formation is provided by the retention time of the diol which is similar to 
that of the ketone Experience with chromatography of halichondrin epimers under 
reverse phase (C 18) conditions has shown that the retention time of the C38 epimer is 
considerably than that of the parent halichondrin (refer Section 2.2). 
38-epi-homohalichondrin B diacetate 26-diol (5.9) 
5.3.9 Periodate Cleavage of 5.7 
The combined tetraol material (Section 1.3.1 and 1.3.3) was treated with an aqueous 
solution of sodium periodate for 21 hours before extraction with EtOAc to give the 
diketone The molecular formula of C63H86023 determined by HRF ABMS 
confirmed dike tone formation. The IH NMR spectrum of was comparable to that of 
an authentic sample. 
Some of this material was subsequently used for a trial methylenation reaction (Section 
5.4.1.2). 
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o of5.6 
The deprotection of homohalichondrin B diacetate diol (5.6) was undertaken to enable 
the comparison of activity between the diol 5.6 and the deprotected tetraol. 
Diol (0.3 mg) was treated with a 4: 1 MeOH!H20 solution of 1% K2C03 for 
hours. The reaction mixture was diluted with water and the product extracted with 
EtOAc. A sharp singlet resonance at OH 2.04 in the IH NMR spectrum of the organic 
extract indicated incomplete cleavage of the 55-acetate group. 
The reaction was repeated, treating a sample of the diol 5.6 with a 4: 1 MeOH!H10 
solution of 1 % K2C03 for 72 hours at room temperature before extraction with EtOAc. 
NMR spectrum of the product showed that cleavage of the acetate protecting 
groups was complete. However, two sets of resonances were observed for the 
9 and CH2=19' protons. A molecular formula of C6lHss021 for the major 
constituent of the product mixture homohalichondrin B 26-diol (5.11) was determined 
by HRF ABMS. This is consistent with cleavage of the acetate groups. Other ions were 
observed in the mass spectrum at 18 mu and 32 mu greater than the parent ion, 
consistent with cleavage of the lactone to furnish the acid and the methyl ester 
respectively. 
yH3 
H I:l 
43 37 
H H 
0 O~L M -55 0 N 47 ~ 0 
HO A 34 
52 0 
OH H H CH3 
homohalichondrin B 26-diol 1) 
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11 Biological Activity 
The biological aelivily or selected derivatives was evaluated against the P388 murine 
leukemia cell linc, alld againsl the Net's GO-cell linc panel. The results from the 
sereening are ::;hown below in Table S.3.!I, together with the resulLs for the parent 
h()1110 i1al iehondrin 13 (1.25) and the COMPARE "seed" compound halichondrin B (1.8). 
The tetrahydro derivative has also been included.95 
Tn blc 5.3.11 In Vitro Cytotoxicities of Selected Halichondrins 
Compound P388lC5u NCI Gl50 COMPARE 
(ng/mL) (Xl0, 10 M) Correlation 
halichondl"in B (1.8) 0.78 1.38 1.00 
homohulichondrin n (1.25) 0.22 3.16 0.95 
homohalichondrin B > 12500 85.1 0.46 
di-Ac 19,26-tetraol (5.7) 
homobalichondrin B 27.7 49.0 0.64 
di-Ac 19,26-diketone (5.1) 
homohalichondrin B 1414 3890 0.12 
di-Ac 26-diol (5.6) 
homohaHchondrin B 2602 7079 0.08 
26-diol (5.11) 
tctnlhydro 12.6 3G2 0.87 
homohalichondrin B 
These data clearly illustrate the importance of the exocyclic methylenes to the biological 
activity in the halichondrin series. All of the derivatives described in this chapter 
exhibit significantly reduced biological activity rclative to the parent homohalichol1drin 
B (1.25). Polarity also appears to be have a role in the retention of cytotoxicity. Both 
the diketone 5.1 and the tetrahydro derivative are significantly more cytotoxic than the 
hydroxy derivatives in the P388 ceil line. However, the NCI's GO cell line panel is more 
sellsi tive to the tetraol It is interesting to note that the tetraol 5.7 is more cytotoxic 
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than the diol 5.6, which still contains the 19-01efin. This would seem to reflect a change 
in conformation for the diol, relative to the tetraol, that has a detrimental effect on the 
activity of the diol evidence from the NOESY spectrum of 5,6 indicates 
that the conformation of the diol in the region of the 19 methylene is similar to that of 
the parent homohalichondrin B (1.25). The characteristic NOESY correlation (across 
the lactone ring) between the H20 and H2' protons was observed, together with a 
correlation between the H29 and CH2-19' protons. 
5.4 Radioactive Labelling 
The formation of radiolabelled halichondrin B (1.8) would provide a means of detection 
of 1.8 and possibly some of its metabolites in biological systems. This would be useful 
for pharmacokinetic studies of 1.8. Radioactive labelling would also be useful for 
fmiher probing of the mechanism of action of halichondrins in in vitro cell studies. 
5.4.1 Methylenation 
Incorporation of a radioactive label into halichondrin B (1.8) requires the reformation of 
1.8 from one of its derivatives. The diketone 5.1 was seen as a likely starting material. 
Any method that was successful in methylenating the homohalichondrin B derivative 
5.1 could then be applied to the equivalent halichondrin B derivative. It had already 
been established that the exocyc1ic methylenes could not be formed using Wittig 
chemistry.95 
Alternative methods for ketone methylenation were investigated. The addition of a 
methylene chloride solution ofTiCl4 (0.7 parts), to a mixture of CH2Br2 (1 part) and zinc 
dust (3 parts) yields a reagent which smoothly olef1nates a variety of ketones. tQ2 
variation of the original procedure has been used in gibberellin synthesis. 103 The reagent 
(commonly referred to as 'Lombardo's reagent') is prepared from CH2Br2 (1 part), zinc 
dust (3 parts) and TiCl4 (0.73 parts) in THF at low temperatures and is then allowed to 
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age at 5°C ror three days. The resultant grey slurry reacts smoothly with ketones 
containing sensitive functionality.I04 The Tebbe reagent l05 is an isolable well 
ciwraelcrised compound which also olefinates carbonyl compounds. However, the 
ahility oj' Tehhe's reagcnt to mclilylcnHtc cstcrs and lactoncs IO(, is undesirable in this 
case. A number or related methylenating reagents have been prepared and tested. 107 
()IlC or the main advantagcs or CI1 2Br)Zn/TiCI.I is its ready availability. 
The conversion of a carbonyl to an alkene can also be achieved by Peterson 
alkenation lOX (Scheme 5.4.1). This method requires the use of strong base or acid for 
elimination of the silanolate. The addition of (N-methylphenyl 
slill'onimidoyl)melbyllithium followed by reductive elimination (Scheme 5.4.2) is the 
basis of the Johnson methylenation procedure. 109 
+ 
Scheme 5.4.1 Peterson Alkenation 
)=0 THF 
Scbeme 5.4.2 Johnson Methylenation 
OH 0 Ph ~I \8/ ~\\ 
NMe THF, AcOH 
Lombardo's reagent l04 was chosen because it had been used successfully with complex 
natural products that are acid sensitive, and was selective for ketones over esters. Free 
hydroxy groups are tolerated by this reagent, and it is suitable for reaction of sterically 
hindered ketones. I 10 
5.4.1.1 Trial Reaction 
The conditions for methylenalion using Lombardo's reagent were first established using 
choleslanone as a model. The appearance of a broad resonance at 6H 4.54 in the IH 
NMR spectrum of the product was consistent with the formation of the CH{"3 olefin. 
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Several attempts were required before the reaction was successful. A variation on the 
Lombardo procedure using catalytic leadlll was attempted. It was found that the zinc, 
although previously purified, required purification ll2 immediately prior to use. 
5.4.1.2 Methylenation of 
A solution of (1.5 mg) in THF was treated with ice cold Lombardo's reagent for 5 
minutes. The reaction mixture was neutralised with saturated NaHC03 and extracted 
with diethyl ether. Low level resonances corresponding to the HI8' proton and the 
CH2= 19 olefinic protons were observed in the IH NMR spectrum of the ether extract 
The chemical shift of the olefinic proton resonances (8H 4.97, 8H 5.02) were identical to 
those observed for the CH2=19 olefinic resonances in homohalichondrin B diacetate 26-
ketone (5.8). No evidence was seen for the formation of the CH2=26 olefin. The poor 
recovery of material indicated there may be some decomposition occurring. This would 
most likely be due to the acidic nature of the reaction conditions. 
The selective formation of the 9 olefin is in contrast to the relative reactivity of 
the olefinic groups. This indicates the conformation of the CI-C30 lactone ring in the 
diketone derivative 5.1 may be different to that of the parent 1.25. 
5.5 Summary 
The EMCH hapten was not prepared because the relationship with Hawaii 
Biotechnology Group Inc had fallen through, and as a result there was uncertainty as to 
the future direction of the immunoassay development. It was found that the ketone 5.8 
deteriorated over time, and consequently there was insufficient material to revisit this 
work. However, methodology for the selective derivatisation of the halichondrin C26 
exocyclic methylene has been established. Reaction of the ketone with EMCH 
should provide a hapten that would elicit antibodies recognising the terminus of the 
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halichondrin skeleton. This would allow the development of an inmmnoassay with the 
ability to distinguish between members of the B-series halichondrins. 
Chapter 6 Polymer Drug Conjugates 166 
6 
6.1 Introduction 
A general overview of polymer therapeutics is presented in Section 1.4. The synthesis 
of a polymer drug construct incorporating a halichondrin was perceived as a means of 
enhancing the future prospects of the clinical development of the halichondrins. 
Attaclunent of a halichondrin to a polymer should improve the pharmacokinetic profile, 
and enhance the selectivity of the drug. 
The polymer therapeutics work was undertaken in collaboration with Ruth Duncan's 
group at the School of Pharmacy, University of London. This group provided the 
polymer precursor used in the work described in this chapter. 
The polymer precursor (6.1) is constructed by the copolymerisation of N-(2-
hydroxypropyl)methacrylamide with methacryloylglycylphenylalanylleucylglycyl p-
nitrophenyl ester (MA-Gly-Phe-Leu-Gly-ONp) using the method described by 
Kopecelc1l3 The estimated nitro phenyl ester content of the polymeric precursor is 3.98 
mol%.114 
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The optimal number and combination of amino acids In the spacer required for 
controlled cleavage by lysosomal enzymes was determined as Gly~Phe-Leu-Gly.115 
Attachment of the drug to the linker by displacement of the p~nitrophenoxide (ON p) can 
be achieved tlu'ough a number of functional groups including esters, amides, urethanes, 
hydrazones and thioethers.' 16 Controlled release of the drug at the site of action requires 
this linkage to be stable in the blood stream. 
The formation of an ester linkage through the terminal hydroxy group of 
norhomohalichondrin B (4.17) would be a simple means of attaching a halichondrin to a 
polymer precursor. However, ester linkages have been found to be unstable in vivo in 
some cases, leading to uncontrolled release of the drug,SJ The attachment of 
norhomohalichondrin B aldehyde (4.13) to the polymer via a hydrazone linkage would 
use chemistry already shown to be successful in the attachment of the hydrazine linker 
EMCH (Section 4.5). However, the UV-active ONp is displaced from the polymer 
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precursor with hydrazine prior to the linking of norhomohalichondrin B aldehyde (4.13). 
This means that it would not be possible to quantify the amount of halichondrin bound 
to the polymer. Aminolysis of the ONp ester with an alkyl amine was chosen as the 
preferred method of halichondrin attachment. Spectroscopic measurement of the 
ONp released upon displacement by the halichondrin could be used to quantify the 
amount of halichondrin attached. 
The attachment of halichondrin to polymer through an amide bond required the 
formation of an aminohalichondrin. Reductive amination of the aldehyde with an 
amine was attempted, as a one-pot route to the desired product. An alternative route via 
an azide intermediate was also investigated. 
6.2 Reductive Amination 
6.2.1 Trial Reactions 
Cholestan-3-one was used as a model compound to establish conditions required for 
reductive amination because of its size, multiringed structure and availability. Sodium 
cyanoborohydride (NaCNBH3) was selected as the reducing agent because reduction of 
aldehydes by this reagent at pH 6-7 in MeOH is negligible. ll7 
In the initial attempt phenethylamine hydrochloride, sodium acetate and acetic acid were 
added to cholestanone and stirred for 30 minutes before the addition ofNaCNBH3. The 
reaction was stirred for 64 hours at room temperature. The solvent was evaporated and 
the CH2Cl2 soluble material was absorbed onto a normal phase (DIOL) caliridge. The 
product was eluted with CH2CliEtOAc (1: 1) and CH2CI2• The presence of a multiplet 
at ca 011 2.97 in the IH NMR spectrum of the product, together with the molecular 
formula of C3sHs7N, determined by HRF ABMS, confirmed reductive amination had 
occulTed. 
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To ascertain the feasibility of generating a primary amine, cholestanone, ammOnIum 
acetate and acetic acid were stined at room temperature before the addition of 
NaCNBH3• After stining the reaction for a further 68 hours the solvent was evaporated. 
The residue was purified by reverse phase (CI8) chromatography. Visualisation of the 
TLC of the products with Dragendorffs l25 spray reagent confirmed the presence of a 
primary amine, consistent with the reductive ami nation of cholestanone with ammonium 
acetate. 
6.2.2 Halichondrin Reactions 
Norhomohalichondrin B aldehyde (4.13, 0.5 mg), ammonium acetate and acetic acid in 
MeOH were stined together for 15 minutes before the addition of NaCNBH3• The 
reaction was stined at room temperature for 65 hours. The complex nature of the 
methyl region in the IH NMR spectrum of the reaction mixture indicated that more than 
one component was present. The mixture was separated by reverse phase (CI8) HPLC 
using 55% CH3CN/H20 as the mobile phase into five fractions. There was insufficient 
material « 0.1 mg) for investigation of these fractions by IH NMR spectroscopy. 
The use of activated 3A molecular sieves can improve the yield of a reductive amination 
reaction. 117 The reductive amination of 4.13 with ammonium acetate was repeated, with 
the inclusion of crushed 3A molecular sieves. The complexity of the reaction mixture 
again was indicated by the presence of five halichondrin-like peaks in the HPLC 
chromatogram. The scale of the reaction (0.6 mg) meant that separation of these 
components was not productive. 
Owing to the difficulties experienced with the reductive amination of 
norhomohalichondrin B aldehyde (4.13), it was decided that further trial reactions 
would be attempted using an aldehyde (citronellal) rather than a ketone (cholestanone) 
as a model compound. 
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6.2.3 
Citronellal was obtained by oxidising citronellol using Dess-Martin periodinane. 1l8 
Reaction of citronellal with ammonium acetate was unsuccessful. It was suggestedl19 
that ethylenediamine hydrochloride would be a more suitable amine, as it has a pKa in 
the desired range of 6-8. 
A solution of ethylenediamine hydrochloride (2.7 M) in MeOH was made by combining 
equimolar amounts of ethylenediamine and ethylenediamine dihydrochloride in MeOH 
(10 mL). 
Ethylenediamine hydrochloride and citronellal were stirred with NaCNBH3 until TLC 
indicated the reaction was complete (17 h). The reaction mixture was made alkaline by 
the addition ofNa2C03 before extraction with EtOAc. Analysis of the extract by GCMS 
indicated that the major component (> 80%) was the reductive amination product 6.2. 
A minor component was identified as the dimer of 6.2. 
6.2 
6.2.4 Further Halichondrin Reactions 
Norhomohalichondrin B aldehyde (4.13, 1.0 mg) and ethylenediamine hydrochloride 
were stirred in MeOH for 30 minutes before the addition of NaCNBH3 . The reaction 
was stirred for 65 hours at room temperature. The lack of an aldehyde proton resonance 
in the I H NMR spectrum of the reaction mixture indicated that a reaction had occurred. 
Additional resonances in the region of DB 2.5-3.0 were observed. The FABMS spectrum 
contained a number of seemingly unrelated high mass peaks (m/z 1140-1280). There 
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was 110 evidence (or production or the desired diamine, nor was there evidence of 
reduction of 3 to the alcohol 4.17. 
NorlwllwhalicholHlrin B aldehyde (4.I:J, 0.5 Il1g) in MeOl1 was treated with NnCNBH\ 
1'01' 65 hours at room temperature after which time the integral of the aldehyde proton 
resonance (Oil 9.(9) lwei reduced to 2()(Yc, of the original. LRF ABMS ions for lVINa+, 
MK' and MCs' for the alcohol 4.17 contlrmed that partial reduction of the aldehyde 
4.13 had taken place. MNa' and MCs+ ions for the aldehyde 4.13 were also observed. 
Owing to the lack of progress with reductive amination of l1orhomohalichondril1 B 
aldehyde (4.13), alternative routes to the halichondrin amine were considered. The 
azide route (Scheme 6.2.1) utilised simple chemical transformations and did not require 
the use of acid. Although it was envisaged that the reduction of the azide to the amine 
may cause problems, a number of methods for conversion of an azide to an amine under 
relatively neutral conditions exist. 120 
o ~ HO~ 
X 
TsCI 
[H] 
o ~ TSO~ 
X 
Scheme (,.Z.t An Overview of the Proposed Azide Route 
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6.3 Route 
Citronellol (6.3) was used as the starting material for a series of reactions to establish a 
route to the amine. The stability of the olefinic functionality to the reaction sequence 
was an important consideration. 
Treatment of 6.3 with p-toluenesulfonyl chloride yielded the tosylate 6.4. The shift of 
the a-methylene resonance to a less shielded position (OH 4.05) relative to the alcohol 
(OH 3.63) was consistent with tosylate formation, along with the presenc-e of a methyl 
resonance at OH 2.45. The azide 6.5 was formed by reaction of 6.4 with NaN3• The 
expected shift in the a-methylene resonance to a more shielded position (OH 3.28) was 
observed. 
NaN3.DMF 
• 
OR OTs 
6.3 6.4 6.5 
Initial attempts to reduce the azide used Staudinger methodology. 121 The removal of 
excess triphenylphosphine from the reaction mixture proved to be an insurmountable 
problem, not helped by the volatility of the citronellamine. It was never established if 
any product was formed. Reduction using phase transfer catalysisl22 (ammonium 
formate, Pel/C, 23 hours, 20°C) was also unsuccessful, with only starting material being 
recovered. 
Tosylation of 6.3 was repeated on a larger scale (7.2 mmol) to enable a more accurate 
mass balance to be achieved following reduction of the azide. A solution of 6.3, DMAP 
and diisopropylethylamine in CH2Cl2 was cooled to O°C before adding TsCI. The lH 
NMR spectrum of the worked up extract contained two sets of olefinic and a-methylene 
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resonances. The relative integrals of the a-methylene resonances indicated that 55% of 
the mixture was tosylate. The chemical shift of the a-methylene resonance of the other 
component (OH 3.68) was consistene23 with substitution of the tosylate by chloride. This 
was subsequently confirmed by ElMS. The mixture was treated with NaN3 to give a 
mixture of the azide and the chloride. Pure azide was obtained by flash 
chromatography on silica, eluting with petroleum ether. 
Selective hydrogenation of the azide 6.5 was achieved by the use of Lindlar catalyst. 124 
The retention of the olefin was confirmed by the presence of a multiplet at OH 5.07 in the 
IH NMR spectrum of the product. GCMS was used to ascertain that the amine 6.6 was 
95% pure. The molecular formula of C IOH21N, determined by HREIMS, was consistent 
with amine formation. 
H2, Lindlar catalyst, EtOH 
6.5 6.6 
6.3.2 Halichondrin Reactions 
6.3.2.1 Attempted Tosylation of Norhomohalichondrin B (4.17) 
p-Toluenesulfonyl chloride was added to a solution of norhomohalichondrin B (4.17, 
0.9 mg), DMAP and diisopropylethylamine in CH2Cl2 at O°C. The reaction was allowed 
to warm to room temperature and stirred for 2 hours. The IH NMR spectrum of the 
EtOAc extract showed that no reaction had occurred. The reaction was repeated, 
doubling the quantities of reagents used. Once again, the lH NMR spectrum of the 
EtOAc extract was comparable to that of the starting material. A third attempt was 
made, using a large excess (ca twenty-fold) of TsCl. The lH NMR spectrum of the 
organic extract was dominated by an unidentified contaminant. Low-level halichondrin-
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type resonances were observed. TLC (DIOL, 4% MeOH/CH2C12) indicated that stmting 
material was present in the contaminated mixture. 
6.3.2.2 Tosylation of Homohalichondrin B (1.25) 
Tosyl chloride was added to a solution of homohalichondrin B 1.5 mg), DMAP 
and diisopropylethylamine in CH2C12 at O°C. The reaction was allowed to warm to 
room temperature and stirred for 2 hours. The observation of a shoulder on the H47 
resonance indicated that reaction had occurred. However the starting material was 
largely intact. The reaction was repeated and stirred for 18 hours. The absence of the 
characteristic H55/55' resonance at 51! 3.69 was consistent with tosylation of the 55 
hydroxy group. The H47 resonance had shifted to a more shielded position (5H 3.05) 
relative to that in homohalichondrin B. The molecular formula of C6&Rn0 21S 
determined by HRFABMS indicated that the monotosylate of homohalichondrin B had 
been formed. 
H 
0 
5 0 N 
0 I 0 I H H o=s=o OH CH3 6 
H ~ 
9~ ? 
22 ('''V''''CH3 
'I" ~ I 
homohalichondrin B 55-tosylate (6,7) 
6.3 Tosylation of Norhomohalichondrin B (4,17) 
The reaction conditions used for the tosylation of homohalichondrin B (1.25) were 
applied to norhomohalichondrin B (4.17). TsCI in CH2Cl2 was added to an ice-cold 
solution of (0.5 mg), diisopropylethylamine and DMAP in CH2C12• The reaction 
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was allowed to warm to room temperature and stined for 17 hours. The H54 and H54' 
resonances of the alcohol 4.17 were not observed in the NMR spectrum of the EtOAc 
extract, indicating that reaction had occurred. A small amount of TsCl was still 
Changes to resonances in the region of OH 3.45-4.l5 relative to those of 4.17 were 
observed. The characterisation of norhomohalichondrin B tosylate (6.8) is described in 
Section 6.3.2.6. 
6.3.2.4 Reaction ofNorhomohalichondrin B Tosylate (6.8) with Sodium Azide 
Norhomohalichondrin B tosylate (6.8, 0.3 mg) was treated with an excess of NaN3 in 
DMF at 40°C for IS hours. Analysis of the EtOAc extract by reverse phase (CIS) 
HPLC, using a mobile phase of 70% CH3CN/H20, showed that two major components 
were present. The tosylate 6.8 eluted at 10S0 s, after a component of similar polarity at 
996 s. The UV spectrum of the tosylate contained absorbance maxima at "'194 and 
The UV spectrum of the component at 996 s contained an end absorption maxima only 
("'194)' This was consistent with substitution of the tosylate by azide. The ratio of azide 
to tosylate was estimated to be 4: I from the refractive index-detected chromatogram. 
6.3 Attempted Hydrogenation 
The azide/tosylate mixture was used without further purification in an effort to establish 
if selective reduction of the azide in the presence of the exocyclic methylenes of the 
halichondrin skeleton was possible. It was anticipated that this hydrogenation could be 
accomplished successfully based on the selective reduction of the azide in the model 
compound (see Section 6.3.2.3). 
Hydrogenation of the azide/tosylate mixture was canied out with Lindlar catalyst in 
ethanol at room temperature and atmospheric pressure for 5 hours. The reaction was 
filtered through Celite to remove the catalyst and the solvent evaporated. The 1H NMR 
spectrum of the residue was identical to that of the starting material. 
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Hydrogenation was repeated using a longer reaction time of 48 hours. The exocyclic 
methylenes were retained under these conditions, but it was not possible to asceltain if 
any reduction of the azide had occuned. 
The apparent robustness of the exocyclic methylenes to hydrogenation with Lindlar 
catalyst was promising enough to commit further halichondrin material to the reaction. 
"large scale" reaction was undertaken with the periodate cleavage of mg of 
homohalichondrin B (1.25). Representative examples of this reaction and the 
subsequent reduction of the aldehyde 4.13 with sodium borohydride in IP A are 
described in Section 4.4 and 4.6. The IH NMR spectra obtained for the reaction 
products were comparable to those obtained previously. 
6.3.2.6 Formation of Norhomohalichondrin B Tosylate (6.8) 
Norhomohalichondrin B (4.17, 19.1 mg), diisopropylethylamine and DMAP were 
cooled to OCC in CH2C12• TsCl in CH2C12 was added dropwise. The reaction was 
allowed to warm to room temperature and stined for 14 hours. The IH NMR spectrum 
of the organic extract (Figure 6.3.1) was comparable to that obtained previously for the 
tosylate 6.8 (Section 6.3.2.3). 
Chapter 6 - Polymer Drug Conjugates l77 
Figure 6.3.1 IH NMR Spectrum of Norhomohalichondrin B Tosylate (6.8) 
A full range ofNMR experiments were performed on 6.8 viz COSY, 1D-TOCSY, 2D-
TOCSY (mixing time 100 ms), HSQC, HMBC and APT (Figure 6.3.2) experiments. 
These data enabled the complete assignment of the IH NMR and l3C NMR resonances 
of 6.8 to be achieved. The IH and 13C NMR data are listed in Table 6.3.1 and Table 
6.3.2, and the important correlations from the 2D experiments are shown in Figure 6.3.3 
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6.3.1 'H NMR Data for Norhomohalichondrin B Tosylate (6.8) 
Proton" <5 ppmb Protona <5 ppmb Protolla <5ppmh 
2.33 1.38 16 
2.58 1.87 2.16 
3.87 1.59 H40 3.87 
1.36 1.59 3.54 
H4' 1.72 3.52 2.30 
HS 1.36 1.02 CH:;-42 0.89 
HS' 2.08 1.67 H43 1 
H6 4.31 2.19 1.37 
2.93 1.05 1.37 
HS 4.30 4.75 1.37 
H9 4.02 4.80 H46 2.13 
HI0 4.16 3.52 CH3-46 0.86 
HU 4.58 H28 1.93 H47 3.02 
HI2 4.67 illS' 1.99 H4S 3.48 
H13 1.92 4.18 H49 1.74 
2.13 H30 4.64 2.08 
HIS 1.59 H3I 2.00 HSO 3.81 
H15' 2.16 0.98 3.96 
HI6 1.41 H32 3.16 1.87 
H16' 2.14 3.79 2.02 
HI7 4.08 H34 1.77 4.32 
HIS 2.24 H34' 2.13 HS4 4.02 
HIS' 2.78 H35 4.09 H54' 4.08 
I9=CH2 4.91 H36 4.08 H56 7.77 
I9'=CHz 4.98 H37 1.88 7.32 
H2O 4.35 H37' 2.32 H59 2.40 
a The symbol' represents the less shielded proton of a geminal pair. 
b Data recorded at 23°C in CDCl) at 300 MHz with chemical shifts in ppm and referenced to CRCl), OH 
7.26, 
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Table 13C NMR Data for Norhomohalichondrin B Tosylate (6.8) 
oppma <5 ppma Carbon <5 ppmu 
170.9 C22 32.1 79.3 
C2 40.4 C23 74.8 .7 
C3 .8 C24 43.4 17.7 
30.7 35.9 C43 36.8 
30.1 C-CH3-25 18.0 C44 96.5 
C6 68.2 26C=CH2 151.6 C45 36.8 
C7 77.6 26C=CH2 104.0 C-CH3-46 28.7 
C8 74.3 73.6 C-CH)-46 17.1 
C9 73.4 C28 36.7 C47 73.1 
C10 76.5 C29 71.1 C48 63.5 
Cll 82.1 C30 76.9 C49 31.1 
Cl2 81.0 C-CH3-31 36.6 C50 74.4 
C13 48.3 C-CH)-31 15.1 C51 76.6 
Cl4 109.9 C32 77.5 C52 36.7 
CI5 34.4 C33 66.5 C53 75.1 
Cl6 28.2 C34 29.1 C54 71.5 
Cl7 75.3 C35 75.1 132.9 
Cl8 38.7 C36 76.2 C56 127.8 
19C=CH2 151.4 C37 43.5 C57 129.6 
19C=CH2 104.4 C38 112.2 C58 144.5 
C20 75.3 C39 42.6 C59 21.7 
C21 29.4 C40 70.7 
n Data recorded at 23°C in CDCl} at 75 MHz with chemical shifts in ppm and referenced to CHCI" Dc 
77.0. 
160 :LOO 60 
Figure 6.3.2 APT Spectrum ofNorhomohalichondrin B Tosylate (6.8) 
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These data confirmed the connectivities and chemical shifts of the nngs were 
identical to those of norhomohalichondrin B (4.17). TOCSY con-elations between the 
H47 resonance (OH 3.02) and OH 1.37, 2.13, 0.86, 3.48 and 1.74 allowed the assignment 
of H45/45\ H46, CH}-46, H48 and H49. A COSY con-elation between the H49 
resonance and OH 2.08 allowed the assignment of the geminal H49' resonance. The H50 
resonance (OH 3.81) was likewise assigned from a COSY correlation to the H49 
resonance. COSY correlation between H50 and a proton resonating at OH 3.96 
allowed the assignment of H51. A ID TOCSY with a mixing time of 100 ms was used 
to detect the resonances of H52 (OH 1.87), H52' (OH 2.02), H53 (OH 4.32), H54 (OH 4.02) 
and H54' (OH 4.08). The molecular formula of C67H90020S determined by HRF ABMS 
was consistent with formation of the tosylate 6.8. 
norhomohalichondrin B tosylate (6.8) 
6.3.2.7 Formation of Nor hom ohali chondrin B Azide (6.9) 
Norhomohalichondrin B tosylate (6.8, 8.5 mg) was stin-ed with an excess of NaN} in 
DMF at 40°C for 19 hours. The EtOAc extract was analysed by reverse phase (CI8) 
HPLC (mobile phase 70% CH3CNIH20) with RI detection. Seventy per cent conversion 
of tosylate to azide was observed. The reaction with sodium azide was repeated, and 
progress monitored by HPLC. When the azide peak in the RI chromatogram had 
maximised, and only trace levels of tosylate remained, the reaction was diluted with 
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"vater and extracted into EtOAc. The extract was washed, dried and the solvent 
evaporated to yield norhomohalichondrin B azide (6.9,5.4 mg). 
The most notable difference in the lH NMR spectrum of 6.9 (Figure 6.3.4) compared to 
that of the tosylate 6.8 was a multiplet at 8H 3.12, which overlaps with the H32 and H47 
resonances. Differences in the regions of 8H 3.60-4.00 and 8H 4.25-4.50 were also 
apparent. 
5.0 4.5 4.0 3.5 3.0 2.5 2.0 LS La ppm 
Figure 6.3.4 lH NMR Spectrum ofNorhomohalichondrin B Azide (6.9) 
An array of NMR experiments were performed on 6.9 viz COSY, ID-TOCSY, 
TOCSY (mixing time 100 ms), HSQC, HMBC and APT (Figure 6.3.5) experiments. 
The lH and DC NMR data extracted from these experiments are listed in Table 6.3.3 and 
Table 6.3.4. The important NMR correlations are shown in Figure 6.3.6. 
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IH NMR Data for Norhomohalichondrin B Azide (6.9) 
Proton" oppmb Proton" oppmb Protona o ppmb 
H2 2.34 H2O 4.37 H37 1.89 
2.59 1.38 H37' 2.33 
3.88 1.87 2.18 
H4 1.35 1.60 2.18 
H4' 1.73 H22' 1.60 H40 3.92 
H5 1.35 H23 3.53 H4I 3.58 
2.08 1.03 H42 2.37 
H6 4.33 H24' 1.68 CH3-42 0.92 
H7 2.94 H25 2.20 H43 1.29 
H8 4.30 CH3-25 1.07 H43' 1 
H9 4.05 26=CH2 4.76 H45 1.41 
HIO 4.18 26'=CH2 4.81 1.41 
Hll 4.59 H27 3.51 H46 2.18 
H12 4.68 H28 1.90 CH3-46 0.91 
HI3 1.94 H28' 2.00 H47 3.07 
14 H29 4.18 H48 3.54 
5 1.59 H30 4.66 1.80 
HI5' 2.16 H31 2.02 H49' 2.17 
H16 1.42 CH3-31 0.99 H50 3.95 
H16' 16 H32 3.17 H51 4.05 
HI7 4.09 H33 3.80 H52 1.97 
H18 2.25 1.78 1.97 
HI8' 2.80 H34' 2.15 H53 4.40 
19=CH2 4.92 H35 4.11 H54 3.12 
I9'=CH2 4.99 H36 4.11 H54' 3.59 
" The symbol' represents the less shielded proton of a geminal pair. 
b Data recorded at noc in CDCll at 300 MHz with chemical shifts in ppm and referenced to CHCIl , OH 
7.26. 
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6.3.4 DC NMR Data for Norhomohalichondrin B Azide (6.9) 
Carbon 8 ppm" 8 ppm" Carbon 8 ppm" 
Cl 171.0 C20 75.1 43.5 
C2 40.5 C21 29.5 C38 1 
C3 73.7 C22 32.1 C39 42.6 
30.8 C23 74.8 C40 70.7 
30.1 43.4 C41 79.4 
C6 68.2 C-CH3-2S 36.0 C-CH3-42 25.7 
C1 77.7 C-CH3-25 18.1 C-CH3-42 17.7 
C8 74.3 26C=CH2 151.6 C43 37.1 
C9 73.9 26C=CHz 104.1 C44 96.6 
CIO 76.3 C21 73.5 C45 37.1 
Cll 82.1 C28 37.0 C-CH3-46 28.9 
Cl2 81.1 C29 71.2 C-CH3-46 17.2 
C13 48.4 C30 76.7 C47 .1 
C14 110.0 C-CH3-31 36.6 C48 63.6 
CIS 34.5 C-CH3-31 15.1 C49 31.4 
C16 28.2 C32 77.6 CSO 74.3 
C17 C33 66.6 CSt 76.9 
CIS 38.8 C34 29.1 C52 37.4 
19C=CH2 151.4 C35 CS3 76.5 
19C=CH2 104.4 C36 53.9 
a Data recorded at 23°C in CDCl3 at 75 MHz with chemical shifts in ppm and referenced to eHCI3, Dc 
77.0. 
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These data confirmed that the connectivities and chemical shifts of the A-M rings were 
identical to those of norhomohalichondrin B (4.17). The new multiplet at OH 3.12 was 
assigned to the H54 proton. Three selective ID-TOCSY experiments with variable 
mixing times (l0, 20, 40, 80 and 120 ms) were lUn on to confirm this assignment, 
and enable the assignment of the chemical shift and connectivity of the O-ring and 
terminal proton resonances. A ID-TOCSY experiment for the selective irradiation of 
the H54 proton is shown in Figure 6.3.7. Correlations to the (OH 4.40) and geminal 
H54' (OH 3.59) proton resonances were clearly observed with a mixing time of 20 ms. 
The H51 and H52/52' resonances were observed as the mixing time was increased to 80 
ms. 
mixing time (ms) 
120 
80 
40 
20 
10 
5.0 4.5 4.0 
H54' H54 
3.5 3.0 2.5 2.0 1.5 ppm 
Figure 6.3.7 ID-TOCSY Spectra for Selective Irradiation of H54 with Variable 
Mixing Times 
Irradiation of H53 in a ID-TOCSY experiment (Figure 6.3.8) also perturbed the H20 
proton. It was therefore important to have the spin-system involving H20 well 
characterised to provide certainty to assignments arising from the irradiation ofR53 and 
H20. Correlations to the H54 and H54' protons were observed with a mixing time of 
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just 10 ms. Correlations to the HS2IS2', HSI and finally HSO (mixing time 120 ms) 
protons were seen as the mixing time was increased. The assignment of these protons 
was confirmed by a 1D-TOCSY experiment selectively irradiating HSO. CorTelations to 
HSl, HS2IS2', H49, H49' and H48 were observed. The molecular formula of 
C6oHs3017N3 determined by HRFABMS confirmed formation of the azide 6.9. 
H53!H20 
• ~ .. """.' .1' 
",j 
5.0 4.5 4.0 3.5 3.0 2.5 2.0 
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Figure 6.3.8 ID-TOCSY Spectra for Selective Irradiation of HS3 with Variable 
Mixing Times 
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norhomohalichondrin B azide (6.9) 
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6.3.2.8 Reduction of Norhomohalichondrin B Azide (6.9) 
Hydrogenation of norhomohalichondrin B azide (6.9, 2.0 mg) was carried out with 
Lindlar catalyst in ethanol at room temperature and atmospheric pressure. The reaction 
was monitored by reverse phase (C 18) HPLC using a mobile phase of 70% 
CH}CNIH20. After 32 hours the reaction was filtered through Celite and the solvent 
evaporated to give an orange oil. The H54 resonance was significantly reduced in the 
'H NMR spectrum of the product. The exocyclic methylene resonances were present, 
indicating that the olefinic groups remained intact. Resonances associated with an 
unidentified component were observed in the region of 8H 0.75-0.85. Reverse phase 
(C 18) chromatography in a Pasteur pipette was used to separate the components. The 
column )Vas eluted with a gradient from 50% CH3CN/H20 to CH3CN and then stripped 
with CH2C12• The orange material remained on the C18 column. Trace levels « 0.1 
mg) of the azide 6.9 were recovered. No product was obtained, even after stripping the 
column with MeOH/TF A. 
Hydrogenation of the remaining azide (1.4 mg) was carried out using Lindlar catalyst in 
ethanol at room temperature and atmospheric pressure for 41 hours. The reaction was 
filtered through Celite and the solvent evaporated to yield an orange oil. The 
disappearance of the H54 resonance from the lH NMR spectrum (Figure 6.3.9) of the 
product indicated that reaction of the azide had occurred. The extra resonances upfield 
of 8H 0.90 were present once again. 
Owing to the difficulties encountered previously in trying to purify the product it was 
decided to leave the purification step until after reaction of the amine with polymer 
precursor. It was thought that the large difference in molecular weight of the 
components would enable purification by gel permeation chromatography on LH20. 
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ppm 
Figure 6.3.9 IH NMR Spectrum of Norhomohalichondrin B Amine (6.10) 
COSY, ID-NOESY, 20-TOCSY (mixing time 100 IDS), HSQC, HMBC and APT 
experiments were performed on norhomohalichondrin B amine (6.10). These data 
enabled the partial assignment of the IH NMR and l3C NMR resonances of 6.10 to be 
achieved. The IH and l3C spectral data .are collated in Table 6.3.5 and Table 6.3.6 
respectively. Important 2D NMR correlations are shown in Figure 6.3.10. 
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IH NMR Data for Norhomohalichondrin B Amine (6.10) 
Proton" 8 ppmb 8ppmb Protona 8ppmb 
H2 2.34 4.37 1.89 
H2' 2.59 1.39 H37' 2.79 
H3 3.88 H39 2.18 
H4 1.35 1.60 H39' 2.18 
H4' 1.72 1.60 H40 3.92 
H5 1.37 3.54 H41 3.56 
H5' 2.09 1.03 
H6 4.34 1.67 0.90 
H7 2.94 2.20 H43 1.40 
H8 4.32 1.07 H43' 
H9 4.06 4.76 1.40 
HI0 4.20 4.81 
H11 4.60 3.52 H46 2.17 
H12 4.68 H28 1.94 CH3~46 0.89 
H13 1.98 3.04 
H13' 2.16 H29 4.19 H48 3.51 
H15 H30 4.66 H49 1.80 
H15' H31 2.01 H49' 2.15 
H16 0.99 
H16' 3.18 4.01 
H17 4.09 3.80 
H18 2.25 H34 1.77 
H18' 2.80 H34' 2.15 
19=CH2 4.92 4.11 
19'=CH2 4.99 H36 4.11 
l The symbol' represents the less shielded proton of a geminal pair. 
b Data recorded at 23 Q C in CDCl] at 300 MHz with chemical shifts in ppm and referenced to CHCI» OH 
7.26. 
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Table 6.3.6 DC NMR Data for Norhomohalichondrin B Amine (6.10) 
Carbon o ppma Carbon o ppma o ppma 
Cl 171.0 C20 43.5 
C2 40.5 29.5 C38 112.3 
C3 73.7 32.1 42.6 
C4 30.1 74.4 C40 70.7 
C5 29.8 C24 43.5 C4I 79.4 
C6 68.3 C-CH3-25 36.0 25.8 
C7 77.6 C-CH3-2S 18.1 17.8 
C8 74.4 26C=CH2 151.6 C43 
C9 73.9 26C=CH2 104.1 C44 96.7 
CI0 76.3 C27 73.5 C45 
Cll 82.1 C28 28.8 
Cl2 81.1 C29 71.2 C-CH3-46 17.2 
CI3 48.4 C30 77.0 C47 73.2 
CI4 110.0 36.6 C48 63.6 
CIS 34.5 15.1 C49 30.8 
CI6 28.3 77.7 C50 
CI7 66.6 CSI 
C18 38.8 29.1 C52 
I9C=CHz 151.4 C53 
I9C=CH2 104.4 C36 C54 
a Data recorded at 23 Q C in CDCI) at 75 MHz with chemical shifts in ppm and referenced to CHCl). Dc 
77.0. 
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These data confirmed the connectivity and chemical shifts of the A-M rings were 
comparable to those of the azide Unfortunately the complex overlapping nature of 
the COSY and 2D-TOCSY spectra of the amine 6,10 made the assignment of H54/54' 
and the majority of the O-ring protons impossible. The H51 proton was assigned from 
the observation of an NOE enhancement arising from selective irradiation of the H47 
proton in a ID-NOESY experiment. 
The molecular formula of C6oHssOl7N determined by HRF ABMS confrrmed that 
reduction of the azide had occurred. 
9H3 
H 
H H 
0 
53 0 N 47 
0 
NH2 H H -CH3 
37 
31 
H 
A 34 A 0 
norhomohalichondrin B amine (6,10) 
6,4 Polymer Therapeutics 
6.4.1 Introduction 
Before the attachment of norhomohalichondrin B amine (6.10) to the polymer precursor 
could be undertaken, a method of quantifying the amount of amine attached had to be 
established. The lack of a UV chromophore prevented direct spectroscopic 
measurement of the attached an1ine. The measurement of displaced p-nitrophenoxide 
(ONp) offered the only means of determining the quantity of amine bound to the 
polymer. The small scale of the reaction also meant that it was not possible to purify 
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the polymer product by the usual method of crystallisation. The considerable difference 
111 between the polymer, the halichondrin amine and the free ONp was exploited by 
using size exclusion chromatography to separate the components. 
6.4.2 Determination of 0400 p-Nitrophenoxide 
The absorption of ONp at 400 nm was measured in duplicate at six different 
concentrations. The two absorbance readings above 2.0 were excluded as these lay 
outside the range at which measurements were going to be made. The molar 
absorbtivity coefficient (E) for p-nitrophenoxide (ONp) at 400 nm was determined using 
Beer's Law as 13097 M'!cm· l . 
6.4.3 Trial Reaction 
A series of reactions were undertaken to optimise conditions for attachment of an amine 
to the polymer precursor. The effect of solvent (DMSO) and triethylamine (TEA) on 
absorption was investigated. The absorption of ONp at 400 nm was found to be pH 
dependent, while the addition of DMSO had no effect. In order to minimise the 
variation in absorbance with variation in TEA, phosphate buffered saline (pH 7.68) was 
used as the diluent for spectroscopic measurements. Absorbance measurements were 
made immediately upon diluting the reaction mixtures with buffer to minimise 
hydrolysis of unreacted ONp. The amount of free ONp contaminant in the polymer 
precursor was also determined, so a correction could be made when calculating the 
quantity of ONp released. 
The polymer precursor in DMSO was treated with an excess of l-amino-2-propanol for 
10 minutes. The absorbance of an aliquot of the reaction at 400 nm was measured. 
From this, the ONp content of the polymer precursor was calculated as 2.7 mol%. This 
is lower than the 3.98 mol% determined previously.114 However the value is similar, 
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and reaction of amine with polymer precursor for a longer period of time should ensure 
release of all the ONp. 
The polymer precursor (5.0 mg) was stirred with 1-amino-2-propanol and TEA in 
DMSO for hours at room temperature. aliquot of the reaction solution was 
diluted to 1 mL with phosphate buffered saline. The absorbance of this dilute solution 
at 400 nm was 1.1938. This value was used to calculate a side chain content of 4.5 
11101% (see Appendix 1 for calculations). 
The remaining reaction mixture was diluted to 1 mL with MeOH and purified on an 
LH20 colunm using MeOH as the eluent. The coluum was plumbed into a single 
wavelength spectrometer, and the elution of the polymer and free ONp at 206 nm 
observed as separate, distinct peaks. This exercise illustrated that the polymer could be 
resolved from the ONp on LH20. Reduction of the flo\:vrate to ca 0.5 mL/minute 
would enhance the separation of these two components. 
6.4.4 Attachment of Norhomohalichondrin 
Precursor 
Amine to Polymer 
Polymer precursor (5.0 mg), norhomohalichondrin B amine (6.10, 1.4 mg) and one 
equivalent of TEA were stirred for hours in DMSO. A small aliquot (6 )-LL) of the 
reaction solution was diluted to 1 mL with phosphate buffered saline. The absorbance 
of this dilute solution at 400 nm was 0.6733. This equates to the addition of ca 0.8 mg 
of nor hom ohali chondrin B amine (6.10) to the polymer mol%, 13.7 weight%). 
An excess of l-amino-2-propanol was added to the reaction solution. Stirring was 
continued for a further 16 hours before another aliquot (6 ~tL) was removed, diluted and 
the absorbance read as described above. The absorbance of the diluted reaction mixture 
at 400 nm was now 1.2134. From this, a value of 4.6 mol% of side chain was 
calculated. 
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The reaction mixture was diluted with MeOH to give a final volume of 1 mL and then 
applied to an LH20 column. The column was eluted with MeOH at a rate of 0,5 
mLlminute. Fractions were collected at 2 minute intervals. Fractions containing 
polymer (8-14) were identified by their IH NMR spectra. Dragendorffs spray reagent l25 
was used to identify fractions containing amine (14-16), Fractions containing 
purely polymer-bound amine were combined and the solvent evaporated to give the 
product (4.12 mg). 
HSQC, COSY and 2D-TOCSY (mixing time 40 ms) NMR experiments were run on the 
halichondrin polymer conjugate. COSY correlations belonging to the halichondrin part 
of the polymer conjugate are shown in Table 6.4,1. No halichondrin-type correlations 
could be seen in the HSQC and 2D-TOCSY spectra. 
Table 6.4.1 Observed COSY Correlations for Halichondrin Polymer Conjugate 
COSY Correlation (H-H) 
6-7 18'-CH2=19' 30-31 
7-8 20-CH2=19' 31-CH3-31 
10-11 20-CHz=19' 31-32 
12-13 20-21 36-37' 
18-18' 25-CH3-25 
6.4.5 Biological Activity 
The biological activity of norhomohalichondrin B amine (6.10) and the halichondrin 
polymer conjugate were evaluated against the P388 murine leukemia cell line. The 
polymer conjugate was also submitted at a concentration equivalent to 0.01 mg/mL of 
amine to compare the activity of the polymer-bound amine with the free amine 6.10. 
i'Jorhomohalichondrin B (4.17) was assayed to allow a comparison of activity between 
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the amine derivative 6.10 and the parent alcohol. The assay results are shown in Table 
6.4.2. 
Tahle 6.4.2 /11 flitro Cytotoxicities or SelecLed Iialichondrim: 
Entry Compound P388 (ng/mL) 
norhomohaHchondrin H (4.17) 1.9 
2 llodlOlUohalichondrin B amine (6.10) 1.4 
3 halichondrin polymer cOIl.jugate" 6.1 
4 halichomlrin polymer conjugate 46.3 
5 aminopropanol polymer con,jugate 4265 
6 norhol11ohaHchond.'ill H tosylatc (6.8) 1.8 
o submitted at concentration of l1orhomohalichondrin B amine in the polymer 
The tirst three results in Table 6.4.2 are the average of seven independent assay results 
lor each ofthose samples, The amine 6.10 and tosylate 6.8 derivatives (entries 2 and 6) 
were as active as the parent norhomohalichonclrin B (4.17). This result is consistent 
with previous observations that alteration of the terminus of the halichondrin skeleton 
does not have significant effect on activity. 
'raking into account the inherent variability of the biological assay, the activity of the 
polymer bound amine against the P388 cell line was comparable to that of 
norhomohalichondrin B amine (6.10) when assayed at equivalent amine concentrations 
(entries 2 and 3). The activity of the halichondrin polymer conjugate assayed by total 
weight (entry 4) is an order of magnitude less active than the free amine This 
result gives a good indication as to the purity of the halichondrin polymer. In order to 
achieve a comparable result should the halichondrin polymer be contaminated with fl'ee 
amine, a large proportion of the sample would need to be free amine. The activity of the 
halichondrin polymer is encouraging evidence that the llorholl10halichondrin amine is 
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being released from the polymer. A more extensive in vitro and in vivo evaluation of 
the halichondrin polymer is in progress. 
6.5 Summary 
route to a halichondrin amme has been established. This amme (6.10) was 
subsequently incorporated into a polymer drug conjugate. Preliminary biological testing 
against the in vitro P388 cell line indicates that the polymer drug conjugate has a level 
of c:ytotoxicity equivalent to that of the unbound norhomohalichondrin B amine (6.10). 
The halichondrin-containing polymer drug conjugate represents an exciting advance in 
the future prospects of the halichondrins as anticancer therapeutics. 
Chapter 7 - Experimental 199 
7 
7.1 General Methods 
Nuclear Magnetic Resonance (NMR) 
Proton detected NMR spectra were recorded on a Varian Unity 300 spectrometer at 23 
DC, operating at 300 MHz. Carbon detected NMR spectra were recorded on a Varian 
XL300 spectrometer at 23°C, operating at 75 MHz. Other NMR experiments described 
in this thesis viz 1D and 2D-TOCSY, NOE, COSY, NOESY and the reverse detected 
HSMQC, HSQC and HMBC experiments were recorded on the Unity spectrometer, at 
300 MHz. For the work detailed in Chapters 4 (except Section 4.7) and 5 the 
instrument was fitted with a Nalorac Z.spec MID300 3 mm Indirect Detection Probe. 
For the work detailed in Section 4.7 and Chapter 6 the instrument was fitted with a 
Pulsed Field Gradient MLD driver with a 5 mm Indirect Detection Probe. Chemical 
shifts in this thesis are described in parts per million (ppm), on the D scale, and were 
referenced to the appropriate solvent peaks: CDCl3 referenced to CHC13 at DH 7.26 CH) 
and eHCl3 at Dc 77.0 (l3C). All spectra, unless stated, were obtained in CDCI) with 
0.1 % CsDsN to remove any traces of acid from the solvent. lH NMR spectra were 
recorded using an acquisition time (AT) of 2.0 s; 13C NMR spectra were recorded using 
an AT of 0.878 s. APT experiments were recorded using an AT of 0.878 s, Dl=O s, 
D2=0.07 sand D3=0.01 s. All difference NOE experiments were recorded in 
undegassed solutions, with an AT of 1.0 s and an irradiation time (D2) of 2.0 s. The 
decoupler was offset 10 000 Hz for the control experiments. NOESY experiments were 
run using an AT of 0.384 s and a mixing time of 0.30 s. COSY experiments were 
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recorded using an AT of typically 0.2 s and a relaxation delay CDl) of 1.0 s. 
TOCS Y spectra were recorded using an AT of typically 0.2 s and a relaxation delay 
(Dl) of 1.0 s, with mixing times indicated in the discussion. ID TOCSY were recorded 
using a AT of 2.0s, with or without aD 1 of 1.0 s. HSMQC experiments were recorded 
with an AT of 0.178 s, a Dl of 0.333 sand JCH of 145 Hz. HSQC experiments with the 
Pulsed Field Gradient system were run with an AT of typically 0.14 s, a Dl of 1.0 s and 
J C-H of 140 Hz. HMBC experiments were recorded with an AT of typically 0.18 s, a 
relaxation delay of 0.333 s, 30 Hz and a nJCH of 8.3 Hz. HMBC experiments with 
the Pulsed Field Gradient system were run with an AT of ca 0.2 s, a Dl of 1.0 s, a J of 
140 Hz and a nJCH of 8.3 Hz. 
7.1.2 Mass Spectrometry 
Mass spectrometry was performed on a Kratos MS80 RF A Mass Spectrometer operated 
at 4000 V. All halichondrin derivatives were analysed by the soft ionisation technique 
of fast atom bombardment (F AB). F AB was performed with an Ion Tech ZNIIFN ion 
gun using Xe as the reagent gas, operating at 8 kV and 2 rnA with an m-nitrobenzyl 
alcohol (NOBA) matrix. Electron impact ionisation at 70 e V was used to analyse some 
of the trial reaction products. Some samples (stated) were sent to Lewis Pannell 
(NIDDK, NIH) in the USA for HRF ABMS analysis. Where the matrix varied from 
NOBA this will be stated. 
7.1 Performance Liquid Chromatography 
The HPLC work described in this thesis was performed on either one of three 
instruments. A Philips PU4100 Liquid Chromatograph equipped with a Philips PU4120 
Diode Array Detector interfaced to a PC General 486 computer running Philips PU6003 
Diode Array Detector System Software (V3.0), and a Philips PPG 3160/10 colour 
plotter was used for analytical and small scale preparative HPLC described in Chapters 
. Solvents were degassed using a flow of helium. The remaining analytical HPLC 
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(Chapter 6) was performed on a Shimadzu VP system. The complete setup involved a 
Shimadzu LC-IOAC VP liquid chromatograph coupled to a SIL-lOA VP autoinjector, a 
lOA VP column oven set to 40°C, a SPD-MIOA VP diode array detector and a 
R[D-IOA VP Refractive index detector. This system was controlled by Shimadzu 
CLASS-VP (Version 5.02) software. A Shimadzu degasser was utilised for the 
degassing of all solvents used in this machine. Both instruments were equipped with a 
reverse-phase Brownlee Labs CI8 column (dimensions 220 mm (L) x 4.6 mm (ID), 5 
flm particle size). Stated pre-mixed solvent mixtures of acetonitrile (BDH HiperSolvTM 
UV' grade) and water (purified using a MilliQ deionising system) were used with a 
solvent flow rate of 1 mLlminute. A Shimadzu LC-4A instmment equipped with a 
Shimadzu UV Spectrotometric Detector SPD-2AS (wavelength A,=199 nm) and Hewlett 
Packard 3390A integrator was used for preparative reverse phase work using a Rainin 
Dynamax-60A C18 column (dimensions 250 mm (L) x 21.4 mm (ID), 8 flm average 
paliicle size CAPD», the stated acetonitrile (CH3CN) and water mixture with a flow rate 
of 10 mLlminute. 
1 Column Chromatography 
All column chromatography was performed with glass columns of stated dimensions. 
Solvents used were all of commercial grade, distilled once in glass distillation 
apparahls, except MeOH, which was distilled twice. "Flash" columns were mn under 
N2 (oxygen free) pressure (0.5 kPa). 
Silica flash chromatography was performed on Merck silica gel 60 (230-400 mesh). 126 
Normal phase column chromatography of halichondrin material was performed using 
Merck DIOL (40 flm APD). Small scale column chromatography was carried out using 
disposable Adsorbex 200 mg Merck DIOL cartridges. Sephadex LH20 (Pharmacia 
Biotech AB) presoaked overnight in CH2C12 was used for gel permeation 
chromatography. 
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Octadecyl (CI8) reverse phase packing used for preparative and flash column 
chromatography was either Bakerbond (40 )lm) or prepared from silica gel (Davisil, 
70 ~tm) using a solution of octadecyltrichlorosilane (2% v/v, EGA-Chemie) in carbon 
tetrachloride. 127 The silica gel was stirred gently overnight with a teflon coated 
magnetic follower before washing with carbon tetrachloride (x2). Unreacted chloro 
groups were substituted by washing with dry MeOH. carbon tetrachloride solution of 
trimethylchlorosilane (2% v/v, Aldrich) was used to end-cap any unreacted hydroxy 
groups. The reverse phase material was finally washed with CH2Cl2 (x2) and MeOH 
(x2). Small scale reverse phase (C18) column chromatography was performed using 
either 500 mg Bakerbond spe or 200 mg BondElut disposable C18 cartridges. 
7.1 Layer Chromatography 
The analytical silica TLC described in this thesis was performed using Merck silica gel 
60 F254 aluminium-backed sheets, the silica 0.2 mm in thickness. DIOL analytical TLC 
was performed using Merck F254 glass-backed plates, the DIOL 0.2 mm in thickness. 
DIOL plates were eluted with the stated MeOHlCH2Cl2 mixtures. Silica plates were 
eluted with PElEtOAc mixtures as stated. Merck RP-18 TLC plates of 0.2 mm 
were used for the analytical C 18 TLC performed in this thesis. The C 18 plates were 
eluted with the stated CH3CNIH20 mixtures. TLC plates containing halichondrins were 
visualised using a phosphomolybdic acid (PMA) in ethanol (EtOH) spray (10% PMA in 
EtOH, w/v), followed by heating at ca 80°C for 5 minute to yield characteristic brown 
spots. Some TLC plates (as stated) were initially visualised under a short-wave (A 254 
nm) lamp before dipping in a potassium permanganate in ethanol/H20 dip (l:1, 10% 
w/v). 
1 Solvents 
Technical grade solvents were distilled prior to use. Methanol was distilled twice. 
Acetic anhydride was distilled immediately prior to use. 'Hexanes' were prepared from 
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petroleum ether (10 L, bp 60-70 °C), nitrating with a mixture of cone. HN03 (1L) and 
cone. H2S04 (1L) for two days. After this time the nitrating mixture was removed and 
the petroleum ether was washed with water (20 L), and dried over CaCl2 ovemight. The 
resulting solution was filtered through alumina and distilled. Dry solvents were 
obtained using standard methods. Pyridine was refluxed over CaH2 before distillation. 
Methanol was distilled from magnesium metal and iodine and stored over activated 
molecular sieves (4 A). Tetrahydrofuran was refluxed over sodium metal and 
benzophenone before distillation. Dichloromethane was refluxed over calcium hydride 
before distillation. DMSO was dried over molecular sieves overnight. DMF was dried 
by treating twice overnight with 4 A molecular sieves, followed by storage over 4 A 
SIeves. IP A was refluxed over calcium hydride for 3 hours before distillation. 
7 Work Described in Chapter Two 
7.2.1 Introduction 
Batch 32, fractions 1-2 (1.19 g) and Batch 33, fractions 1-3 (0.89 g) were 1.28-
containing fractions provided by the Hali-N project. Batch 32 was processed in four 
pOliions through Sephadex LH20 gel (100 1260 mm x 18 mm) presoaked in CH2C12 
ovemight. The colunm was eluted with CH2C12• An initial fraction (75 mL) was 
collected followed by a further 10 fractions (10 mL) before the gel was stripped with 1:1 
McOH/CH2Cl2• 
Analytical reverse phase (C 18) HPLC (eluent 90% CH3CNlHzO) wa'l utilised to identify 
fractions from LH20 that contained 1.28 and These combined fractions 
25.6-8,167.2 mg; REL3 27.6-8,181.6 mg; REL3 28.4-6,70.5 mg; REL3 29.6-7,194.2 
mg) were divided in 2 and both chromatographed further on LH20 (loa g, 1260 mm x 
18 mm). Twenty fractions were collected from each column and analysed by reverse 
phase (C18) HPLC for 1.28 and 1.32 content. Compound 1.32 was observed in 
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fractions SH2 101.5 (13.1 mg), SH2 101.6 (3l.0 mg), 101.7 (80.4 mg), SH2 104.4 
(8.6 mg), SH2 104.5 (24.2 mg) and SH2 104.6 (59.3 mg). A mixture of and 1.28 
were seen in fractions SH2 101.8 (95.8 mg) and SH2 104.7 (71.0 mg). Compound 
was also present in fractions SH2 101.9 (63.6mg), SH2 101.10 (28.7 mg), SH2 101.11 
(4.2 mg), SH2 104.8 (60.2 mg), SH2 104.9 (38.7 mg), SH2 104.10 (9.8 mg) and SH2 
104.11 (3.5 mg). 
Formation and Isolation 
7.2.2.1 HPLC Trial 
A mixture of 1.28 and 1.32 (100 Ilg) in CH3CN (1 OOIlL) was treated with aqueous 
HCI04 (20 ~tL; 0.035%) for minutes. Small aliquots (20 ilL) were removed and 
analysed by reverse phase (C18) HPLC (90% CH3CNIH20) after 15, 25 and 35 
minutes of reaction. Conversion of to 1.28 was complete after 5 minutes. A peak 
of similar polarity (Rf=500 s) to 1.32 was observed to increase with increased reaction 
time. 
7.2.2.2 'H NMR Trial 
A mixture of 1.28 and 1.32 (1.0 mg) in CH3CN (80 ilL) was treated with aqueous 
HCI04 (20 ilL, 0.035%) for 5 minutes. The reaction mixture was diluted with water and 
run through a reverse phase (C 18) cartridge. The perchloric acid was washed through 
with H20 before stripping the halichondrin material off the cartridge with CH)CN and 
CH1Cl1. A 'H NMR spectrum of the combined organic fractions (REL3 24.2, 1.0 mg) 
revealed an increase in intensity of the characteristic H55 triplet resonance, 4 clean 
methyl resonances, and the absence of the characteristic methoxy and H47 resonances of 
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7.2.2.3 Scaled up Acid Treatment of 53-Methoxyneoisohomohalichondrin B (1.32) 
The combined fractions SH2 101 101.7, 104.5, 104.6 (198.2 mg) in CH3CN (6 mL) 
were treated with aqueous HCl04 (1.5 mL, 0.035 %) for 6 minutes. The reaction 
solution was diluted with H20 (1.5 mL) and loaded onto a reverse phase (C18) column 
(10 g). The column was flushed with H20 (150 mL) to remove the HCl04, and the 
halichondrin material stripped off the column with CH3CN (250 mL) and CH2Cl2 (100 
mL). The combined organic fraction was evaporated in vacuo to give a pale yellow oil 
(SH2 107.1, 174.6 mg). Analysis of the reaction product by reverse phase (C18) HPLC 
revealed the presence of 2 halichondrin-like species, having end absorption only. The 
more polar component was the expected 1.28. The other component eluted at 487 s 
compared to the retention time for of 505 s. The characteristic methoxy resonance 
of 1.32 was not observed in the NMR spectrum of the mixture. 
7.2.2.4 Acid Treatment of a 1.32/1.28 Mixture 
A subsample of SH2 104.7 (5.6 mg) in CH3CN (250 ilL) was treated with aqueous 
HCI04 (63 ilL, 0.035 %) for 1 minute before diluting the reaction mixture with ca 400 
~lL H20. The diluted solution was loaded onto a reverse phase (CIS) cruiridge. The 
cruiridge was washed with H20 (10 mL) before the halichondrin material was stripped 
with CH3CN (S mL) and CH2C12 (S mL). The combined organic fraction was dried in 
vacuo to give isohomohalichondrin B (1.28, 6.3 mg). 
7.2.2.5 Purification of2.2 
SH2 107.1 in acetonitrile (50 mg/mL) was separated into its 2 component halichondrins 
by semipreparative reverse phase (CI8) HPLC eluting with 90% CH3CN/H20. A series 
of 8 ca 16 ilL injections were made and 2 fractions collected to give SH2 118.1 (1.28, 
2.2 mg) and SH2 11S.2 (2.2, 4.0 mg). The identity of the more polar fraction was 
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conflrmed by comparison of its 
L28. 
Structural Elucidation 
epi-Isohomohalichondrin B 
206 
NMR spectrum to that of an authentic sample of 
IH NMR and \3C NMR data cited in Table 2.3.1 and Table 2.3.2 respectively. 
HRFABMS MNa+ 1145.5653 (C6!Hs6019Na requires 1145.5661). 
7.2.4 Acid Equilibria 
epi-Isohomohalichondrin B 3.1 mg) was treated 4:1 CH3CNIHCI04 (120 )1L, 
0.035%) for 4h. Small aliquots were removed and analysed by reverse phase (CI8) 
HPLC after 0.25,0.5, 1, 3 and 4h. An equilibrium of 1:11.28:2.2 was reached after 3 
hours reaction time. 
7.3 Work Described in Chapter Three 
7.3.1 Sample Details 
95AKLissFebOI 1-18, 95AKLissFeb02 1-18, 95BBLissFebOI 1 Samples were 
combined on the basis of depth for each of the two sites. The resulting five combined 
samples were Beatrix Bay deep (1591 g), Beatrix Bay mid depth (328 g), Beatrix Bay 
shallow (483 g), Akaroa deep (500 g), Akaroa shallow (400 g). 
7.3.2 
Bay 
The thawed sponge was blended with MeOH (300 mL) in a Waring blender. The soupy 
mixture was stirred overnight. Celite (320 g) wet with 4: 1 MeOHlH20 (660 mL) was 
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added to the sponge slurry and stirring continued for 30 minutes before filtering. The 
sponge residue was extracted further with MeOH (4 x 700 mL). H20 (440 mL) was 
added to the combined filtrate before partitioning against PE (750 mL +660 mL). The 
solvent was evaporated in vacuo to afford the aqueous methanol extract. 
Akaroa Shallow 
The combined sponge was blended in a Waring blender with MeOH (400 mL) and then 
stilTed overnight. Celite (80 g) wet with MeOH (130 mL) and H20 (30 mL) was added 
to this slurry and stirred for 30 minutes before filtering. The sponge residue was 
extracted with MeOH (6 x 200 mL). The MeOHIH20 ratio of the combined extracts 
was adjusted to 4:1 with the addition of H20 (210 mL) before partitioning against PE 
(380 + 340 mL). The solvent was evaporated in vacuo to give the aqueous methanol 
pmiition. 
Akaroa Deep 
The combined sponge samples were blended in a Waring blender with MeOH (400 mL) 
and stilTed overnight. Celite wet with 4: 1 MeOH/H20 (200 mL) was added to thc 
sponge slurry and stilTing continued for 30 minutes. The slurry was filtered and the 
sponge residue extracted with MeOH (6 x 300 mL). H20 (430 mL) was added to the 
combined filtrate before partitioning against (580 + 510 mL). The solvent was 
evaporated in vacuo to afford the aqueous methanol partition. 
Beatrix Bay Shallow 
The sponge was blended with MeOH (320 mL) and stirred overnight. The slurry was 
then stirred with Celite (100 g) wet with 4: 1 MeOH/H20 (200 mL), filtered and re-
extracted using the amounts detailed for the Akaroa deep sample. The MeOHI H20 
ratio was adjusted with the addition of H20 (150 mL) before partitioning against PE 
(560 + 500 mL). The aqueous methanol extract was taken to dryness in vacuO. 
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Beatrix Bay Deep 
The sponge was split into thirds, and each third blended with MeOH (400 mL). The 
combined sponge slurry was stirred overnight. Celite (320 g) wet with 1: 1 MeOHlH20 
(640 mL) was added to the slurry and stiuing continued for 30 minutes before filtering. 
The sponge residue was extracted with MeOH (6 x 800 mL), stiffing for one hour 
before each filtration. The combined filtrates were divided into two batches. Batch one 
(3 L) and batch two (2.65 L) were partitioned against PE (600 + 525 rnL and 530 + 460 
mL respectively). The aqueous methanol partition was concentrated in vacuo to provide 
an aqueous extract (1 L). The aqueous extract was partitioned against EtO Ac (4 x 300 
mL). Combination of the organic phases followed by evaporation in vacuo afforded the 
EtOAc extract (923 mg). 
Each of the above extracts was coated onto Celite (4.18 g). The coated Celite was 
packed onto the head of a reverse phase (C18) column (100 g, 30 mm x 600 mm) 
equilibrated to 1: 1 MeOH/H10. Step gradient elution, under "flash" conditions, of 1: 1 
MeOH/HzO to MeOH (200 mLifraction) followed by a 1: 1 MeOHlCH1Cl2 fraction and 
finally CH1Cl1 and MeOH strips (400 mL combined) afforded eight fractions. These 
fractions were assayed against the P388 cell line. 
Results (% MeOH, mass (mg), 1C50 (ng/mL)). 
BB shallow: 50, ?, > 12500; 60, 2886, > 12500; 70, 78.2, > 1250; 80, 58.9, 832; 90 
44.4, :;9.7; 100,22.2,882; 50,11.7, > 1250; strip, 9.1,1146. 
BB mid depth: 50, ?, 5872; 60,45.1, > 12500; 70, 45.5, > 1250; 80, 34.8, > 1250; 90 
46.1, < 9.7; 100, 33.8, > 1250; 50, 20.3, > 1250; strip, 5.6, > 1250. 
BB deep: 50,353.5, > 12500; 60, 74.0, > 12500; 70, 102.5, > 1250; 80, 93.0, 493; 90 
93.5, :;9.7; 100,174.0, > 1250; 50, 37.4, 1050; strip, 6.0, > 1250. 
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AK shallow: ?, > 12500; ?, > 12500; 70, 662.3, > 1250; 80, 414; 90 24.8, 
184; 100, 17.7,218; 50, 10.9,292; 4.7,212. 
AK deep: 50, ?, > 12500; 60, ?, > 12500; 70, 83.5, > 1250; 80, 41 338; 90 15.6,36; 
100,13.1,720; 50, 5 3.1,935. 
The 90% MeOH/H20 fraction from each of the BB samples, and last five fractions 
(80% MeOH/H10 onwards) from the AK samples were subjected to size exclusion 
chromatography on LH20. The LH20 (l00 g) was preswoLien in CH2Cl2 overnight. The 
column (600 mm x 30 mm) was eluted with CH2Cl2 at ca 1 mLimin. Nine fractions (50 
mL) were collected. At the completion of each column, the was emptied into a 
Buchner funnel, washed with MeOH and oven dried (60°C) overnight. The fractions 
were dried in vacuo and assayed against the P388 cell line. 
Results (fraction, mass (mg), 1C50 (ng/mL)). 
BB shallow: 80.1, 1.8,42.7; 80.2, 1.7,3; 80.3, 1.6, > 125; 80.4, 1.2, > 125; 80.5, 1.0, > 
125; 80.6, 0.8, > 125; 80.7,1.2, > 125; 80.8,1.1, > 125; 80,9, 41.6, 276. 
BB deep: 81.1, 0.9,21.2; 81.2, 1.8,1.2; 81.3,1.4,21.2; 81.4, 1, > 125; 81.5,1.9, > 
125; 81.6,3.0, > 125; 81.7, 1.9, > 125; 81.8, 1.0, > 125; 81.9, 39.8,465. 
BB extra deep: 79.1, 11.9; 79.2,4.8, 3.6; 79.3, 2.7, 3.6; 79.4, 2.5, 21.2; 79.5, 2.3, 
21.2; 79.6,1.8,10; 7,1.2, > 125; 79.8,1.1, > 125; 79,9, 88.8,115. 
AK shallow: 82.1, 3 18.9; 82.2,4.4,125; 82.3, 3.0, > 125; 
> 125; 82.6, 2.1, > 125; 82.7, 0.8, > 125; 82.8,1.3, > 
3.0, > 125; 82.5, 1.4, 
61.5,720. 
AK extra deep: 78.1,2.6, > 125; 78.2, 1.7,57; 78.3, 2.2, 114.6; 78.4, 1.0, 32; 78.5, 0.8, 
45; 78.6, 0.9, > 1 0.8,7.9; 78.8, 1.3,108; 78.9, 77.0, > 1250. 
Analysis of selected fractions from the LH20 columns by reverse phase (C 18) HPLC 
used a mobile phase of 60% CH3CNIH20 at ImLimin. 
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Purificatioll of 80.2 (UB shallow, LlI20 fnldioll 2) 
1,'rm:liol1 gO.2 was dissolved in benzene and applied 10 a normal phase (DIOL) cartridge 
(2S0 I1lg). The cartridge wm; eluted with benzene, I: I benzenelCH2Cl2, 1% 
fVIeOH/CI1 2CJ 2, 1:9 fVIeOJ-I1CII 2C12 and MeOH (3 mL each). TLC (DIOL, 1% 
fVIeOH/CI-I 2CI2) of the fractions indicated that the non polar contaminants were eluted 
with benzene and the halichondrins were eluted with I: 1 benzene/CH2C12 and CH2CI2• 
Pul'ification of Adive Fnldions 
The active fractions within each series were combined and further concentrated by 
chromatography on DIOL. Each DIOL cartridge (250 mg) was eluted with benzene, 
CH2Cl2, 1:9 MeOH/CH2Cl2 and I: 1 MeOH/CH2Cl2 (6 mL each). The halichondrins 
were contained in the CH2C1 2 fraction of each series. 
Analysis for Halichondrin Content 
The amount of each of the three halichondrins 1.8, 
were calculated by comparison of their HPLC chromatogram integrals to that of a 
standard sample of halichondrin B analysed under the same conditions. The mass of the 
sHmple of 1.8 was equivalent to that of a CH2C12 ti"actioll containing pLlre halichondrins 
only. The results are shown in Figure 3.4.2. 
Native Spouge Exlnlction 
Native sponge (94K3-1, 500 g) was ble~lded with MeOH ill a Waring blender. The 
sponge slurry was stirred overnight. Celite (100 g) wet with 4: 1 MeOH/H20 (200 mL) 
was added and stirring continued for a further 30 minutes before filtering. The sponge 
residue was extracted with further MeOH (400 + 350 + 4 x300 mL), stirred for one hour 
and filtered. The MeOH/H20 ratio was adjusted to 1 with the addition of H20 (550 
l11L) before partitioning against PE (640 + 560 mL). The solvent was evaporated from 
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the aqueous methanol partition and the residue coated onto Celite (4.18 g). Reverse 
phase (C 18) "flash" chromatography was calried out as described for the aquacultured 
sponge extracts. Results (% MeOH, mass (mg), 1C50 (nglmL)) 50, ?, > 12500; 60, ?, > 
12500; 70, 54.0, 253; 80, 32.4, 106; 90 21.3, < 9.7, 27.8; 100, 37.4, 63; 50, 8.5, 310; 
strip, 2.9, 2250. 
The five fractions eluted with 70% MeOH/H20 through MeOHlCH2Cl2 were combined 
(l mg) and applied to the head of an LH20 column (l00 600 rnrn x 30 rnrn). The 
LH20 column was eluted with CH2C12 and eight fractions (50 mL) collected. Results 
(fraction, mass (mg), 1C50 (nglmL)) 98.1, 4.3, 8.1; 98.2, 1.2, 42.7; 98.3, 1.1, 47.9; 98.4, 
LO, 105; 98.5, 1.1,105; 98.6, 0.7, > ,98.7,0.8, > 125; 98.8, 1.2, > 125. 
Fractions 98.1, 98.2 and 98.3 were combined and further purified by LH20 
chromatography. The LH20 column (4g, 880 x 10 rnrn) was eluted with CH2C12 and a 
20 mL fraction collected, followed by a further four fractions (2 rnL each). 
Halichondrins were identified in the first fraction by TLC (DIOL, 1 % MeOHlCHzCI2). 
This halichondrin content of this fraction was determined, as described for the 
aquaculture samples, by comparison of the integrals of the halichondrin peaks in the 
HPLC chromatogram of this fraction with those of standard samples. 
7.4 Work Described in Chapter Four 
7.4.1 Reaction Isohomohalichondrin B (1.28) with (4. 
A solution of (2.5 mg) and (0.7 mg) in dry CH2Cl2 (200 J-LL) was stirred at room 
temperature for 8 hours. TLC (DIOL, 3% MeOHlCH2Cl2) of the reaction mixture 
indicated the starting material was intact. The reaction was continued for a further 19 
hours at which time analysis by TLC showed that little reaction had occurred. IH 
NMR spectrum of the reaction mixture contained resonances belonging to both intact 
starting material and intact PMSI. The reaction was allowed to continue in the NMR 
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tube (ea 150 ilL CDC13 with 0.1 % CsDsN) for 4 days. The loss of the characteristic 
H54/54' and H55 triplet resonances in the lH NMR spectmm of the reaction mixture 
after this time indicated that reaction of had occurred. There was little PMSI 
present. A shift in the resonances of the styryl protons of PMSI from cH 6.61 and cH 
6.43 to cH 5.92 and cH 7.18 was consistent with formation of the carbamate product. 
The product was purified on LH20 (1 g), eluted with CH2CI2• Fractions containing the 
product were identified by TLC (DIOL, 3% MeOHlCH2CI2) and combined as REL3 
41.1 (4.3,2.0 mg). lH NMR and DC NMR data are located in Table 4.2.1 and Table 
4.2.2. 
7.4.2 Reaction of Homohalichondrin (1.25) with PMSI (4.1) 
Homohalichondrin B (1.25, 1.3 mg) was treated with 4.1 (0.28 mg) in CDCl3 (150 ilL) 
for 5 days at room temperature. The reaction mixture was separated into 4 fractions 
with reverse phase (CI8) HPLC using 60% CH3CNIH20 as the mobile phase (REL3 
51.2,0.4 mg; REL3 51.3,0.1 mg; REL3 51.4,0.3 mg; REL3 51.5, < 0.1 mg). 
REL3 51.2 was identified as the starting material by comparison of retention time and 
lH NMR spectIUm to that of an authentic sample ofhomohalichondrin B. 
REL3 51.3 HRFABMS MH+ 1363.6353 (C74H9S022N2 requires 1363.6376) 
REL3 51.4 HRFABMS MH+ 1363.6386 (C74H9S022N2 requires 1363.6376) 
REL3 51.5 HRFABMS MH+ 1603.6864 (Cs7H10302SN4 requires 1603.6911) 
Reaction of Homohalichondrin (1.25) PMPI 
Homohalichondrin B 0.9 mg) and 4.1 (0.17 mg) were dissolved in CDCl3 (ea 150 
ilL) and transferred to a 3 mm NMR tube. The IH NMR spectIUill of the reaction 
mixture after 64 hours showed a small amount of 4.1 was still present. The complicated 
nature of the methyl region of the spectmm indicated a mixture of products had been 
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formed. Reaction for a further 24 hours had no affect on the appearance of the 'H NMR 
spectrum of the mixture. 
Semipreparative reverse phase (CI8) HPLC using a mobile phase of 60% CH3CNIH20 
was performed on the product mixture. A series of 5 50 JlL injections were made, and 
the peaks eluting at ca 290 s (REL3 46.2, 0.2 mg), ca 510 s (REL3 46.3), ca 600 s 
(REL3 46.4,4.7,0.7 mg) and 1200 s (REL3 46.5) were collected. 
The retention time of was characteristic of the starting material. The identity of 
this fraction was confirmed by comparison of its IH NMR spectrum with that of an 
authentic sample of 1.25. The lH NMR spectrum of the major component 4,7 contained 
a doublet of doublets at 8H 6.2 and 8H 6.4. The characteristic maleimide proton 
resonance (8H 6.8) was barely visible. This indicated addition to the maleimide olefin 
had occurred. Reinjection of 4.7 under the same HPLC conditions employed for 
separation of the reaction mixture gave a reduction in the retention time of 4.7 from 600 
s to 470 s. This increase in polarity would be consistent with the addition of methanol 
to the maleimide olefin. 
Compound 4.7 HRFABMS IvrNa+ 1391.6292 (C73H96N2023Na requires 1391.6301). 
Homohalichondrin B (1.25, mg) and 4.2 (0.48 mg) was transferred to a 3 nun NMR 
tube in CDCl3 (ca 150 JlL). The progress of the reaction was monitored by lH NMR 
spectroscopy. A I H NMR spectrum of the reaction mixture after 5 minutes indicated 
that reaction had occurred, as the methyl region had increased in complexity indicating 
multiple product formation. No fUliher changes were observed in lH NMR spectra run 
after this time. 
Semipreparative reverse phase (CI8) HPLC was used to separate the reaction mixture 
into 4 fractions (REL3 48.2-5). The fractions were dried in vacuo and transferred to 
weighed vials in CH2Cl2 to avoid reaction of the male imide. 
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RI-:l,] 4X.] (4.10) 
Parlial III and 11l' NMR dala ciled ill Table 4.3,4 and Table 4.3.5 respectively. 
RI~LJ 4X,4 (4.9) 
Partial IH and DC NMR data cited in Table 4.3.2 and Table 4.3.3 respectively. 
IIRFi\UMS !Vlll' 1337.6229 (CnILn022N2 requires 1337.6219). 
REL3 48.5 (4.8) 
Partial III NMR data cited in Table 4.3.1. 
7.4.4 Reaction of Halichondrin B (1.8) with PMPI (4.2) 
Halichondrin B (1.8, 1.5 mg) was treated with 4.1 (0.29 mg) in CDCl3 (150 ~LL) for 72 
hI'. The III NMR spectrum of the reaction mixture indicated that at least 3 products had 
been formed, with the observation of three maleimide proton resonances. 
The reaction mixture was separated by reverse phase (C18) HPLC USll1g 60% 
CI-I,CN/I-I20 as the mobile phase. Six fractions were collected (REL3 54.2, 229 s; 
REL3 54.3,285 s, 4.12; REL3 54.4,346 s; REL3 54.5, 374 s, 4.11; REL3 54.6,467-523 
s; REL3 54.7,692 s). 
REL3 54.2 (1.8, 1.1 mg) was identified as starting material by a comparison of its 'H 
NMR spectrum with that for an authentic sample of halichondrin B. 
REL3 (4.12) 
Isolated as a colourless oil « 0.1 mg). HRFABMS MH+ 1325.62377 (C71H93022N2 
requires 1325.6219). 
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REL3 54.5 (4.11) 
Isolated as a colourless oil (0.4 mg). HRFABMS MH+ 1325.6229 (C7IH930nN2 requires 
1325.6219). 
Formation Norhomohalichondrin Aldehyde (4.13) 
Homohalichondrin B (1.25, 0.7 mg) dissolved in MeOH (2 drops) was stirred with 
aqueous sodium periodate (NaI04, 150 }!L, 5 mM) for 16 hours at room temperature. 
TLC (DIOL, 5% MeOH/CH2C12) was used to monitor the reaction. The reaction 
mixture was extracted with CH2Cl2 (4 x 0.5 mL) and the solvent removed to give 0.3 mg 
of the product (4,13). The reaction mixture was reextracted with CH2Cl2 to give 0.7 mg 
of combined 4.13. A doublet resonance at DH 9.70 in the 'H NMR spectrum of 4.13 
confinned aldehyde fonnation. 
A fmiher batch of 1.25 was cleaved with periodate to provide enough material for 
thorough assignment of the 'H and 13C NMR resonances of 4.13, and for reaction with 
4.15. Homohalichondrin B (1.25, 2.9 mg) dissolved in MeOH (5 drops) was stirred 
with aq. Nal04 (200 }!L, 30 mM) at room temperature for 17 hours. The reaction 
mixture was extracted with EtOAc and the solvent removed in vacuo to give 4.13 as an 
oil (2.4 mg). 
'H and 13C NMR spectral data are shown in Table 4.4.1 and Table 4.4.2 respectively. 
HRFABMS MCs+ 1223.4560 (C6oH82018CS requires 1223.4552). 
704.6 of Norhomohalichondrin Aldehyde 
5) 
Sodium acetate (10 }!L, 0.18 M) and (10 }!L, 9.2 mM) were added to 4.13 (1 mg) in 
MeOH (100 flL). The mixture was mixed thoroughly by vOliex and left to sit at room 
temperature for 17 hours. The reaction mixture was freeze dried to give 4.16. 
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HRFABMS MNa+ 1320.6415 (C7oH95020N3Na requires 1320.4602). 
NMR spectral data are cited in Table 4.5.1 and Table 
NMR and 13C 
7.4.7 Reduction of Norhomohalichondrin Aldehyde (4.13) 
Norhomohalichondrin B (4.13, 3.9 mg) was stirred with NaBH.\ (6.8 mg) in IPA (300 
ilL) for 45 minutes at room temperature. The reaction was quenched with aq. NH4CI, 
diluted with H20 and applied to a reverse phase (CI8) cartridge. The cartridge was 
washed thoroughly with H20 before stripping the product off with MeOH (4.17, 3.8 
mg). 
HRFABMS (NIH, 
1 .4709). IH and 
respectively. 
magIC bulletiCsI) MCs+ 1225.4703 (C6oHs40ISCS requires 
NMR spectral data are listed in Table 4.6.1 and Table 4.6.2 
7.4.8 Reaction of Norhomohalichondrin B (4.17) with PMSI (4.1) 
Norhomohalichondrin B (4.17,2.4 mg) and PMSI (1.0 mg) were dissolved in CDCl3 (ca 
150 ilL) and transferred to a 3 mm NMR tube. The reaction was monitored by NNIR 
spectroscopy, and deemed to be complete when the integral of the newly formed styryl 
proton (8H 5.95) was comparable to that of the halichondrin protons H18' and H32. The 
solvent was evaporated under a stream of Nz and the residue dissolved in CH2C12• The 
residue solution was applied to a small (1 g) LH20 column. The colunm was eluted 
with CH2C12 with the collection of 30 fractions. The fractions containing purely 
halichondrin material were identified by TLC (DIOL, 4% MeOH/CH2C12) and combined 
to give the product (2.5 mg, 4.19). 
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7.5 Work Described in Chapter 
Hydroboration-oxidation 
~-Pinene (5 mg) and 9~BBN (5.4 mg) in THF (200 j.tL) were stirred at 30°C for 18 
hours. A drop of water was added to destroy unreacted 9-BBN before the addition of 
NaOH (49 ~lL; 1 M) and 50% H20 2 (14.5 j.tL). The reaction mixture was stirred for a 
further 2 hours at room temperature. The aqueous layer was saturated with K2C03 and 
the product extracted with CH2C12. 
Homohalichondrin B (1.25, 6.2 mg) was stirred with pyridine (200 j.tL) and acetic 
anhydride (200 j.tL) for 16 hours. The reaction mixture was diluted with water and 
extracted with EtOAc (x 3). The solvent was removed in vacuo to give the diacetate 5.3 
'(6.0 mg). HRFABMS MH+ 1207.6078 (C65H9!02! requires 1207.6052). The tH NMR 
spectrum of the product was comparable to that of an authentic sample of 
9-BBN (20 ~lL; 0.027 M) was added to a stirred solution of 5.3 (0.6 mg) in THF (180 
j.tL). The reaction was stirred for 8 hours at 30°C before quenching with a drop of 
water. NaOH (5.5 0.1 M) and 50% H20 2 (17 j.tL; 0.1 M) were added and stirring 
continued for a further 2 hours. The mixture was diluted with water and extracted with 
EtOAc (x 3). A IH NMR spectrum of the organic extract showed that the 
homohalichondrin B diacetate (5.3) was still intact. 
The reaction was repeated using the conditions described above. The hydroboration 
step was allowed to continue for 5 days before treatment with basic hydrogen peroxide. 
A 'H NMR spectrum of the organic extract showed that the exocylic methylene protons 
remained intact. 
Homohalichondrin B diacetate (5.3, 0.5 mg) was treated with 9-BBN dimer (1.0 mg) in 
THF (50 j.tL) for 88 hours before quenching the reaction with ethanol. NaOH (82 j.tL; 
0.1 M) and 50% H20 2 (167 j.tL; 0.147 M) were added (dropwise) and the mixture stirred 
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for 6 hours before extracting with EtOAc (x 3), A IH NMR spectmm of the extract 
showed that the diacetate 5.3 was still intact 
Borane dimethyl sulfide (2.0 M solution in toluene) was used neat or as a dilute 
solution. 
Me2S.BH3 (1.5 ilL; 0.1 M) and CDCl3 (50 ilL) were added to homohalichondrin B 
diacetate (0.5 mg) in dry CDCl3 (100 ilL) in an NMR tube filled with argon. The 
reaction was monitored half hourly by IH NMR spectroscopy, and when no change was 
observed an aliquot of Me2S.BH3 solution (2 ilL) was added. Three such additions were 
made with no change in the IH NMR spectmm of the starting materiaL Freshly 
prepared Me2S.BH) (25 ilL; 0.1 M) was added to the reaction solution to ensure a 
considerable excess of reagent was present. After 16 hours EtOH (10 ilL) was added, 
followed by NaOH (10 ilL; 0.1 M) and 50% H20 2 (20 ilL; 0.147 M). The oxidation was 
continued for 4 hours before the solvent was removed in vacuo. The residue was 
dissolved H20 and EtOAc and extracted with EtOAc (3 x 0.5 mL). 
Me2S.BH} solution (4.2 ilL; 0.1 M) was added to (0.5 mg) in dry THF (100 ilL) and 
stirred for 16 hours. Ethanol (100 ilL), NaOH (14 ilL; 0.1 M) and 50% H20 2 (29 ilL; 
0.147 M) were added to the reaction in this order. Stirring was continued for 6 hours 
before extraction with EtOAc (3 x 0.5 mL). Hydroborationloxidation of the extract was 
repeated using the aforementioned conditions to complete the derivatisation of the 19 
methylene group. 
Benzoic anhydride (4.7 mg), a few crystals ofDMAP, and dry pyridine (200 ilL) were 
added to homohalichondrin B (0,3 mg) and stirred for 42 hours before extraction with 
EtOAc (3 x 0,5 mL), The solvent was removed and the extract dissolved in water and 
transferred to a reverse phase (CI8) cartridge (100 mg), The cartridge was washed with 
H20, eluted with MeOHlH20 (1: 1) to remove the DMAP and stripped with MeOH to 
give the dibenzoate (OA mg), IH NMR (CDCI3 + 0,1 % CDsN) 08,05 (m, 2H, ArH), 
Chapter 7 - Experimental 219 
7.97 (m, 2H, ArH), 7.48-7.57 (m, 2H, ArH), 7.22-7.47 (m, ArH), 4.55-4.65 (m, 
H53/H551H55'), 5.56 (m, IH, H54), 0.80-5.05 (remaining halichondrin protons). 
Dibenzoate 5.4 was treated with a 4:] MeOHlH20 solution of 1 % K2COJ (100 !J.L) and 
the progress of the reaction monitored by TLC (DIOL, 3% MeOHlCH2CI2). After 24 
hours TLC of the reaction mixture gave a single spot of equivalent R f to that of 
indicating that cleavage of the protecting groups was complete. The reaction mixture 
was diluted to a final volume of 1 mL with water before transferring to a reverse phase 
(C18) cartridge (100 mg). The cartridge was washed with water (3 rnL) and 10% 
MeOH/H20 (3 rnL) before stripping with MeOH to give the diol 
Homohalichondrin B (1.25, 1 mg) was protected as the dibenzoate as described above. 
Homohalichondrin B dibenzoate (5.4, 1.0 mg) in THF (100 !J.L) was treated with a THF 
solution of borane dimethyl sulfide (8.4 flL; 0.2 M). The reaction was stirred for 17 
hours. A few drops of ethanol were added followed by NaOH (28 flL; 0.1 M) and HZ0 2 
(58 ~lL; 0.147 M). Stirring was continued for a further 6 hours before extracting with 
EtOAc. Analysis of the extract by TLC (DIOL, 3% MeOHlCH2CI2) showed that there 
was a mixture of products. Semipreparative reverse phase (CI8) HPLC using a mobile 
phase of 60% CHJCN/H20 was used to separate the mixture into seven fractions. Five 
of these fractions (REL3 88.1 (0.1 mg), REL3 88.2 « 0.1 mg), 88.5 (0.3 mg, 
REL3 88.6 (0.2 mg) and 88.7 (0.1 mg)) had IH NMR spectra containing 
halichondrin-type resonances. HRFABMS MCs+ 1499.5597 (C75:E-48023CS requires 
1499.5550). 
Homohalichondrin B (1.25, 1.2 mg) in pyridine (25 !J.L) was stirred with TBDPSCI (25 
~lL) for 42 hours. The reaction mixture was diluted with toluene/hexanes (1: 1) and 
transferred to a normal phase (DIOL) cartridge (100 mg). The cartridge was eluted 
toluene/hexanes (1:1), toluene, toluene/CH2Cl2 (1:1) and CH2Cl2 (5 mL of each). 
Halichondrin-type resonances were observed in the IH NMR spectrum of the fractions 
eluted with toluene and toluene/CH2Cl2• TLC (DIOL, 3% MeOHlCH2CI2) indicated that 
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these fractions contained a mixture of halichondrin-derived components. Attempts to 
puri I'y the product mixture using reverse phase (CIS) HPLC were unsuccessful. 
7.5.2 OSJuylation 
7.5.2.1 OSl11ylation of 5.3 
Ilol11ohalichondrin B diaeetate (5.3, 3.4 l11g) in pyridine (60 ~LL) was treated with an 
ethereal solution of OS04 (17.2 ~LL; 0.2 M). The reaction mixture was stirred at room 
temperature for 4.5 hours. Sodiulll metabisulfite (5.4 mg) in 60% pyridine/water was 
added LInd stirring continued for 25 minutes. The product mixture was obtained by 
extraction with CH2CI2 (4xO.5 mL). TLC (DIOL, 3% MeOH/CH2CI2) showed that the 
extract contained two hal ichondrin-like components. The mixture was 
cilrol11atographed on DIOL (l g in a Pasteur pipette), eluting with a gradient starting at 
hexanes/tolucne (I: I) through toluene to CH2CI2 . Thirty six fractions (0.5 I11L) were 
collected (REL3 105.1-REL3 105.36). 'H NMR spectroscopy was used to identify the 
li"actiolls containing halichondrin-type compounds. Fractions REL3 105.25 - REL3 
105.34, eluted with CH2CI2, were combined as the diol5.6 (1.2mg). 
IH and 1oC NMR spectral data are listed in Table 5.3.1 and Table 5.3.2 respectively. 
HRFABMS MCs+ 1373.5022 (CGSH920nCs requires 1373.50S0). 
The remaining halichondrin-containing fractions (REL3 105.35-REL3 105.43) were 
combined ror re-osmylation. The combined fraction (1.5 mg) was stirred with an 
ethereal solution of OS04 (13 ~LL; 0.2 M) in pyridine (60 ~L) for 4.5 hours. Sodium 
meta bisulfite (l mg) dissolved in pyridine (60 ~LL) and H20 (SO ~LL) was added and the 
reaction stirred for a further 20 minutes. The reaction mixture was extracted with 
EtOAc (4 x 0.5 mL) to give the product 5.7 (1.4 mg). Refer to Section 7.5.2.3 for 
spectral data. 
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7,5 Protection of 1.25 
1.25 (14,4 mg) was stirred with acetic anhydride (l00 flL) and pyridine (100 ilL) for 16 
hours at room temperature, The reaction was quenched with water and extracted with 
EtOAc to give (15,4 mg), The IH NMR spectrum of 5.3 was comparable to that of 
an authentic sample. 
7,5.2,3 Further Osmylation of 5.3 
Homohalichondrin B diacetate 15,4 mg) in pyridine (100 flL) was treated with an 
ethereal solution of OS04 (72 flL; 0,2 M) for 4,5 hours at room temperature. Sodium 
metabisulfite (24.3 mg) dissolved in pyridine (100 flL) and H20 (150 flL) was added 
and the reaction stirred for a further 20 minutes before extracting with EtOAc (4 x 0.5 
mL). The product mixture was chromatographed on DIOL (30 g, 15 x 350 mm). A 
gradient from toluene to CH2Cl2 was used to elute the column, with 26 fractions 
collected (REL3 111.1-REL3 111.26). IH NMR spectroscopy was used to identify 
fractions containing halichondrin-type compounds (REL3 111.7-REL3 111.25). REL3 
111.14-16 were combined on the basis of their identical lH NMR spectra to give 
(3,4 mg). 
IH and IJC NMR spectral data are shown in Table 5.3.3 and Table 5.3,4 respectively. 
HRFABMS MH+ 1275.6148 (C65H)5025 requires 1275.6162). 
REL3 111.8 and REL3 111.9 were combined as REL3 112.1 (3.2 mg). HRF ABMS of 
this combined fi'action gave a parent ion MH+ 1241.6124 (C6,H93023 requires 
1241.6107), isobaric to the dio15.6. 
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.2.4 Periodate Cleavage of 5.6 
Compound 5.6 (0.9 mg) was dissolved in MeOH (2 drops) before adding H20 (100 ilL) 
and aqueous NaI04 (22 ilL; 40 mM). The reaction mixture (milky) was stirred for 15 
hours and then extracted with EtOAc. 
7.5.2.5 Periodate Cleavage ofREL3 112.1 
REL3 11 1 (3.2 mg) was dissolved in MeOH (~ 4 drops) before adding H20 (100 ilL) 
and aqueous NaI04 (78 ilL; 40 mM). The reaction was stirred for 16 hours before 
extracting with EtOAc (4 x 0.5 mL). 
Analytical reverse phase (CI8) HPLC (mobile phase 60% CH3CNIH20) was used to 
identify three halichondrin-like components (retention time 419 s; 595 s 1340s) in the 
organic extracts from both of the above cleavage reactions. Semipreparative reverse 
phase (CI8) HPLC with a mobile phase of 80% CH3CNIH20 was used to separate the 
three components 5.8 (2.0 mg), 5.9 (0.8 mg) and 5.10 (~0.1 mg). 
The IH and 13C NMR spectral data for 5.8 are listed in Table 5.3.5 and Table 5.3.6. 
HRFABMS MCs+ 1341.4834 (C64H88022 requires 1341.4818). 
The IH and 13C NMR spectral data. for 5.9 are listed in Table 5.3.9 and Table 5.3.10. 
HRFABMS MCs+ l373.5104 (C65Hn023 requires l373.5080). 
The IH and 13C NMR spectral data for S,lO are listed in Table 5.3.7 and Table 5.3.8. 
HRFABMS MCsf 1341.4832 (C64Hs8022 requires 1341.4818). 
7.5.2.6 Periodate Cleavage of 
Compound (4.8 mg) was dissolved in a few drops of MeOH before adding H20 (100 
~lL) and aqueous NaI04 (113 ilL; 40 mM). The reaction was stirred for 15 hours before 
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extracting with EtOAc (3 x 0.5 mL). The solvent was evaporated ill vacuo to give the 
diketone (4.5 mg). 
The lH and 13C NMR spectral data have been assigned previollsly.95 HRFABMS (NIH; 
magic bulletlCsI) MCs+ 1343.4602 (C63Hs6023CS requires 1343.4611). 
7.5.2.7 Deprotection of 5.6 
Compound 5.6 (0.3 mg) was treated with a 4: 1 MeOHlH20 solution of 1 % K1C03 (100 
ilL) for hours. The reaction mixture was diluted with water and extracted with 
EtOAc (4 x 0.5 mL). 
Compound 5.6 (0.3 mg) was treated with K2C03 as described above for 72 hours. The 
reaction mixture was diluted with water and the product extracted with EtOAc (4 x 0.5 
mL). 
HRFABMS MCs' 1289.4858 (C61Hss021Cs reqUlres 1289.4869). LRFABMS m/z 
1307.3 (MCs++18), mlz 1321.7 (MCs++32). 
Methylenation 
7.5.3.1 Preparation of Lombardo's Reagent 
Lombardo's Reagent was prepared according to a literature procedure. lO4 The use of 
freshly purified zinc dust was critical to the successful synthesis of the reagent. 
7.5.3.2 Methylenation ofCholestanone 
Ice cold Lombardo's reagent (l mL) was added dropwise to a stirred solution of 
cholestanone (lO mg) in THF (2 mL). Stirring was continued for 5 minutes upon 
completion of reagent addition. The reaction was quenched with saturated NaHC03 and 
the product extracted into diethyl ether, washed with brine and dried over anhydrous 
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MgS04• lH NMR (CDC13) 8 
CI--I3)' 
(m, 2H, =CH2), 0.70-2.25 (m, 43H), 0.65 (s, 
7.5.3.3 Methylenation of Diketone 5.1 
224 
Ice cold Lombardo's reagent (1 mL) was added dropwise to a stilTed solution of 5.1 (1.5 
mg) in THF (2 mL). Stirring was continued for 5 minutes upon completion of reagent 
addition. The reaction was quenched with saturated NaHC03 and the product extracted 
into diethyl ether, washed with brine and dried over anhydrous MgS04• 
7.6 Work Described in Chapter 6 
7.6.1 Reductive Amination 
7.6.1.1 Cholestanone and Phenethylamine Hydrochloride 
Cholestanone (2.0 mg), phenethylamine hydrochloride (5.7 mg), sodium acetate (4.2 
mg) and a solution of acetic acid in MeOH (166 flL; 17.7 mM) were stirred for 30 
minutes at room temperature before the addition of NaCNBH3 (20 flL; 0.26 M). The 
reaction was stirred for a further 64 hours. The solvent was evaporated, and the CH2Cl2 
soluble material applied to a Pasteur pipette packed with DIOL. The column was eluted 
with CH2Cl2, CH2CI/EtOAc (1 : 1) and EtOAc (4mL of each). The product was eluted in 
the first two fractions. lH NMR (CDCI3) 8 7.34-7.18 (m, 3.05-2.89 (m, 2H), 2.00-
0.82 (m, 14H), 0.78 (s, 3H), 0.63 (s, 3H). HRFABMS (NIH, mb/peg/ef) MH+ 492.4537 
(C]SHS8N requires 492.4569). 
7.6.1.2 Cholestanone and Ammonium Acetate 
Cholestanone (2.0 mg), ammonium acetate (4 mg) and acetic acid (167 flL; 1.75 mM) 
were stirred at room temperature for 30 minutes before the addition of NaCNBH3 (20 
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ilL; 0.26 M). The reaction was stilTed at room temperature for a further 68 hours. The 
solvent was evaporated and the residue dissolved in H20 and applied to a reverse phase 
(C18) car1ridge. The cartridge was washed with H20 (4 mL) and stripped with MeOH 
and CH2C12• These fractions gave a positive (bright orange spot) result when visualised 
with Dragendorffs spray reagent on a silica TLC plate. 
7.6.1.3 Norhomohalichondrin B Aldehyde (4.13) and Ammonium Acetate 
Norhomohalichondrin B aldehyde (4.13, 0.5 mg), an1monium acetate (10 ilL; 0.45 M) 
and acetic acid (8 ilL; 0.026 mM) were stirred for 15 minutes before adding NaCNBH3 
(2 ilL; 0.23 M). The reaction was stirred at room temperature for 65 hours before 
evaporating the solvent. The complex nature of the methyl region indicated more than 
one product had been formed. The mixture was separated by reverse phase (C 18) HPLC 
into five fractions using 55% CH3CNIH20 as the mobile phase. There was insufficient 
material recovered for further analysis by 'H NMR spectroscopy. 
Norhomohalichondrin B aldehyde (4.13, 0.6 mg), ammonium acetate (10 ilL; 0.54 M) 
and acetic acid (200 ilL; 0.093 M) were stirred with crushed activated 3A molecular 
sieves for 30 minutes before the addition of NaCNBH3 (10 ilL; 0.11 M). The reaction 
was stirred at room temperature for a further 65 hours. The solvent was removed in 
vacuo and the residue analysed by reverse phase (CI8) HPLC, using a mobile phase of 
60% CH,CNIH70. 
. -
7.6.1.4 Oxidation of Citronellol 
Dess-Martin periodinane (1.75 g) and citronellol (500 ~LL) in CH2Cl2 (40 mL) were 
stirred at room temperature until TLC (Si02, 3:2 PE/EtOAc, vis. with KMn04) indicated 
that the reaction was complete (1.5 h). The reaction was diluted with Et20 (40 mL) and 
poured into saturated NaHC03 containing a 7-fold excess of sodium persulfate. The 
aqueous layer was extracted with Et20 and the combined organic layers washed with 
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NaHC03, brine, dried (MgS04) and the solvent removed in vacuo. Purification of 
residue by flash Si02 chromatography (4: 1 PElEtOAc) yielded citronellal (223 mg). IH 
NMR (CDCl)) 0 9.74 (t, 1H), 5.07(m, IH) 2.44-1.15 (m, 13H) 0.96 (d, 3H). 
7.6.1.5 Citronellal and Ethylenediamine Hydrochloride 
Ethylenediamine hydrochloride (2.7 M) was formed by combining ethylenediamine 
dihydrochloride (1.99 g) slurried in MeOH (10 mL) with ethylenediamine (1 mL). 
Ethylenediamine hydrochloride (100 ilL; 2.7 M) and citronellal (5 ilL) were stirred with 
NaCNBH3 (100 ilL; 0.28 M) at room temperature. The reaction was monitored by TLC 
(Si02, 3:2 PE/EtOAc, vis. with KMn04)' After 17 hours the reaction was basified with 
Na2C03, extracted with EtOAc, dried over MgS04 and the solvent evaporated to give a 
sweetly scented oil. GCMS indicated that the major component was the reductive 
amination product (6.2). A minor component was identified as the dimer of 
7.6.1.6 Norhomohalichondrin B Aldehyde (4.13) and Ethylenedian1ine Hydrochloride 
Norhomohalichondrin B aldehyde (4.13, 1.0 mg) and ethylenediamine hydrochloride (5 
~lL) in MeOH (200 ilL) were stirred at room temperature for 30 minutes before the 
addition of NaCNBH3 (10 ilL; 0.095 M). The reaction was stirred for 65 hours before 
evaporating the solvent. Additional resonances were observed in the region of OH 2.5-
3.0 in the lH NMR spectrum ofthe residue. No useful MS result was obtained. 
7.6.1.7 Norhomohalichondrin B Aldehyde (4.13) and Sodium Cyanoborohydride 
Norhomohalichondrin B aldehyde (4.13, 0.5 mg) in MeOH (200 ilL) was stirred with 
NaCNBH3 (5 ~LL; 0.095 M) at room temperature for 65 hours before the solvent was 
evaporated. The complex nature of the methyl region in the lH NMR spectrum of the 
residue indicated that more than one halichondrin component was present. LRF ABMS 
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mlz 1113.5 (4.13Na\ 1115.5 
(4.17Cs~). 
Na+), 1131.5 (4.17K+), 1223.4 (4.13Cs+), 1225.4 
Azide Route 
7.6.2.1 Tosylation ofCitronellol 
p-Toluenesulfonyl chloride was purified prior to use.128 
A solution of citronellol (12 ilL) and pyridine (11 ilL) in CH2Cl2 (200 ilL) was cooled to 
O°C before the dropwise addition of p-toluenesulfonyl chloride (TsCl, 25 mg) in CH2C12 
(l00 ilL). The reaction was stirred for 2 hours at O°C and at room temperature for 17 
hours. The reaction mixture was diluted with H20 and diethyl ether, washed with 2N 
HCL saturated NaHCO) and H20 and dried over MgS04• The solvent was evaporated in 
vacuo to give the product (15.5 mg). lH NMR (CDCl) 8 7.79 (m, 2H), 7.34 (m, 2H), 
5.02 (m, 1H), 4.05 (m, 2H), 2.45 (s, 3H), 2.03-1.00 (m, 13H), 0.88 (d,3H). 
7.6.2.2 Formation of Citronellazide 
NaN) (42.8 mg) in DMF (100 ).!L) was added to citronellol tosylate (15.5 mg) in DMF 
(600 ).!L). The reaction slurry was stirred for 17 hours at room temperature. TLC (Si02, 
4: 1 PE/EtOAc, vis. with KMn04) showed that the reaction was complete. The reaction 
mixture was diluted with water and diethyl ether and washed twice with water to 
remove any unreacted azide. The ether layer was then washed with NH4Cl, saturated 
NaHCO, and brine and dried over MgS04• The solvent was removed in vacuo to give a 
sweetly scented yellow oil (3.5 mg). 'H NMR (CDCl3) 8 5.08 (m, 11-1),3.28 (m, 
1.98 (m, 2H), 1.72-1.04 (m, lUi), 0.90 (d, 3H). 
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7.6.2.3 Futher Tosylation of Citronellol 
TsCl (1.38 g) in CHI Cl1 (10 mL) was added dropwise to an ice-cold solution of 
citronellol (1.2 mL), DMAP (103 mg) and diisopropylethylamine (1.26 mL) in CH2Cl2 
(10 mL). The reaction was stin-ed for 18 hours, leaving the ice bath to adjust to room 
temperature. The reaction was diluted with CH2Cl2 and washed with H20 (x 2), NH4CI, 
and H20, dried (MgS04) and the solvent evaporated. IH NMR indicated a mixture 
(11 :9) of the tosylate and chloride had been formed. 
7.6.2.4 Formation of More Citronellazide 
The tosylate/chloride mixture was stin-ed with NaN3 (4.28 g) in DlVIF (15 mL) at room 
temperature for 18 hours. The reaction was diluted with water and extracted with 
diethyl ether. The ether extract was washed with water (x 2), ~n4CI, NaHC03 and 
brine, dried (MgS04) and the solvent evaporated to give an orange oil. Flash 
chromatography on silica with petroleum ether gave citronellazide (309 mg). 
7.6.2.5 Reduction of Citronellazide 
Hydrogenation of citronellazide (106.6 mg) was can-ied out with Lindlar catalyst (38.7 
mg) in EtOH (40 mL) at room temperature and atmospheric pressure for 2 hours. The 
reaction was then filtered through Celite and the solvent evaporated to yield 
citronellamine (91.5 mg). GCMS indicated that citronellamine was the major 
component (ca 95%). HREIMS MT 155.1668 (CIOH2IN requires 155.1674). IH NMR 
(CDCI]) 8 5.07 (m, IH), 2.69 (m, 2H), 1.96 (m, 2H), 1.71-1.02 (m, 13H), 0.85 (m, 2H). 
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Reactions 
7.6.3.1 Attempted Tosylation ofNorhomohalichondrin B (4.17) 
Norhomohalichondrin B (4.17, 0.9 mg), diisopropylethylamine (10 ilL; 92 mM) and 
DMAP (10 ilL; 8.2 mM) in CH2C12 (80 ilL) was cooled to O°C. TsCI in CH2C12 (100 
~lL; 8.9 mM) was added dropwise and the reaction stirred for 2 hours (O°C to RT). The 
reaction was diluted with H20 and extracted with diethyl ether. The ether layer was 
washed with NH4Cl, brine and H20, dried (MgS04) and the solvent evaporated. The 'H 
NMR spectrum of the extract indicated that no reaction had occurred. 
The reaction was repeated using the starting material recovered above. The quantities of 
reagents used above were doubled, and the reaction stirred for 2 hours as before. Once 
more, the 'H NMR spectrum of the organic extract of the reaction mixture contained 
resonances belonging to the starting material. The aromatic resonances of TsCl were 
also observed (07.93, 7.41). 
Norhomohalichondrin B (4.17, 0.6 mg), DMAP (1 crystal) and diisopropylethylamine 
(2 ~lL) in CH2C12 were cooled to O°C before the dropwise addition of TsCl (2.0 mg) in 
CH2Cl2 (100 ilL). The reaction was stirred for 2 hours (O°C to RT) and then diluted 
with water and extracted with diethyl ether. The organic extract was washed as 
described previously, dried (MgS04) and the solvent evaporated to yield an oily residue 
(8.5 mg). The lH NMR spectrum of the residue showed that contamination had 
occlllTed. Base-line halichondrin-type resonances were observed. The source of this 
contamination was traced to the diethyl ether. 
TLC (DIOL, 4% MeOH/CH2C12) indicated that the contaminated residue contained 
starting material 
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7.6.3.2 Tosylation of Homohalichondrin B 
Homohalichondrill B (1.25, 1.5 mg), diisopropylethylamine (2.5 ilL) and DlVlAP (1 
crystals) in CH2C12 were cooled to O°C before the dropwise addition of TsCI mg) in 
CH2Cl2 (100 ilL). The reaction was stirred for 2 hours (O°C to RT). The reaction was 
diluted with H20 and extracted with EtOAc. The EtOAc extract was washed with 
NH4CI, brine and H20, dried (MgS04) and the solvent evaporated. The development of 
a shoulder on the H47 resonance in the IH NMR spectrum of the residue indicated that 
reaction was beginning to occur. However, the starting material 1 was largely intact. 
The recovered starting material was reacted as described above. The reaction was 
stilTed for 18 hours before working up as described previously. The H47 resonance was 
observed upfield OH 0.02 relative to that of 1.25. The absence of the characteristic 
H55/H55' methylene resonance was consistent with tosylation. HRF ABMS MCs~ 
1409.4918 (C68Hn0 2l SCs requires 1409.4903). LRFABMS 1563.5 (homohalichondrin 
B ditosylateCs-). 
7.6.3.3 Tosylation ofNorhomohalichondrin B (4.17)· 
Norhomohalichondrin B (4.17, 0.5 mg), diisopropylethylamine (2.5 ilL) and DMAP (l 
crystal) in CH2Cl2 (100 ilL) were cooled to O°C before the dropwise addition of TsCI (2 
mg) in CH2Cl1 (100 jlL). The reaction was stilTed for 17 hours (O°C to RT) and then 
diluted with EtOAc, washed with H20, NH4CI, brine and dried over MgS04. The 
solvent was removed in vacuo to yield the product. HRF ABMS (NIH, mb/CsI) MCs-
1379.4844 (C67H90020SCS requires 1379.4797). 
7.6.3.4 Azide Substitution of Norhomohalichondrin B Tosylate (6.8) 
Norhomohalichondrin B tosylate (6.8, OJ mg) was stilTed with NaN] (51 mg) in DMF 
(400 ~tL) at 40°C for 18 hours. Once cooled, the reaction was diluted with H20 and 
extracted with EtOAc. The organic extract was washed with H20, NH4CI, brine and 
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H20, dried (MgS04) and the solvent evaporated. Two H47 resonances were observed in 
the lH NMR spectrum of the residue (0.4 mg). Analysis of the mixture by reverse phase 
(CI8) HPLC (mobile phase 70% CH3CNIH20) equipped with both diode array and 
refractive index (Rl) detection found that the ratio of components was 4:1 
azide:tosylate. 
7.6.3.5 Hydrogenation 
Hydrogenation of the azide/tosylate mixture (- 0.4 mg) was carried out with Lindlar 
catalyst (- 0.9 mg) in EtOH (l mL) at room temperature and atmospheric pressure for 5 
hours. The reaction was filtered through Celite and the solvent evaporated. The lH 
NMR spectrum of the residue was identical to that of the starting materiaL 
Hydrogenation of the azide/tosylate mixture was undertaken for a further 48 hours using 
the conditions described above. The exocyc1ic methylenes remained intact but it was 
difficult to ascel1ain if any amine had been formed. 
7.6.3.6 "Large-scale" Preparation of Norhomohalichondrin B Azide (6.9) 
Homohalichondrin B (1.25,44.0 mg) in MeOH (20 IlL) was treated with NaI04 (l mL; 
50 mM). H20 (500 jlL) was added to dissolve the white precipitate. The reaction was 
stirred for 18 hours at room temperature. The reaction was diluted with H20 and 
extracted with EtOAc (4 x 1.5 mL). The solvent was evaporated to give 
norhomohalichondrin B aldehyde (4.13, 43.3 mg). 
N orhomohalichondrin B aldehyde 24.5 mg) and NaBH4 (22.7 mg) in IPA (2 mL) 
were stirred for minutes. The reaction was quenched with NH4Cl and extracted with 
EtOAc. The extract was washed with brine and H20, dried (MgS04) and the solvent 
evaporated to yield norhomohalichondrin B (4.17, 19.3 mg). 
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Norhol110halichondrin B (4.17,19.1 mg), diisopropylethylarnine (7 f.lL) and DMAP (4.2 
mg) in CH2Cl2 (150 ~lL) were cooled to O°C before the dropwise addition of TsCl (6.7 
mg) in CH2Cl2 (100 f.lL). The reaction was stirred 14 hours. The reaction was 
diluted with H20 and extracted with EtOAc. The extract was washed with NH4Cl, brine 
and H20, dried (MgS04) and the solvent evaporated to yield the tosylate 6.8 (20.1 mg). 
HRFABMS (NIH, magic bullet/CsI) MCs+ 1379.4844 (C67H90020SCS requires 
1379.4797). lH and J3C NMR data are listed in Table 6.3.1 and Table 6.3 
Norhomohalichondrin B tosylate (6.8, 8.5 mg) was stirred with NaN3 (50 mg) in DMF 
(400 f.lL) at 40°C for 19 hours. The reaction was diluted with H20 and extracted with 
EtOAc. The EtOAc extract was washed with H20, NH4CI and brine, dried (MgS04) and 
the solvent evaporated. Reverse phase (C18) HPLC (mobile phase 70% CH3CN/H20) 
showed that the residue was a mixture of azide and starting material. 
The mixture was stilTed with NaN) (51.3 mg) in DMF (400 ~lL) at 40°C. Periodically 
an aliquot (10 f.lL) was removed and diluted with CH3CN (990 f.lL) for HPLC analysis. 
After 57 hours the reaction was diluted with water and extracted with EtOAc. The 
extract was washed with H20, NH4Cl and brine, dried (MgSO.t) and the solvent 
evaporated to yield the azide 6.9 (5.4 mg). HRFABMS (NIH, magic bullet/CsI) MCs+ 
1250.4822 (C6oHs3017N3CS requires 1250.4773). lH and 13C NrvIR data are shown in 
Table 6.3.3 and Table 6.3.4. 
7.6.3.7 Reduction of Norhomohalichondrin B Azide (6.9) 
Hydrogenation of norhomohalichondrin B azide (6.9, 2.0 mg) was carried out with 
Lindlar catalyst (1.5 mg) in EtOH (1 mL) at room temperature and atmospheric 
pressure. The reaction was monitored by reverse phase (CIS) HPLC using a mobile 
phase of 70% CH]CN!H20. Aliquots (10 f.lL) were removed from the reaction and 
filtered through a 0.45 ~Lm filter capped with Celite. The solvent was evaporated and 
the residue dissolved in CH3CN (80 f.lL). After 32 hours the reaction was filtered 
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throllgh ('clitc and the solvent evaporated. The H54 azide resonance was significantly 
reduccd in thc 1/1 NMR spectrum 0(' the orange residue. The .exocyclic methylene 
resonances were present. The complicated nature of the methyl resonances indicated the 
presence of more than onc halichondrin-type compound. Resonances associated with all 
unidentified contaminant were observed in the region of 8H 0.8-0.9. 
Reverse phase (CI8) chromatography was used to separate the components. Trace 
amounts or azide 6.9 were recovered, but the remaining halichondrin material was lost. 
Hydrogenation of 6.9 (3.4 mg) was carried out with Lindlar catalyst (1. 9 mg) in EtOH 
(1 mL) at room temperature and atmospheric pressure for 41 hours. The reaction was 
[i Jtered through Celite and the solvent evaporated to yield an orange oil (3.8 mg, 6.10). 
HRFABMS (NIH, magic buliet/CsI) MCs+ 1224.4812 (C6oHs50'7NCs reqUlres 
1224.4868). IH and 13C NMR data are listed in Table 6.3.5 and Table 6.3.6. 
7.6.4 Polymer Reactions 
7.6.4.1 Determination of £>100 for ONp 
Two dilutions were made from each of two solutions of p-nitrophenol in phosphate 
buffered saline (pH 7.68). Duplicate absorbance readings of the six samples were 
obtained at 400 11111. A (1.858 X 10-4 M) = 2.2672, 2.2653; A (1.4988 x \(t>1 M) = 
1.9292. 1.9707; A (1.199 x 10->1 M) = 1.5901, 1.5693; A (7.43 x 10-5 M) = 0.96690, 
0.9671 0; A (6.79 X 10-5 M) = 0.90921,0.84628; A (5.575 x 10-5 M) = 0.72824, 0.69614. 
£.11111 13097 M-1cnf l . 
7.6.4.2 Trial Reactions 
All aliquot (60 ~lL) of polymer precursor (5.0 mg) in DMSO (lmL) was diluted to 1mL 
with phosphate buffered saline. The absorbance of this diluted solution at 400 nm was 
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0.1087. The number of moles of 
calculated as 1.38 x 10-7• 
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amine in the polymer precursor (5 mg) was 
Polymer precursor (5.0 mg) was stirred with l-amino-2-propanol (5 ilL) and TEA 
ilL) in DMSO (990 ilL) for 10 minutes. An aliquot (60 ilL) of the reaction solution was 
diluted to 1 mL with phosphate buffered saline. The absorbance of the diluted solution 
at 400 nm was 0.7992. This value was used to calculate an estimated ONp content of 
mol%. 
l-Arnino-2-propanol (S ilL) and (9 ilL) was added to polymer precursor (5.0 mg) 
in DMSO (86 ~tL). The reaction was stirred at room temperature for 23 hours. An 
aliquot (6 ilL) of the reaction mixture was diluted to 1 mL with phosphate buffered 
saline and the absorbance at 400 nm measured against a phosphate buffered saline blank 
(1.1938). This equates to a side chain content of 4.S mol%. The remaining sample was 
diluted with MeOH to a total volume of 1 mL and applied to an LH20 column (5 g; 13 x 
220 mm). The eluent was run through a single wavelength (206 nm) spectrometer. A 
fraction collector was used to collect 2 minute fractions of ca 1-1.2 mL each. The 
polymer containing fractions (S-8) were combined for use as a standard. ONp was 
concentrated in fractions 18-24. 
7.6.4.3 Reaction of Nor hom ohali chondrin B amine (6.10) with polymer precursor 
Korhomohalichondrin B amine (6.10, 1.4 mg) and TEA (10 ilL; 0.13 mM) was stirred 
with polymer precursor (S.O mg) in DMSO (90 ilL) at room temperature for hours. 
An aliquot of the reaction solution (6 ilL) was diluted to 1 mL with phosphate buffered 
saline. The absorbance of the dilute solution at 400 nm was 0.67325. This equates to 
the addition of 7.2 mol of 6.10. l-Arnino-2-propanol (5 ilL) was added and the reaction 
was stirred for a further 16 hours at room temperature. Another aliquot (6 ilL) was 
diluted to 1 mL with phosphate buffered saline and the absorbance recorded at 400 nm 
(1.2134). The remaining reaction mixture was diluted to 1 mL with MeOH and then 
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applied to an LH20 column. The column was eluted with MeOH at 0.5 mLlmin, and 1 
mL fractions collected. TLC (Si02, 5% MeOr-IICH2C12) visualised with Dragendorffs 
spray reagent was used to identify fractions containing free amine (14-16). Fractions 
containing purely polymer-bound amine (8-13) were combined (4.12 mg). 
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1.1 Calculation of side chain content in polynler precursor 
Polymer precursor (5.0 mg) was treated with an excess of l-amino-2-propanol in 
DMSO (1 mL) for hours. A subs ample (60 ilL) of the solution was diluted to 1 mL 
with phosphate buffered saline. The absorbance of this dilute solution was measured at 
400 nrn. 
absorbance of polymer precursor sample 1.1938 
corrected absorbance 1.0851 
(-0.1087 to account for free ONp in polymer precursor) 
concentration 
(absorbance/molar absorbti vity 
moles side chain in measured sample (1 mL) 
moles side chain in total sample 
(used 6 ilL from the total sample of 100 ilL) 
mass of side chain 
(M(SideChuil1) 58l.6 gmot l ) 
mass of HPMA 
(5.0 - 8.03 x 10-4 g) 
moles of HPMA 
(M(HPMA) 143.2 gmor l ) 
mol% side chain 
(A/(A+B» 
8.29 x 10-5 mol L-1 
8.29 x 10-8 mol 
1.38 X 10-6 mol (A) 
8.03 X 10-4 g 
4.20 X 10-3 g 
2.93 x 10-5 mol (B) 
4.5% 
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